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It is now well established that there is a high prevalence of exercise-induced 
bronchoconstriction (EIB) amongst athletes. There is still debate however regarding the 
optimal method of diagnosis in this group and current treatment guidelines are mainly based 
on recommendations for the general population with asthma. The aim of this thesis was to 
address these gaps in the literature by investigating methods of diagnosing EIB, the impact 
of standard asthma treatment upon airway inflammation, EIB severity, health and 
performance in elite athletes, and the effect of reducing environmental exposure upon EIB 
severity.  
Study 1 compared two objective methods of diagnosing EIB; eucapnic voluntary hyperpnoea 
(EVH) and an exercise challenge (EX) on a cycle ergometer in a dry (26%RH) environment. 
Twenty-seven recreational athletes completed both an EVH and EX challenge in a 
randomised order. Challenges were deemed positive if there was a fall in FEV1 of ≥ 10% 
from pre to post challenge. Six participants were positive to EVH (% fall in FEV1 16 ± 5%, 
range -11 to -25%), of these, only two were positive to Ex (both with an 11% fall in FEV1). 
These findings demonstrated that EVH provides greater sensitivity than a standardised EX 
challenge in a dry environment in the diagnosis of EIB. 
Study 2 reports results of the largest EIB screening in elite footballers to date and evaluates 
the prevalence of EIB and the impact of standard asthma therapy on airway health and 
exercise performance. Ninety-seven male professional football players completed an EVH 
challenge. Players demonstrating a positive result (EVH+) were prescribed standard asthma 
therapy and underwent repeat assessment after 9 weeks of treatment. Eight players (3 EVH+, 
5 EVH-) completed a V̇O2 peak test at initial and follow-up assessments. Of the 97 players, 
27 (28%) demonstrated EVH+. Seven of the 27 (24%) EVH+ players attended follow-up 
and demonstrated improved post-challenge spirometry (FEV1 post-test; pre = -22.9 ± 15.4%, 
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post = -9.0 ± 1.6%, p = 0.018). At follow-up V̇O2 peak improved by 3.4 ± 2.9 ml/kg/min in 
EVH+ players compared to 0.1 ± 2.3 ml.kg-1.min-1 in EVH- players. It was concluded that 
elite footballers have a high EIB prevalence and treatment with inhaler therapy reduces EIB 
severity and may also lead to improved exercise performance. 
In study 3 a three-part body of work with elite British swimmers was undertaken: (I) To 
investigate the effects of screening for EIB and treating appropriately on health and 
availability for training. (II) To monitor lung function, airway inflammation and respiratory 
symptoms in relation to a change in training environment from an indoor to an outdoor pool. 
(III) To report the findings of a systematic evaluation of total airway health in elite swimmers 
with EIB. A 75% prevalence of EIB was found in swimmers entering the GB funded 
programme. Treating this group with standard asthma therapy led to no differences in the 
percentage of time swimmers spent carrying out modified training in the 6 months post 
screening compared to the 6 months pre-screening (p = 0.17). No differences were found in 
FEV1 (p = 0.41), FeNO (p = 0.12) or PNIF (p = 0.67) in response to a change in training 
environment to an outdoor pool. Despite being prescribed treatment for EIB on assessment 
3 swimmers still demonstrated airflow obstruction at rest with bronchodilator reversibility 
of FEV1 by 12.9 ± 7.7% above baseline. FeNO was reduced compared to initial consult (pre: 
27.7 ± 15.1, post: 16.3 ± 6.5 ppb (p < 0.01). It was concluded that respiratory health in elite 
swimmers can be optimised through systematic assessment, however larger well controlled 
studies are still required to determine the impact of this approach upon performance and 
wellness. 
Study 4 investigated if a heat and moisture exchange mask (HME) face mask could be 
effective in protecting against EIB in response to a cycle challenge in a cold, dry environment 
(9°C, 24% RH) in asthmatic individuals. Seventeen participants completed three EXs on a 
cycle ergometer wearing either an HME mask (MASK), a sham mask (SHAM) or no mask 
(CON) in a randomised order. There was a significant difference in the % fall in FEV1 
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following EX (MASK: -6.00, SHAM: -10.00, CON: -13.00%, p <0.01), with the % fall 
following CON greater than that of MASK (p < 0.01).  Chapter 6 concluded that HME masks 
can attenuate EIB in individuals with asthma/ EIB when exercising in cold, dry 
environments.  
This thesis concludes that case detection programmes for EIB should be established for 
athletes training and competing in sports which put them at risk of developing EIB. Standard 
asthma therapy is effective in the treatment of EIB in athletes, however more work is 









The benefits of regular exercise for maintaining good health have long been known.  
Exercise is now even prescribed as medicine in the treatment of various chronic diseases 
including psychiatric, neurological, metabolic, cardiovascular and pulmonary disease, 
musculoskeletal disorders and cancer (Pedersen and Saltin, 2015). It might be expected 
therefore that elite athletes would be the healthiest of all populations, however, this appears 
not to be the case when looking at respiratory health: One in four athletes have been found 
to report troublesome respiratory symptoms such as cough, wheeze and dyspnoea (Turcotte, 
et al. 2003); UK primary care physicians report that they come across an amateur athlete 
with exercise related respiratory symptoms at a frequency of once a month (Hull et al., 2009); 
Respiratory illness has been the most common athlete illness within TeamGB at recent 
Olympic games (Palmer-Green and Elliott, 2015); and there is a wealth of evidence 
demonstrating a much higher prevalence of exercise induced bronchoconstriction (EIB) 
amongst elite British athletes (21 – 68% (Dickinson et al., 2005; Levai et al., 2016)) , than 
their recreational counterparts (13% (Molphy et al., 2014) ) and the general population 8 -
10% (AsthmaUK, 2014). 
Regular physical activity is recommended for asthmatic individuals, because although 
exercise cannot improve lung function, an improved level of cardiorespiratory fitness is 
thought to reduce the risk of exacerbation during exercise due to a reduced ventilation (Ram, 
2000) and exercise training may also have an anti-inflammatory effect in the lungs (Silva et 
al., 2010). At the opposite end of the spectrum however, it seems that there may be too much 
of a good thing and frequent, repeated periods of high ventilation in certain environmental 
conditions may in fact be disadvantageous to respiratory health (Weiss and Rundell 2011). 
EIB is defined as the transient airway narrowing that occurs in association with physical 
activity in susceptible individuals. EIB has been reported to have a negative impact on both 
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health (i.e. deterioration in condition), athletic performance  (Price et al. 2014; Stensrud et 
al., 2007; Brukner et al. 2007; Spiteri et al. 2014) and in severe cases heightened risk of 
mortality (Becker et al., 2004). With repeated exposure to high intensity exercise, coupled 
with potentially noxious training environments athletes are more at risk of developing EIB 
over the course of their careers (Knöpfli et al., 2007). These risk factors make EIB a 
particularly prevalent condition for many of the high participation sports in the UK such as 
swimming, athletics, cycling and football, where the ventilatory demand of the sport is high 
and training and competition often takes place the presence of aero allergens such as 
trichloramine, pollution, pollens and moulds. Such is the risk to endurance athletes in 
particular, one group has investigated if in fact this airway dysfunction in elite athletes 
should be classified as an occupational lung disease (Price et al., 2013). 
Regulatory bodies of sport have a mandate of care to athletes and as such when the 
International Olympic Committee – Medical commission (IOC-MC), noticed an apparent 
increased prevalence of asthmatic athletes, from an increasing trend in the notification by 
athletes for the use of inhaled short acting β2-agonists (SABA) (Fitch et al., 2008), they 
intervened. There were concerns that athletes without asthma or EIB were using SABAs, 
and to protect athlete health, in 2002 the IOC made it a requirement that any athlete wishing 
to use SABAs had to demonstrate evidence of asthma or EIB. The World Antidoping Agency 
(WADA) incorporate this into their Therapeutic Use Exemption Certificate (TUE) system 
and SABAs including salbutamol then remained on the prohibited list until 2010.  
These changes in regulations, did not affect the prevalence of asthma and EIB within 
TeamGB between the 2000 and 2004 Olympic games (Dickinson et al., 2005), but did serve 
to highlight EIB as a relevant health issue amongst athletes and lead to improved guidelines 
for the management of EIB in athletes (Fitch et al., 2008). By screening TeamGB athletes 
for EIB using bronchoprovocation challenges, Dickinson et al., (2005) identified a large 
number of athletes (21%) who had previously been misdiagnosed with EIB and conversely 
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a high proportion (9%) of previously undiagnosed athletes demonstrating evidence of EIB. 
The authors concluded that the implementation of the IOC guidelines amongst TeamGB 
athletes had led to an improved level of care to these athletes. 
The discrepancy between a prior diagnosis and objective evidence of EIB highlighted by 
Dickinson et al., (2005) is in part due to the non-specific nature of common respiratory 
symptoms such as cough, wheeze and dyspnoea. Research has consistently shown that 
respiratory symptoms during and after exercise correlate very poorly with objective evidence 
of airway narrowing (Rundell et al. 2001; Turcotte et al. 2003; Simpson et al., 2015). Despite 
clear guidelines created following the changes in the prohibited list (Carlsen et al. 2008; 
Fitch et al. 2008), following WADA relaxing the guidelines regarding SABAs in 2011, 
athletes continue to be misdiagnosed, with Ansley et al., (2012) reporting that 49% of elite 
footballers had an inappropriate diagnosis of EIB. Recent studies have also demonstrated a 
high proportion of athletes who are either asymptomatic or do not report respiratory 
symptoms as troublesome, when screened are susceptible to EIB (Dickinson et al., 2011; 
Molphy et al. 2014; Levai et al. 2016). 
Due to the high prevalence of EIB, the difficulties with  symptom diagnosis, its effect upon 
health and the potential impact on performance, some authors have called for screening for 
EIB to be implemented amongst athletic populations (Dickinson et al., 2005; Holzer and 
Brukner, 2004; Vakali et al., 2017). Before a screening programme can be put in place 
however, a number of stringent criteria must be met (Wilson and Jungner, 1968), which 
includes demonstrating the prevalence, having the ability to detect the condition of interest 
and also having an understanding of the impact in the population of interest (Wilson and 
Jungner 1968; Ansley et al., 2013; Hull et al. 2007; Hull and Rawlins 2016). 
The high prevalence has been demonstrated in many sports (Larsson et al. 1993; Mannix et 
al. 1996; Helenius et al., 1998; Dickinson et al. 2005; Levai et al. 2016). Many of these 
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studies however have small sample sizes and have been focussed primarily on Olympic 
sports. Due to the nature of EIB it would appear to be a relevant condition in many more 
high participation sports and as such further investigation is required in sports such as 
football.  
The best method and criteria to detect EIB remains somewhat debated. Eucapnic voluntary 
hyperpnoea (EVH) has been endorsed by the IOC-MC as the optimal bronchoprovocation 
challenge to diagnose EIB in elite athletes (Anderson et al., 2001) and has previously been 
reported to possess a high specificity and provide greater sensitivity in comparison to other  
airway challenges in the diagnosis of EIB in elite athletes (Dickinson et al. 2006; Holzer et 
al., 2002). However despite EVH often being termed as the gold standard, Hull et al., (Hull 
et al., 2016) suggested that the wide sensitivity and specificity along with apparent poor 
repeatability particularly in mild cases still prevent EVH from being termed the gold 
standard. There is also some discussion regarding the current 10% fall in FEV1 following 
EVH being indicative of a positive test for EIB, with some authors suggesting that a cut off 
of 15% might be a more appropriate threshold in athletes (Price et al. 2016). 
The impact of both untreated and treated EIB in athletes and the effects of both upon health 
and performance is largely unknown. Recommendations for the pharmacological treatment 
of EIB in athletes is predominantly based on guidelines for standard asthma care alongside 
expert opinion, due to the absence of adequately powered randomised clinical trials in elite 
athletes (Boulet and O’Byrne, 2015). Therefore, it is not known whether or not treating a 
screen detected athlete with EIB with standard asthma treatment will improve their airway 
health and reduce the risk of further exacerbation, potentially limiting disease progression. 
As well as the impact upon health, in an elite athletic population, there is the potential for 
EIB and its subsequent treatment to have a significant impact on performance and therefore 
livelihood. It is fairly well established that therapeutic dosing of inhaled asthma therapies 
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has no ergogenic impact in healthy individuals (Pluim et al., 2011; Dickinson et al., 2014; 
Kuipers et al., 2008). There is limited evidence however that left untreated, EIB may have 
deleterious effects of performance (Stensrud et al., 2007) and therefore treatment with 
appropriate therapy may improve performance in athletes with EIB. The small number of 
studies examining this have shown promising results (Haverkamp et al. 2007; Brukner et al. 
2007; Spiteri et al. 2014), however the paucity of evidence leaves a consensus unable to be 
drawn (Price et al., 2014).  
Addressing undetected and untreated EIB may also have an impact on an athlete’s general 
health. Upper respiratory tract infection (URTI) is the most common medical condition 
amongst athletes (Bermon, 2007) and there appears to be an association between a high 
prevalence of EIB (Bonini et al., 2015) and uncontrolled EIB  (Helenius and Haahtela, 2000) 
and recurrent URTIs. There are however no studies which have investigated the effect of 
treating EIB on overall wellness in athletes. 
This thesis will address some of the aforementioned gaps in the current body of knowledge 
to provide evidence that can be used to develop optimal strategies to manage EIB in athletes. 
Specifically, this thesis will look to investigate methods of diagnosing EIB, the impact of 
both short- and long-term standard asthma treatment upon airway inflammation, EIB 
severity, overall health and performance and the effect of reducing environmental exposure 




1.1 What is Exercise-induced bronchoconstriction (EIB)? 
“If from running, gymnastic exercises, or any other work, the breathing becomes difficult, it 
is called asthma” Aretaeus (81–138 AD) (Adams, 1856). 
This phenomenon is now known as Exercise-induced bronchoconstriction (EIB) and is 
defined as the transient airway narrowing that occurs in association with physical activity in 
susceptible individuals (Weiler et al., 2007). In EIB, bronchoconstriction will peak within 3 
to 15 minutes following exercise and then return to normal either spontaneously, usually 
within 30 - 45 minutes (Godfrey and Bar-Yishay, 1993), or with administration of treatment 
in the form of inhaled short acting β2-agonist (SABA). EIB can be a sign of uncontrolled 
asthma, however it can also occur in those without clinical asthma, particularly in athletes 
(Carlsen et al. 2008) and those with rhinitis or atopy (Bousquet et al., 2012). As such, 
although EIB has in the past been used interchangeably with exercise induced asthma (EIA), 
the Thoracic Society Clinical Practice Guidelines (Parsons et al., 2013) recommended 
abandoning the term ‘EIA’, because exercise triggers bronchoconstriction and does not 
induce the clinical condition of asthma. It is now widely accepted that EIB occurs in athletes 
without accompanying features of asthma, often in the absence of respiratory symptoms 
(Boulet and O’Byrne, 2015) and it is thought that EIB has particular pathologic and clinical 
features making it a distinct clinical entity from EIB with asthma (Couto et al., 2017). 
Consistent with this opinion, Haahtela et al., (2008) identified two distinct phenotypes in 
elite Finish athletes; ‘classical asthma’ characterised by childhood asthma, responsiveness 
to methacholine, atopy and eosinophilic airway inflammation  and ‘another distinct 
phenotype’ with late onset of symptoms, airway responsiveness to eucapnic voluntary 
hyperpnoea (EVH) but not always to methacholine, and a variable association with atopy 
and eosinophilic inflammation.  Using latent class analysis, Couto et al., (2015) agreed with 
this finding and also concluded that there are two distinct phenotypes of asthma in athletes 
‘atopic asthma’ (defined by the occurrence of atopy, increased levels of fraction of exhaled 
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nitric oxide (FeNO), rhinitis and other allergic co-morbidities) and ‘sports asthma’ (defined 
by the presence of exercise-induced respiratory symptoms and bronchial 
hyperresponsiveness (BHR) in the absence of allergic features). They also discovered that 
the type of sport in which an athlete participates was associated with the different 
phenotypes, with water and winter sport athletes having a three and nine-fold respectively 
increased risk of ‘sports asthma’. Indeed, a higher prevalence of EIB is seen within these 
sports (Dickinson et al., 2005) which supports the hypothesis that high intensity training, 
particularly in certain environmental conditions may lead an athlete to develop EIB.  
Within this thesis, EIB is used to define EIB without accompanying general asthma 
including both ‘atopic’ and ‘sports’ asthma defined by Couto et al., (2015) above. 
 
1.2 The pathogenesis of EIB 
The pathogenesis of EIB is multifaceted and is still not completely understood. Currently, it 
is widely accepted that it is the exercise induced increase in ventilation which leads to the 
changes in airway physiology. At rest, inspired air is warmed and humidified through heat 
exchange in the nasal cavity, however when minute ventilation (V̇E) exceeds approximately 
35 L/min there is a switch from a nasal to oral predominant breathing pattern (Niinimaa et 
al., 1980). As a result, during intense exercise where V̇E can exceed 150 L/min, the airways 
are compromised in their ability to condition the air and are exposed to an increase in 
unconditioned (relatively cold and dry) air and depending upon which sport is being 
practiced, this may also be coupled with increased penetration from environmental irritants 
such as airborne allergens, ozone and chloramines. This leads to  airway osmotic changes, 
epithelial injury, airway inflammation and neuronal activation (Couto et al., 2017) all of 





Figure 1.1. Mechanisms of EIB from Couto et al., (2017) 
 
Historically there have been two main concepts regarding the acute development of EIB; the 
‘osmotic’ and ‘thermal’ theories, both of which are built around the key factor being the 
increased ventilation leading to mucosal cooling and dehydration. Dehydration of the airway 
surface liquid (ASL) drives a local osmotic stimulus which causes cell shrinkage, triggering 
the release of inflammatory mediators such as histamine, prostaglandins, and cysteinyl 
leukotrienes from mast cells and eosinophils (Hallstrand et al., 2005), ultimately leading to 
airway smooth muscle contraction, airway obstruction (Anderson and Kippelen, 2005) and 
the release of mucus into the airways (Hallstrand et al., 2007). In addition, the thermal theory 
suggests that post exercise, following the cooling of the airways a rewarming takes place 
leading to vasodilation which contributes to the airway obstruction (McFadden  Jr, 1990). 
These mechanisms explain how EIB is triggered in susceptible individuals, however do not 
explain the occurrence of EIB in athletes with no evidence of general asthma. Recently a 
hypothesis of airway injury caused acutely by the osmotic and mechanical stress of exercise 
has been put forward to explain the development of EIB in elite athletes (Anderson and 
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Kippelen, 2008). Repeated bouts of exercise induced hyperpnoea, particularly in noxious 
environments have been shown to lead to a continuous cycle of injury and repair of the 
bronchial epithelium (Karjalainen et al., 2000). This results in an increase of cellular 
inflammatory mediators, proinflammatory cells, airway remodelling and increase airway 
hyperresponsiveness (Anderson and Kippelen, 2008; Kippelen and Anderson, 2012). These 
modifications to airway structure and function may play a key role in the increased 
prevalence of EIB in endurance athletes who often train and compete in asthmogenic 
environments. 
Airway smooth muscle is innervated by sympathetic and parasympathetic nerves and as such 
it has been suggested that dysfunction of the nervous system may contribute to the 
pathogenesis of EIB (Langdeau and Boulet, 2001).  During exercise, airway cooling causes 
parasympathetic stimulation leading to bronchoconstriction and increased cholinergic 
inflammation (Wessler and Kirkpatrick, 2008). The mechanism behind modulation of 
bronchial tone and the possible role in the development of EIB in athletes requires further 
investigation, however it is thought that intensive endurance training increases 
parasympathetic tonus and modulation as a compensatory response to the sympathetic 
stimulation associated with frequent, intense exercise (Goldsmith et al., 1997). This not only 
induces the well-known bradycardia in athletes but may also increase basal bronchomotor 
tone and it is this autonomic dysregulation which is thought to be an etiologic factor for EIB 
(Langdeau and Boulet, 2001). Couto et al., (Couto et al., 2015) found that amongst 
swimmers, a positive response to a methacholine challenge (PD20) was correlated with 
parasympathetic activity. Another group however concluded that this parameter showed 
only a weak correlation with PD20 and suggested that although parasympathetic activity may 
act as modulator of airway responsiveness, the increased prevalence of EIB observed in elite 
athletes is mostly due to the nature and content of the inhaled air and not exercise itself or 
neurogenic mechanisms. (Langdeau et al., 2000). 
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1.3 The prevalence of EIB 
There is substantial data showing that EIB occurs very commonly in athletes at all levels. 
EIB has been reported to affect around 8-10% of the general population in the UK 
(AsthmaUK, 2014), whereas recreationally active individuals have been shown to have a 
13% prevalence (Molphy et al., 2014) and in elite British athletes this number appears to be 
higher still; Dickinson et al., (2005) reported that the prevalence of EIB at the 2000 and 2004 
Olympics was 21.2% and 20.7% respectively, with the highest prevalence (~ 40%) in 
endurance athletes and more recently Levai et al., (2016) found that the prevalence of EIB 
within elite British swimmers was 68%, which appears to be the highest reported in any 
athletic group. 
With repeated exposure to high intensity exercise, coupled with potentially noxious training 
environments athletes are more at risk of developing EIB over the course of their careers. 
Knopfli et al., (2007) concluded that athletes develop EIB quickly, at a rate of increase 195-
286 times that of the normal rate for development of asthma. They assessed bronchial 
reactivity on three occasions over a two-year period in the Swiss national triathlon team; All 
athletes were free from respiratory disease at entry, but over the course of the study all 
developed incidence of increased bronchial reactivity and almost half developed EIB. As 
previously discussed, prolonged hyperpnoea along with environmental influences such as 
the presence of aero allergens play an important role in the development of EIB. This has 
implications for the top participation sports in the UK; Swimming, athletics, football and 
cycling (Sport England, 2016). In the UK athletes training and competing in running, cycling 
and football spend the majority of this time outdoors and over the course of a year will be 
exposed to varying environmental conditions: All athletes will be affected by poor air quality 
from pollution, cold and dry air and allergens such as pollens and moulds are also of concern 
to atopic athletes (Rundell and Sue-Chu, 2013). These sports also require high ventilation 
which enables more irritants to reach the distal airways.  
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There have been a limited number of studies looking into gender differences in the 
prevalence of EIB. It has been reported that female athletes have a higher prevalence of 
asthma than their male counterparts (Norqvist et al., 2015). However, despite a higher 
prevalence of respiratory symptoms in females, studies have shown no differences in 
evidence of EIB as assessed by a physician’s diagnosis (Romberg et al., 2017), mannitol or 
sports specific challenge (Pignataro et al., 2017). 
There is a wide range of prevalence of EIB reported in different sports around the world 
(Table 1.1). As well as this being down to differing demands of sports and the environments 





Table 1.1. Studies highlighting the prevalence of EIB in athletes 
 
Population n  Methodology Prevalence 
(%) 
Reference 
     
Olympic winter sport 
athletes 
170 Field test 23 (WILBER et 
al., 2000) 
Cross-country skiers 42 Methacholine 55 (Larsson et 
al., 1993) 
Cross-country skiers 171 Methacholine 14 - 43 (Sue-Chu et 
al., 1996) 
Figure skaters 124 Sports specific 35 (Mannix et 
al., 1996) 
National runners 32 Field test 25 (Helenius, et 
al., 1996) 
National swimmers 29 Histamine 48 (Helenius et 
al. 1998) 
National runners 58 Field test 9 (Helenius et 
al., 1998) 
Figure skaters 29 EVH & Sport 
specific 
55 (Mannix et 
al., 1999) 
Elite winter sport 
athletes 
158 Sports specific 26 (Rundell et 
al., 2001) 
Olympic summer sport 
athletes 
77 EVH 21 - 44 (Dickinson et 
al., 2005) 
Elite swimmers &  
winter sport athletes 
64 Methacholine 69 
28 
(V. Bougault 







(Levai et al., 
2016) 
Swimmers 16 EVH 50 (Pedersen et 
al. 2008) 
Professional footballers 54 Field test 7 (Mousinho et 
al. 2018) 
     
 




EIB and swimming 
Swimming is one of the most popular participation sports in the UK (Jones et al., 2011) and 
has been considered particularly beneficial for patients with asthma and other respiratory 
diseases due to the warm, humid pool environment lowering likelihood of EIB compared to 
other sports (Bar-Yishay et al., 1982; Bar-Or and Inbar, 1992). Amongst elite swimmers 
however, there is now a substantial body of evidence demonstrating a high incidence of 
respiratory disorders, including asthma, EIB, rhinitis and allergic diseases compared to the 
general population and other elite athletes (Helenius and Haahtela 2000; Levai et al. 2016; 
Bougault et al., 2010; Bougault et al. 2009). Whereas once thought the result of an early 
selection bias, due to the recommendation to parents of asthmatic children to take them 
swimming, a study of adolescent swimmers has also shown that elite swimmers do not begin 
their careers with EIB (Pedersen et al. 2008). It is thought that this high prevalence is likely 
to arise due to the combined effects of the high ventilatory requirement of swimming, the 
large training volume swimmers complete, and the noxious environment in which training 
is carried out (Bougault et al. 2009).  
Swimmers in the UK generally train in indoor pools all year round. This is a unique training 
environment not least because the majority of pools use chlorine as the main disinfectant 
agent and often have inadequate ventilation in place. Although effective in controlling 
microbial growth, chlorine reacts with nitrogen containing products in the water, such as 
urine and sweat resulting in the release of chloramines and nitrogen trichloride into the local 
atmosphere. Chloramines are heavy gases and will sit just above the water surface and it is 
these which have been suggested to be harmful for respiratory health (Drobnic et al. 1996). 
Swimmers inhale this air which is just above the water surface at high ventilation rates and 
Drobnik et al., (1996) found that the levels of chlorine a swimmer was exposed to in a two 
hour session was above that recommended for a worker in an eight hour shift.  
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Athletes who regularly train in chlorinated swimming pools for a prolonged period of time 
have a higher risk of developing respiratory health problems than the general population and 
non-aquatic elite athletes (Bougault et al. 2009). It has been proposed that with repeated 
exposure to trichloramine there may be a sensitisation process which induces airway 
inflammation (Anderson and Kippelen, 2008) and a recent finding by Bougault et al., (2012) 
showed that there was significant airway inflammation and remodelling on bronchial 
biopsies in swimmers similar to what is found in those with mild asthma. In contrast to 
indoor competitive swimmers in whom the prevalence of EIB has been found to be up to 
67% (Levai et al., 2016), sea swimmers are reported to demonstrate a much lower prevalence 
of 14% (Bonsignore et al., 2003), highlighting the potential  impact of the training 
environment. The phenomenon of high rates of airway hyperresponsiveness also appears to 
be transient in nature; Bougault et al, (2011) found that after a period of 15 days without 
intense swim sessions, airway responsiveness was significantly reduced and Helenius et al, 
(Helenius et al., 2002) reported that following retirement from competitive swimming 
heightened airway hyperreactivity appeared to resolve. 
In addition, to EIB, competitive swimmers have also been found to have a high prevalence 
of rhinitis, thought to occur due to chlorinated water irritating the nasal mucosa. Current 
thinking is that rhinitis precedes the development of EIB and managing rhinitis can improve 
asthma control (Brożek et al., 2017). The Allergic Rhinitis and its Impact on Asthma (ARIA) 
recommends that all patients with rhinitis are screened for asthma and as such Bonini et al., 
(2006) have suggested that this should be extended to athletes.  
 
Football and EIB 
The majority of previous research investigating EIB in athletes has focussed its attention on 
Olympic sports, however the risk factors for the development of EIB as previously discussed 
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make it a relevant condition for many more. Football is the world’s most popular sport and 
within the UK it is the sport with the highest number of professional athletes. The nature of 
elite level football suggests that EIB may pose a risk for this group of athletes; during a game 
elite footballers will cover between 10 – 13 km (Bangsbo et al., 2006), at an average work 
rate of approximately 70% V̇O2max (Bangsbo, 1994) resulting in a high ventilatory 
requirement. Players are also exposed to high training loads from a young age (Read et al., 
2016) whilst often training and competing in asthmogenic environments, for example in cold 
air, high pollen and in areas of high pollution. Despite this, very little is currently known 
regarding the nature of EIB in professional footballers. One small scale study suggested that 
the prevalence of EIB in football is likely to be around 30% (Dickinson et al., 2013) and 
demonstrated that the use of objective airway testing identified Premier League football 
players with EIB who had no previous history of asthma or EIB (Dickinson et al., 2013). 
Recent data has also demonstrated considerable level of mis-diagnosis of asthma/EIB in 
English Premier League and Championship footballers. Ansley et al., (2012) reported that 
only 33 of 65 (51%) Premier League and Championship level players who had received a 
previous diagnosis of EIB could provide a positive response to a bronchoprovocation 
challenge. This finding is striking and indicates professional football players reporting 
exercise respiratory symptoms are not always receiving adequate care.  
 
1.4 Respiratory symptoms and EIB 
Athletes frequently report respiratory symptoms during and after exercise, in particular 
cough, wheeze, chest tightness, dyspnoea and excess mucus production (Dickinson et al. 
2005; Dickinson et al., 2011).  Research has consistently shown however that respiratory 
symptoms during and after exercise correlate very poorly with objective evidence of airway 
narrowing, thereby limiting the accuracy of symptom based diagnosis (Rundell et al., 2001; 
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Dickinson et al., 2005).  In fact, when respiratory symptoms are used to diagnose EIB in 
elite football players independently of indirect airway challenges, they have been shown to 
result in 49% mis-diagnosis (Ansley et al., 2012). Despite this well-known discrepancy 
between the absence of symptoms and the presence of EIB, when questioned, one third of 
primary care physicians indicated that they would initiate treatment based on clinical 
information alone (Hull et al., 2009). It is common to encounter athletes who experience a 
significant reduction in lung function following exercise but perceive few respiratory 
symptoms; Turcotte et al., (2003) found that in a group of 698 athletes only a minority of 
asthmatic athletes reported troublesome respiratory symptoms and Simpson et al., (2015) 
found that self-reports of respiratory symptoms in conditions of induced and inhibited 
bronchoconstriction do not correlate with changes in airway calibre in athletes with EIB. 
This group found that 48% of the athletes they assessed reported at least one respiratory 
symptom despite their fall in FEV1 post bronchoprovocation challenge being blunted by the 
use of inhaled terbutaline, and in fact 28% had a higher symptom score when this fall was 
blunted. Despite this, some authors have shown that questionnaires could still provide a role 
in the diagnosis of EIB; Turcotte et al., (2003) concluded that questions on symptoms and 
associated nociceptive sensations may help to detect airway hyperresponsiveness (AHR), 
however for some athletes, in particular swimmers and triathletes, there is a risk of false 
negatives being observed. Price et al., (2016) built on this in their in depth qualitative 
approach to the assessment of breathlessness and discovered that there are several features 
which can differentiate between EIB and non-EIB causes of exertional dyspnoea in athletes. 
These are: The location of symptoms, recovery time following exercise and response to β2-
agonist therapy.  
To confound the problem with the diagnosis of EIB in athletes, baseline spirometry is also 
poorly predictive of EIB, in most cases being within the normal ranges with disease present 
(Bonini et al., 2007), or even above the predicted normal  (114 - 121%) (Rundell et al., 2001). 
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Thus, in order to establish a secure diagnosis of EIB it is important to perform objective 
testing to confirm dynamic changes in airway function (Parsons et al., 2013).  
 
2.5 Diagnosis of EIB 
As highlighted above the diagnosis of EIB cannot reliably be made by symptoms alone and 
as such requires objective testing by way of a bronchial provocation challenge. There are 
two main types of airway challenge; direct and indirect challenges both of which require 
measurement of lung function using spirometry before and after a challenge to monitor any 
changes in lung function. Direct challenges are predominantly used to exclude current 
asthma, when the test result is negative, whereas indirect challenges are more specific for 
the diagnosis of asthma and EIB, however are less sensitive in excluding asthma (Randolph, 
2011). 
 
Direct airway challenges 
The majority of direct challenges are pharmacological. In these a pharmacological agent 
such as methacholine or histamine is administered which acts directly on the airway smooth 
muscle receptors causing contraction in susceptible individuals (Holzer and Brukner, 2004). 
Methacholine directly interacts with muscarinic receptors on smooth airway muscle by 
mimicking the neurotransmitter acetylcholine, resulting in contraction and airway narrowing 
(Coates et al., 2017). During a methacholine challenge increasing doses of methacholine is 
delivered to the participant via a hand-held nebuliser. The initial dose of methacholine is 
inhaled and forced expiratory volume in 1 second (FEV1) measured at 60- and 90-seconds 
post with the highest value recorded. The dose of methacholine is then increased and FEV1 
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measurement repeated. This continues until either the fall in FEV1 reaches > 20%, or the 
participant reaches the maximal dose. 
A low sensitivity has been shown for methacholine in the diagnosis of EIB in summer 
athletes (Holzer et al., 2002). It is common however for winter athletes to be positive to 
methacholine but negative to either exercise, eucapnic voluntary hyperpnoea (EVH) or 
mannitol challenge (Rundell et al., 2004). Due to this disparity, Anderson and Kippelen 
(2012) warn against using methacholine in the diagnosis of EIB in athletes training and 
competing in cold or polluted environments. The reason behind this phenomenon is still 
unclear however it is thought that the hyperresponsiveness may be due to airway remodelling 
and an increase in parasympathetic tone to cold air (Anderson and Kippelen, 2005). Support 
for this hypothesis was shown in a study of cross country skiers who despite a positive 
methacholine challenge showed no improvement with inhaled corticosteroid  (ICS) therapy 
(Sue-Chu et al., 2000). 
 
Indirect airway challenges 
Indirect airway challenges include exercise, eucapnic voluntary hyperpnoea (EVH) and 
osmotic challenge tests such as mannitol and hypertonic saline. These stimuli act indirectly 
causing bronchoconstriction by contraction of the airway smooth muscle via the release of 
mediators such as prostaglandins, leukotrienes and histamines from inflammatory cells in 
the airways (Fitch et al., 2008). The response to indirect challenges has shown to be inhibited 
by inhaled corticosteroids (ICS) and as such this process is thought to be a result of active 
airway inflammation (Anderson, 2016). Indirect challenge tests require measurement of 
forced expiratory volume in one second (FEV1) prior to and following the challenge. The 
result of the challenge is determined by calculating the maximal percentage change in FEV1 
as a consequence of the challenge and this is used to determine the presence and also the 
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severity of EIB. Measurement of FEV1 is required as it has good repeatability (Enright et al., 
2004). At least two reproducible FEV1 manoeuvres are measured at set time intervals 
following the challenge, with the highest acceptable value recorded at each time point (Crapo 
et al., 2000).  
Osmotic challenges 
Osmotic challenge tests such as hypertonic saline and mannitol induce hyperosmolarity and 
hypertonicity of the airways in the absence of exercise, resulting in the release of 
inflammatory mediators that lead to bronchoconstriction (Holzer and Brukner, 2004). A 
mannitol challenge requires administration of increasing doses of dry mannitol powder 
through an inhaler device with spirometry measured after each dose. The threshold for a 
positive mannitol challenge is a fall in FEV1 of ≥15%, or a fall of ≥10% between consecutive 
doses (Anderson et al., 2009). This challenge has been shown to possess both sensitivity and 
specificity in the diagnosis of EIB in elite athletes (Holzer et al., 2003). Mannitol has the 
advantage that it can be performed with minimal equipment. The disadvantage of the 
Mannitol challenge is that is has been shown to provoke cough during testing, which on 
occasion can prevent participants from effectively inhaling the next dose (Brannan et al., 
2005). 
Exercise challenges 
Exercise challenge testing is often considered the most logical method to detect EIB, after 
all it is an ‘exercise’ induced condition. Despite clear guidelines however (Crapo et al., 2000; 
Weiler et al., 2016), there remains no single standardised protocol for exercise testing, 
meaning that there remains limitations when employing this approach in an athletic 
population. The  sensitivity of an exercise challenge is highly dependent on control over the 
two main contributors to the airway response: the water content of inspired air (Evans et al., 
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2005) and minute ventilation (V̇E) (Carlsen et al., 2000) and as such any challenge needs to 
make efforts to maintain strict control over these two variables.  
Laboratory exercise tests may be performed on a cycle ergometer or a treadmill. Early 
studies suggested that treadmill tests were preferable to cycling (Cropp, 1979), however, 
more recently cycle tests have proven effective, providing the work rate is able to raise V̇E 
to the target within four minutes of exercise initiation (Crapo et al., 2000). Current thinking 
suggests the best protocol to detect EIB in lab conditions with exercise is to achieve a rapid 
increase in exercise intensity over 2 – 4 minutes in an attempt to achieve a high level of 
ventilation and to continue this intensity for a further 4 – 6 minutes. As pulmonary ventilation 
is more closely related to the stimulus of bronchoconstriction than heart rate, it is suggested 
that V̇E is measured to guide exercise intensity. During the final 4 – 6 minutes of exercise, 
V̇E should be sustained between 40 – 60% of predicted maximal voluntary ventilation 
(MVV), calculated as FEV1 × 35 for a clinical population (Anderson, 2016) or > 25 times 
the FEV1 (70% MVV) in an athlete population (Anderson and Kippelen, 2012), or 80-90% 
of predicted maximal heart rate (220-age) (Bonini and Palange, 2015). Standardisation of 
exercise intensity is crucial as Carlsen et al., (2000) found that the mean fall in FEV1 after 
an exercise challenge was more than doubled after achieving 95% predicted maximum 
compared to 85%. It is vital also to maintain control over the water content of inspired air. 
Dry air is required for exercise challenges and a water content of 10 mg/L is recommended 
(Rundell and Slee, 2008) whilst a nose clip is worn to ensure oral breathing. Crapo et al., 
(2000) advises that this can be accomplished by using an air-conditioned lab with an ambient 
temperature of 20-25 °C and relative humidity of  ≤ 50%. To highlight this importance, 
Stensrud et al. (2006) demonstrated a 50% reduction in severity of EIB (24% and 12% falls 
in FEV1) when comparing exercise challenges in conditions of 40% and 95% RH at 20°C. 
As a way of controlling the water content of inspired air, some authors recommend using 
medical grade dry air (Anderson et al., 2010). Anderson et al., (2010); found that using a 
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standardised exercise challenge where participants inspired medical dry air, there was 
agreement in results of even mild responders to the exercise (< 15% fall in FEV1) when two 
exercise challenges were completed within four days.  
Standardised lab challenges may provide an insufficient stimulus to induce a positive 
response in some athletes, particularly if it is certain environmental conditions which appear 
to trigger bronchoconstriction in these athletes. As such, sports specific challenges can also 
be employed. For these challenges the same guidelines regarding the exercise intensity 
apply. Although this type of challenge is highly specific for the diagnosis of EIB, the 
disadvantages are the lack of control over the environmental conditions. However in one 
study by Rundell et al., (2000) a comparison of lab and field based challenges was carried 
out and they reported that in cold weather athletes, carrying out tests in the outdoor 
environment is important so as not to have a large number of false negative tests. The authors 
found that 18 (78%) of the cold weather athletes who demonstrated EIB positive following 
a field test, demonstrated no evidence of EIB following a laboratory challenge.  The lab 
conditions in this study however were 21°C and 60% RH and so were not as recommended.  
Exercise challenges whilst intuitive and highly specific may lack sensitivity if strict control 
of V̇E and water content of inspired air is not adhered to thereby creating the potential for 
high rates of false negative diagnoses. The lack of a standardised protocol for an exercise 
challenge may in part explain the wide range in the reported prevalence within specific sports 
and the reported rate of false-negative tests (Rundell et al., 2000). 
Eucapnic Voluntary Hyperpnoea EVH 
The variability in exercise tests prompted the development of surrogate methods which could 
more easily be standardised for use in a laboratory or clinic setting. Exercise itself was found 
not necessary to elicit an airway response and as such a challenge utilising eucapnic 
voluntary hyperpnoea (EVH) was developed by members of the US army (Hurwitz et al., 
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1995). A full detailed description of the EVH challenge can be found in chapter 2, however, 
in brief the EVH challenge requires ventilation of medical grade dry air containing 5% 
carbon dioxide (CO2), 21% oxygen (O2), and the balance nitrogen (N2). This concentration 
of gas has been shown to maintain normal end-tidal CO2 levels throughout the challenge. 
Six minutes of breathing at a high level of ventilation equivalent to 85% MVV (calculated 
by 30 ×FEV1) is used as a target for athletes to reduce the possibility of false negative results. 
Lung function is then measured for up to 15 minutes following the challenge. Because high 
ventilation can lead to large decreases in FEV1 EVH is recommended for use only in those 
who exercise regularly and intensely at high ventilation (Anderson et al., 2001), and 
guidelines state that an EVH challenge should not performed if resting FEV1 is less than 
70% of predicted (Weiler et al., 2016). EVH has previously been reported to possess a high 
specificity and provide greater sensitivity in comparison to other  airway challenges in the 
diagnosis of EIB in elite athletes (Dickinson et al., 2006; Holzer et al., 2002). On this basis, 
EVH has been endorsed by the International Olympic Committee Medical Commission 
(IOC-MC) as the optimal bronchoprovocation challenge to diagnose EIB in elite athletes 
(Anderson et al., 2001). Because of its high potency, EVH can be used to exclude EIB in 
elite athletes particularly in those with suspected dysfunctional breathing (Anderson and 
Kippelen, 2013). There are numerous advantages in using EVH to identify EIB in athletes, 






Table 1.2. Advantages to EVH as a bronchoprovocation method (Anderson et al., 2001) 
EVH is a potent challenge test for provoking bronchoconstriction in clinically 
recognised asthmatics responsive to exercise 
 
Symptoms provoked by EVH (cough, dyspnoea, and wheeze) are the same as those 
reported with exercise. 
 
EVH requires less expensive equipment and fewer personnel than exercise testing. 
 
EVH can induce V̇E equivalent to, or higher than most modes of exercise, and can be 
sustained over six minutes. 
 
The maximum airway response to EVH is similar to that achieved by exercise and 
occurs within the first 10 minutes of cessation of the hyperpnoea. 
 
As with exercise β2-agonists are effective in inhibiting the airway narrowing to EVH. 
 
As with exercise, inflammatory mediators, including histamine, prostaglandins and 
leukotrienes are involved in the response to EVH. 
 
EVH has a very high specificity for identifying persons with clinically recognised 
asthma. 
 
Guidelines are readily available on the standardisation, application, and interpretation of 
EVH testing. 
 
EVH has been used safely in many thousands of subjects. 
 
EVH has been used with some success to identify EIB in cold weather athletes. 
 
 
EVH, eucapnic voluntary hyperpnoea; V̇E, minute ventilation. 
 
Comparison of indirect challenges 
Several authors have carried out comparison studies between EVH and different exercise 
challenge for screening of EIB in athletes. Dickinson et al., (2006) reported that out of 14 
winter sports athletes tested, 10 were EVH positive, however only three were positive to a 
sport specific challenge (8°C and 35% RH or 1.5°C and 33%RH), and no athletes were 
positive to a lab based challenge (18°C and 56% RH). Rundell et al., (2004) also screened 
38 winter sport athletes for EIB; they identified 17 athletes by EVH and only 11 by exercise 
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challenge. Similarly, Mannix et al., (1999) compared an on ice skating challenge to EVH in 
29 ice skaters and found 12 skaters were positive by EVH, 9 by on ice testing and 5 
individuals were positive for EIB on both tests. The authors concluded that ‘for the 
evaluation of EIB in athletes who train and compete in cold environments, exercise testing 
in the cold air along with a challenge test such as EVH should be conducted to increase the 
yield of positive responders.’ 
Holzer et al., (2003) assessed the sensitivity of a mannitol challenge to identify 
responsiveness to EVH in 50 asymptomatic elite summer sport athletes, reporting that 
mannitol had a sensitivity of 96% and specificity of 92% to identify a positive response to 
EVH. This group used a 10% threshold however as opposed to the recommended 15%. In a 
comparison between mannitol, exercise and methacholine in 509 participants, Anderson et 
al., (2009) found that mannitol was equivalent to methacholine in identifying EIB, with the 
sensitivity and specificity being 59% and 65% respectively. The authors reported that there 
was a similar positive response for both exercise (43.5%), and mannitol (44.8%), with a test 
agreement of 62%. They concluded that in this group with mild EIB, the sensitivity and 
specificity of mannitol to identify EIB was lower than previously documented (Brannan et 
al., 1998). 
Eucapnic voluntary hyperpnoea is often quoted as the ‘gold standard’ challenge, however as 
exercise is the provocative stimulus to induce bronchoconstriction in athletes, the true gold 
standard may be a sport and environment specific exercise challenge. Such discrepancies in 
the methods above however show that a standardised, sensitive exercise protocol still needs 






Threshold for a positive test 
There remains some debate regarding which percentage fall in FEV1 defines a positive 
challenge indicative of EIB. Currently, a positive test for EIB when employing either EVH 
or EX is defined as a pre-to post challenge fall in FEV1 of ≥10% (Weiler et al., 2016). For 
elite athletes to demonstrate evidence of EIB, a decrease of 10% or more in the FEV1 is 
preferable at two consecutive time points post challenge, reducing the possibility of a false 
positive due to a reduced FEV1 immediately post challenge as a result of respiratory muscle 
fatigue (Johnson et al., 1993). EIB severity can be graded based on the percentage fall in 
FEV1 post EVH or exercise challenge, these grades are mild, moderate, or severe based on 
a percent fall in FEV1 of ≥ 10% to < 25%, ≥ 25% to <50% ≥ 50% respectively (Parsons et 
al., 2013).  
The 10% diagnostic threshold for a positive EVH test was proposed following  a study of 
army recruits with asthma (Hurwitz et al., 1995). This study demonstrated that a drop of 14% 
was 100% specific for asthma but had a sensitivity of only 53% and as such a threshold of 
10% was recommended on the basis of an improved relationship between specificity (90%) 
and sensitivity (63%). This 10% cut off is also the most widely used in exercise studies 
(Crapo et al., 2000). Hull et al., (2016) conducted an analysis of EVH test results from 860 
athletes across 12 studies and discovered a mean drop of approximately 9%. They noted that 
the large standard deviation of 8.4% may suggest that a greater fall in FEV1 from baseline 
may be more appropriate. A recent retrospective analysis of data from asymptomatic athletes 
also challenged the widely accepted 10% threshold suggesting that 15% might be a more 
appropriate threshold in this population (Price et al. 2016), particularly because they have 
found poor diagnostic reproducibility of EVH suggestive of mild EIB (10-15% fall in FEV1 
following EVH) has been demonstrated in recreational athletes over a short time period 
(Price et al., 2015). Others however, have found a good reproducibility of EVH at all 
severities in physically active participants in both the short term (21 days) and long term (70 
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days) (Williams et al., 2015). These discrepancies may in part be due to the transient nature 
of EIB (Cockcroft and Davis, 2006).  
It is not only the threshold for a positive EVH test which has been challenged, but also the 
response to exercise. The ‘normal’ response to exercise is mild bronchodilation (Todaro, 
1996) and as such, there have been suggestions that the criteria for a positive exercise 
challenge should be less than the 10% threshold originally suggested. A 6.5% fall in FEV1 
following an exercise challenge has been shown to be the threshold of an abnormal response 
in elite runners (Helenius et al., 1998), and a 7.1% fall in a population of winter athletes 
(Rundell et al., 2000).  
Anderson and Kippelen (Anderson and Kippelen, 2013) suggest that the appropriate cut-off 
for both EVH and Exercise will ultimately be dependent on the investigator’s need to be 
either more sensitive or more specific and whereas a 10% fall in FEV1 may be an appropriate 
threshold for demonstrating the need for inhaled β2-agonists for antidoping purposes, a value 
of 20% may be more appropriate for subjects to be included in clinical trials to assess new 
drugs for EIB. It would also be pertinent to consider whether or not small falls in FEV1 (~ 
10%) are of functional significance (Dickinson et al., 2006). 
 
1.6 Treatment for EIB 
Treatment for EIB can be broken down into pharmacologic and non-pharmacologic therapy. 
Recommendations for the pharmacological treatment of EIB in athletes is largely based on 
guidelines for standard asthma care and expert opinion, due to the absence of adequately 
powered randomized clinical trials in elite athletes (Boulet and O’Byrne, 2015), in fact 
Weiler et al., (2016) recommends using the recommended general treatment for asthma to 




The initial step in treatment for those with EIB and still the most common therapeutic 
recommendation for athletes is the administration of an inhaled short-acting β2-agonist 
(SABA) 15 - minutes prior to exercise. SABAs act on the adrenergic β2-receptors that are 
distributed in the lungs (primarily and heart and skeletal muscles) and relax the smooth 
muscle cells surrounding the airways, causing bronchodilation and relieving symptoms such 
as coughing, wheezing and chest tightness (Davis et al., 2008). The use of inhaled SABA in 
sports is restricted by anti-doping regulations. Over the years inhaled β2-agonists have 
alternatively been allowed and prohibited by the World Anti-Doping Agency (WADA). 
Currently the 2018 prohibited list it states “All selective and non-selective β2-agonists, 
including all optical isomers, are prohibited. Including, but not limited to: fenoterol, 
formoterol, higenamine, indacaterol, olodaterol, procaterol, reproterol, salbutamol, 
salmeterol, terbutaline, tulobuterol, vilanterol. Except: Inhaled salbutamol: maximum 1600 
micrograms over 24 hours in divided doses not to exceed 800 micrograms over 12 hours 
starting from any dose. Inhaled formoterol: maximum delivered dose of 54 micrograms over 
24 hours and inhaled salmeterol: maximum 200 micrograms over 24 hours.”  
Although still common practice, the advice for a SABA to provide the mainstay of treatment 
in an athlete should be obsolete (Price and Hull, 2014). Parsons et al., (2013) recommends 
that treatment for EIB should be stepped up if athletes ‘continue to have symptoms despite 
using an inhaled SABA before exercise, or who require a SABA daily or more frequently’. 
Discussion previously in this chapter showed that athletes rarely correctly recognise or 
identify the symptoms of EIB and elite athletes are often training twice daily. Furthermore, 
the sole use of SABAs can have adverse effects such as tremor and tachycardia and there is 





Due to the adverse effects of the sole use of SABAS, guidelines recommend that controller 
pharmacotherapy for athletes who have EIB should include daily inhaled corticosteroids 
(ICS) (Weiler et al., 2016). ICS are the most effective treatment of asthma and the only drugs 
which successfully supress airway inflammation in asthmatic airways. This suppression of 
inflammation is mainly achieved due to ICS switching off multiple activated inflammatory 
genes by reversing histone acetylation through the recruitment of histone deacetylase 2 
(HDAC2) (Barnes, 2010). 
Regular use of ICS has been shown to provide significant prevention against airway 
inflammation and bronchoconstriction in those diagnosed with mild airway 
hyperresponsiveness (Boushey et al., 2005) and to reduce the number and severity of 
exacerbations and thereby asthma mortality in asthmatics (Suissa et al., 2000). It is thought 
however that ICS may be less protective in elite athletes without asthma who experience 
EIB (Sue-Chu et al., 2000), but relatively few studies on the effect of ICS on EIB have been 
performed in athletes, and no studies have been carried out in elite athletes (Carlsen et al. 
2008).  
In moderate to severe EIB, combination therapy (an inhaler containing both an ICS and a 
long acting β2-agonist (LABA)) can have added benefit (Weiler et al., 2016). Combination 
therapy of fluticasone and salmeterol has been shown to be more effective than fluticasone 
alone in preventing EIB (Weiler et al. 2005; Reynolds et al., 2005) and Noonan et al., (2006) 
showed better asthma control with treatment of budesonide and formoterol in combination 
compared with budesonide alone. It is thought that this additive effect may be due to the ICS 
increasing the gene transcription of β2-receptors, resulting in increased expression of cell 
surface receptors (Barnes, 2010). The drawback of these studies is that they were all 
conducted in an asthmatic population.  
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Leukotriene receptor antagonists (LTRAs) are an additional add on therapy. LTRAs are a 
non-steroidal oral medication and have both bronchodilator and anti-inflammatory effects 
which are as a result of by interfering with the activity of leukotrienes. LTRAs act by 
blocking the specific leukotriene receptors on bronchial tissue, preventing 
bronchoconstriction, mucus secretion, and oedema. They also reduce the influx of 
eosinophils, which acts to limit inflammatory damage in the airway. Daily therapy with 
montelukasts have also been found to reduce EIB (Duong et al., 2012), particularly when 
caused by exposure to pollutants (Rundell et al., 2005). Steinshamn et al., (2002) 
demonstrated that montelukast reduced the maximum post-exercise fall in FEV1 and in 
addition improved the running time to exhaustion in 11 of 16 adults with EIB. However, 
Helenius et al. (2004) could not find any effect upon asthma-like symptoms in response to a 
histamine challenge or fraction of exhaled nitric oxide (FeNO) in 16 ice-hockey players with 
EIB using a randomized placebo-controlled cross-over study.  
 
Treatment for coexisting conditions 
It is also important that athletes are treated for any co-existing conditions. Conditions and 
symptoms such as nasal obstruction, rhinorrhoea, sneezing, congestion and itching are 
reported by 74% of competitive elite swimmers (Bougault et al., 2010). The ‘united airways 
disease’ theory (Rimmer and Ruhno, 2006; Daabis, 2016) suggests that it is a single 
inflammatory process within the respiratory tract which leads to manifestations in both the 
upper and lower airways. As previously discussed, it is recognised that chronic rhinitis is a 
contributing factor to the development of asthma and may affect its control (Pedersen and 
Weeke, 1983), as such in the case of athletes with rhinitis, nasal inhaled glucocorticoids and 
nasal ipratropium antihistamines may be considered. It should be understood however these 
are not effective against EIB (Boulet and O’Byrne, 2015). 
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Does therapy have an ergogenic action? 
With the increase in the number of athletes using inhaled β2-agonists and the changes with 
the exclusion/ inclusion on the WADA prohibited list, there have been questions as to 
whether asthma therapy, in particular β2-agonists have performance enhancing effects. Many 
studies have been conducted using non-asthmatic, well-trained individuals and a systemic 
review by Pluim et al. (2011) concluded that ‘no significant effects were detected for the 
inhaled β2-agonists salbutamol, formoterol, terbutaline or salmeterol on aerobic or anaerobic 
capacity or strength in healthy athletes. Additionally, more recently Dickinson et al., (2014) 
reported that there was no improvement in 5 km time-trial performance following the 
inhalation of up to 1600 µg of salbutamol in non-asthmatic athletes, and a study by  Kuipers 
et al., (2008) investigating the effect of four weeks of ICS or placebo inhalation in healthy, 
well-trained athletes found no effect on maximal power output or mood state.  
 
Non-pharmacological therapy 
Alongside pharmacological interventions, there are a number of alternative ways in which 
an athlete may be able to reduce EIB severity and exacerbations.  
Warm-up 
A pre-exercise warm up is well documented to lead to a significant reduction in post exercise 
bronchoconstriction in some athletes (Elkins and Brannan, 2013; Stickland et al., 2012). This 
has been attributed to a refractory period during which time the airways are less likely to 
constrict again. It is thought that this is induced by the release of prostaglandins and airway 





Dietary modification may have the potential to reduce the severity of EIB (Mickleborough, 
2008) and a number of dietary factors have been investigated because of their role in 
inflammatory reactions, activities of airway smooth muscle and modulation of pulmonary 
and microvascular volume and pressure. In a recent review Dickinson et al., (2018) showed 
that there are numerous dietary factors which may have the potential to effectively reduce 
the severity of EIB, including; Omega-3 fatty acid supplementation, vitamin and antioxidant 
supplementation and caffeine. The majority of these studies however have been conducted 
on subjects with mild to moderate persistent asthma, who also exhibited EIB. Despite this 
Weiler et al., (2016) suggest that although evidence is weak, consideration of the reduction 
of sodium intake and supplementation with fish oil and vitamin C should be made. 
Avoidance of triggers 
Avoidance of potential triggers is standard advice given to asthma patients to control EIB. It 
is impossible for athletes to avoid training particularly in environmental conditions such as 
cold, dry, high pollen levels or pollutants, however where possible it is recommended that 
athletes avoid training in areas with levels of high pollution or particular allergens to which 
they know they are sensitised (Kippelen et al., 2012). The pool environment in which 
swimmers train in should also be optimised for example by ensuring adequate ventilation 
(Bougault and Boulet, 2012).  
Facemasks 
An increase in temperature and water content of inspired air has long been shown to prevent 
EIB in asthmatic subjects (Chen et al., 1979). One method of increasing inspired air 
temperature thereby potentially diminishing airway dehydration is by the use of a face mask.  
There are a number of studies which have investigated the use of facemasks and have shown 
a protective effect against EIB, following exercise (Beuther and Martin 2006; Brenner et al. 
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1980; Millqvist et al., 2000; Nisar et al. 1992). However, Parsons et al., (2013) suggest 
recommendations to use facemasks are weak based on the current availability of low-quality 
evidence. Finally, education of an athlete with EIB is a crucial element and should include 
EIB self-management and inhaler use and technique (Page et al., 2017). 
 
1.7 Impact of treating athletes for EIB 
There are numerous studies regarding the high prevalence of EIB in athletes and the potential 
mechanisms for its development. Despite this however, there is a distinct lack of well-
designed studies investigating the impact of treating EIB or what the consequences may be 
of leaving EIB untreated on both health and performance.  
 
Impact on health 
Undetected and uncontrolled EIB can lead to fatal consequences in both elite and sub-elite 
athletes (Becker et al., 2004).  Left untreated, an element of irreversible airflow obstruction 
may also develop, which is thought to be the result of chronic inflammation (Barnes, 2010). 
An association between uncontrolled asthma/ EIB has also been suggested to predispose 
athletes to upper respiratory tract infection (URTI) (Helenius and Haahtela, 2000). In the 
general population asthma is associated with an increased incidence of pneumococcal 
disease and pneumonia, with a decreased risk when asthma is well controlled (O’Byrne et 
al., 2013). However, there are no studies investigating the effects of treating EIB in athletes 





Impact on performance 
Left untreated, EIB may also have deleterious effects of performance; Stensrud and 
colleagues (Stensrud et al., 2007) reported impaired oxygen uptake in individuals with EIB, 
however in a cohort of army recruits EIB was found not to hinder physical performance 
including peak oxygen uptake (Sonna et al., 2001).  
As previously discussed in this chapter, there appears to be no or limited ergogenic effect of 
asthma/ EIB therapy in healthy athletes. There are very few studies however in athletic 
populations with EIB. This lack of literature was recently highlighted by Price et al.,  (2014) 
who concluded that although it would seem logical that EIB would affect performance, there 
is not sufficient evidence to give a definitive answer. In fact, there was such little evidence 
that the authors reported an n = 0 of studies which could be included in their meta-analysis. 
EIB may compromise not only performance during competition but the capacity to train 
effectively (Mannix et al., 2003). It has been hypothesised that airway narrowing during 
exercise compromises ventilatory capacity and efficiency; Haverkamp et al., (2007) showed 
that bronchoconstriction during and following exercise can result in reduced exercise 
performance, alveolar ventilation and efficiency of alveolar-to-arterial blood O2 exchange 
and Price et al., (2014) provided a detailed discussion as to the potential mechanisms for the 





Figure 1.2. Potential mechanisms for the performance impact of EIB (Price et al., 2014). 
 
The acute effect of treatment on performance in athletes with EIB has been examined in a 
limited number of studies; Koch et al. (2013) concluded that the inhalation of salbutamol 
induced a significant increase in resting lung function in EVH positive and negative athletes, 
but this improvement did not translate to improved exercise performance. There were 
however several limitations to this study: although athletes were asked to withhold β2-
agonists for at least 12 hours prior to arriving at the laboratory, they were allowed to continue 
their ICS treatment and it is well known that ICSs taken on a daily basis may reduce the 
severity of EIB (Subbarao et al., 2006). Athletes were wearing a facemask during their 
performance, which may have reduced any EIB (Millqvist et al., 2000). Athletes were also 
allowed a warm up prior to their performance trial, and prior warm is known to induce a 
refractory period for around 4 hours. Conversely, although inhalation of SABA in permitted 
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doses, did not improve swim performance in elite swimmers, swim ergometer sprint 
performance has been found to increase (Kalsen et al., 2014).  
There is a paucity of studies looking at the long-term effects of standard asthma preventative 
treatment. Haverkamp et al., (2007) showed that in habitually active asthmatic participants 
treatment with ICS significantly improved arterial blood oxygenation in exercise. 
Furthermore, all but one subject in the ICS treatment group was able to exercise longer in a 
time to exhaustion trial after treatment. From a very small number of studies there appears 
be a potential positive impact upon aerobic performance when athletes with EIB are treated 
with standard therapy. Brukner et al. (2007) found that Australian rules football players with 
newly diagnosed EIB had a significant improvement (9%) in the V̇O2 max following six 
weeks of treatment compared to controls. In addition, Spiteri et al., (2014) demonstrated that 
appropriately medicating elite rugby players with previously undiagnosed EIB improved 
their performance in a rugby specific aerobic exercise challenge by 8% over the course of 
12 weeks compared to 6% in the control group, however this was not a statistically 
significant finding and both of these studies had a small number of participants.  If this 
performance benefit is demonstrated additional encouragement for sports to look after the 
respiratory health of their athletes may be provided. 
 
1.8 Should we screen for EIB? 
Due to the high prevalence of EIB, its effect upon health and the potential impact on 
performance, some authors have called for screening for EIB to be implemented (Dickinson 
et al., 2005; Holzer and Brukner, 2004; Vakali et al., 2017). Screening for EIB in an athletic 
population may be important, mainly due to the difficultly in relying on symptoms as a 
method of diagnosis as discussed previously in this chapter. 
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Numerous studies have shown that screening for EIB using objective testing identifies EIB 
in asymptomatic athletes with no asthma history who may benefit from treatment: Dickson 
et al., (2011) screened 228 elite athletes using EVH and found 78 (34%) presented as EVH 
positive (EVH+), 57 (73%) of whom had no previous history. The same group (Dickinson 
et al., 2013) also found a similar prevalence in a small sample of English premier league 
football players; 29% demonstrated as EVH+ and 66% of these players had no prior history. 
Recently 67% of swimmers with objective evidence of EIB had no previous history, whereas 
12% of the swimmer who had no objective evidence of EIB had a prior diagnosis of asthma/ 
EIB (Levai et al., 2016). More alarmingly Ansley et al., (2012) found that almost half of the 
professional football players they tested with a physician’s diagnosis of asthma/EIB 
presented no objective evidence of either condition. 
There are implications for both the under and over diagnosis of EIB. Being susceptible to 
EIB means an athlete may be vulnerable to exacerbations and evidence suggests that a high 
proportion of asthma related deaths occur in high level athletes in conjunction to training 
and competition (Becker et al., 2004; Lang, 2005). Asymptomatic EIB as well as being 
associated with airway inflammation and remodelling has also been linked to an increased 
risk for the later development of asthma (Boulet, 2003) and as such the timely detection and 
treatment of EIB may prevent this.  
Failing to implement appropriate treatment presents a potential for deterioration and 
exacerbation of EIB, however there are also implications when prescribed medication is 
prescribed unnecessarily. The long term use of SABAs have been associated with 
degenerative changes in lung function and the development of tachyphylaxis (Bonini et al., 
2013) and appropriate diagnosis would also enable athletes to seek treatment for differential 
diagnoses where necessary which often present with asthma like symptoms (Hull, 2015).  
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Before a screening programme can be put in place, a number of stringent criteria must be 
met (Wilson and Jungner, 1968), this includes demonstrating the prevalence, having the 
ability to detect the condition of interest and an understanding of the impact in the population 
of interest (Wilson and Jungner 1968; Ansley et al., 2013; Hull et al. 2007; Hull and Rawlins 
2016). In the ATS workshop report regarding screening for asthma (Gerald et al., 2007) it 
was concluded that although the adoption of case detection programmes were unwarranted 
due to a lack of evidence, it was felt that ‘limited case detection programmes may be 
appropriate in areas where there is a high prevalence of undiagnosed asthma and where 
newly identified patients have access to quality care’. This report looked at a population of 
children but could also be relevant to elite athletes. Parsons et al., (2013) reported that they 
were unable to find any well conducted studies evaluating the overall efficacy of screening 
programmes for EIB on either health or performance in athletes.  
 
1.9 Summary 
It is clear that there is a high prevalence of EIB in the elite athlete population, with this 
prevalence seemingly particularly high in the UK amongst swimmers and athletes who train 
outdoors all year round, in sports with a high ventilatory demand. Much work has been 
undertaken into the mechanisms of how EIB occurs in this population, however what isn’t 
clear is how best to make a firm diagnosis and manage these athletes appropriately to 
optimise both their health (short and long term) and their sporting performance. There are 
already best practice guidelines in these areas, however much of these are founded on 
guidance for care in a general asthmatic population and expert opinion. Based on previous 
evidence for screening for EIB in the athletic population, more work needs to be undertaken 




1.10 Aims and Hypotheses 
The overall aim of this thesis was to investigate the optimal way to diagnose and manage 
EIB within an athletic population. More specifically the main aims were to: 
1. Investigate if a positive EVH test is predictive of a positive standardised exercise 
challenge. 
2. Investigate the impact of appropriate standard asthma therapy on airway inflammation, 
EIB severity, performance and wellness in athletes with screen detected EIB. 
3. Investigate the effect of methods to reduce exposure to an asthmogenic training 
environment upon airway inflammation, EIB severity, and athlete wellness. 
It was hypothesised that: 
1. A positive EVH challenge would be predictive of a positive exercise challenge.  
2. Treatment with appropriate standard asthma therapy would reduce airway inflammation, 
decrease EIB severity, improve exercise performance and increase athlete wellness. 
3. Reducing exposure to an asthmogenic training environment would lead to a reduction of 
























This chapter describes the general methods used in the respiratory assessments in the 
experimental chapters of this thesis. These details are for methods common to two or more 
chapters. Tests and procedures which are used only in one chapter are defined within the 
chapters themselves. 
 
2.0 Preparation for respiratory assessment 
Participants were asked to adhere to the following criteria in preparation for testing: They 
were required to be free of any chronic medical condition apart from asthma or EIB, and free 
of any respiratory infections for four weeks prior to assessment (Bolger et al., 2011; Spiteri 
et al., 2014; Levai et al., 2016). Participants were required not to undertake any exercise for 
at least four hours before their assessment. This was because following exercise, there may 
be a refractory period which occurs (McNeil et al., 1966) and Edmunds et al. (1978) 
demonstrated that it is at four hours following exercise that the initial airway response to an 
exercise challenge is re-established. Participants were instructed not to consume any food or 
beverages containing caffeine in the morning of their assessment as caffeine has been found 
to decrease bronchoconstriction following eucapnic voluntary hyperpnoea (EVH) (Duffy 
and Phillips, 1991) and moderate to high doses of caffeine have been found to be as effective 
as albuterol in providing a protective effect against exercise induced bronchoconstriction 
(EIB) (Vanhaitsma et al., 2010). In addition, participants with a prior diagnosis of asthma 
and/ or EIB were required to withhold medication for the relevant time (Table 2.1) to ensure 
wash out of their medication. The exception to this was in experimental chapters where 
repeat testing occurred to look at asthma/ EIB control and this is highlighted within the 
relevant chapters. Finally, participants were advised not to consume a large meal within 2 
hours prior to their assessment to ensure comfort during spirometry and any use of nitrate 
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supplementation was recorded due to their potential to elevate fraction of exhaled nitric 
oxide (FeNO) (Kroll et al., 2017). 
 
Table 2.1. Required times to withhold medication use prior to respiratory assessment 
(Anderson et al. 2001; Dickinson et al., 2011) 
Medication Minimum time to withhold medication 
Inhaled SABA, sodium cromoglicate, 
nedocromil sodium or ipratropium 
bromide. 
8 hours 
Inhaled LABA or antihistamines 48 hours 
ICS  72 hours 
LTRA  4 days 
 
SABA, short acting β2-agonists; LABA, long acting β2-agonists; ICS, inhaled 
corticosteroids; LTRA, leukotriene receptor antagonists. 
 
2.1 Respiratory assessment 
 
Assessment of respiratory symptoms 
Prior to respiratory assessments participants were asked to complete a questionnaire 
(appendix 1) which asked if they experienced coughing, chest tightness, dyspnoea or excess 
mucus during or after exercise and if exposure to the cold, dry air, high pollen levels, high 
pollution, altitude or any other environmental conditions exacerbated these symptoms 
(Dickinson et al., 2011). 
64 
 
Assessment of airway inflammation 
Airway inflammation was assessed by determining the fraction of exhaled nitric oxide 
(FeNO) using a NIOX VERO (NIOX, Aerocrine, Sweden). Nitric oxide is a gaseous 
molecule is produced in the airways and therefore present in exhaled breath. Within the 
respiratory system, NO regulates vascular and bronchial tone, acts as a neurotransmitter for 
non-adrenergic and non-cholinergic neurons in the bronchial wall and facilitates the 
synchronised beating of ciliated epithelial cells. It is formed by the action of one of three 
isoforms of the enzyme nitric oxide synthase (NOS); namely endothelial (eNOS), inducible 
(iNOS), and neuronal (nNOS) (Hart, 1999). In atopic asthmatics high concentrations of NO 
have been found in expired air due to the upregulation of iNOS in the respiratory epithelium 
by pro-inflammatory Th2- cytokines interleukin (IL)-4 and IL-13 (Alving and Malinovschi, 
2010). FeNO has previously been regarded as a surrogate marker of eosinophilic airway 
inflammation, however it is now thought FeNO is more representative of the Th2-driven 
local inflammation, specifically of the bronchial mucosa, rather than general eosinophilic 
inflammation (Bjermer et al., 2014). Measuring FeNO has been found useful to distinguish 
asthma from other respiratory conditions, assess the etiology of respiratory symptoms 
(Dweik et al., 2011), to predict responsiveness of treatment with inhaled corticosteroids 
(Smith et al., 2005) and it also correlates with bronchial hyperresponsiveness and atopy 
(Tinkelman et al., 2009) rendering it a useful marker of airway health. 
Assessment of FeNO was performed in accordance with ATS/ERS recommendations 
(Dweik et al., 2011). Participants remained seated and were instructed to put the NIOX 
mouthpiece between their lips forming a tight seal and to inhale fully. They were then 
instructed to exhale against the slight resistance of the machine for 10 seconds at a steady 
rate (a flow rate of 50 mL˙s-1 + 10% at a pressure of 16 cmH2O) guided by an on-screen 
animation. This test was performed in duplicate and a mean of the two measurements 
recorded. Interpretation of results was as follows: <25 ppb Normal; eosinophilic airway 
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inflammation unlikely. 25-50 ppb Elevated; eosinophilic airway inflammation likely. >50 
ppb High; eosinophilic airway inflammation significant (Dweik et al., 2011).   
 
Assessment of maximal lung function 
Lung function was assessed by maximal flow volume spirometry using a Spiro-USB and 
MicroLab software (CareFusion, Germany). Prior to each day of testing, and after 4 hours 
of use the spirometer was calibrated using a 3 L syringe at three different flow rates; low, 
medium and high (0 - 0.9 L/s, 1.6 - 4.5 L/s and 7 - 12 L/s respectively), with the procedure 
repeated three times at each flow rate. Verification was accepted if the accuracy of the 
volume was within 3% at all flows. 
Prior to testing, participants were assessed for any contraindications to spirometry (Table 
2.2) and excluded from participation where necessary. Spirometry was performed in 
accordance with ATS/ERS recommendations (Miller et al. 2005). The full procedure was 
first explained to the participant and a demonstration provided. Participants were asked to 
sit in an upright position throughout the manoeuvre. They were instructed to take a deep 
breath, ensuring they reach total lung capacity. Without pausing, they sealed their lips around 
the mouthpiece and exhaled with the maximum possible effort, continuing to exhale to 
residual volume. On reaching residual volume, they finally inhaled maximally to total lung 
capacity. A soft nose clip was worn to prevent air escaping through their nose and 
encouragement was provided throughout to ensure maximal effort. Measurement was 
repeated with a minimum of 30 seconds rest in between efforts until three acceptable (Miller 
et al. 2005) attempts had been obtained (Table 2.3), with a maximum of eight attempts 
performed.  
For each flow-volume manoeuvre the following parameters were recorded: forced expiratory 
volume in one second (FEV1), forced vital capacity (FVC), peak expiratory flow (PEF) and 
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FEV1: FVC ratio (FEV1/FVC). The best of the three acceptable measurements of FEV1 and 
FVC were selected in accordance with the acceptability criteria in Table 2.3. 
 
Table 2.2. Contraindications to spirometry extracted from Cooper (2011)  
 
Contraindication Recommendation Reason 
Thoracic/ abdominal 
surgery 
Relative Rupture of injury site, pain, 
discomfort 
Brain/ eye/ear/ EN 
surgery 
Relative Rupture of injury site, pain, 
discomfort 
Pneumothorax Relative Worsen pneumothorax, 
pain, discomfort 
Myocardial infarction Absolute/ relative Induce further infarction 
leading to cardiac arrest 
Ascending aortic 
aneurysm 
Absolute/ relative Rupture of aneurysm, 
catastrophic/ fatal event 
Haemoptysis Absolute/ relative Pulmonary emboli or 
myocardial infarction 
Acute diarrhoea Relative Discomfort, embarrassment, 
infection risk 
Angina Absolute/ relative May lead to cardiac arrest in 
severe cases, discomfort 
Severe hypertension 
(systolic > 200mm Hg, 
diastolic > 120 mm Hg) 
Measure BP before 
if suspected 
Risk of blackout/ collapse, 
rupture of cerebral blood 
vessels 
Confusion / dementia Balance need for test 
against obtaining 
results 
Lung function tests are 
volitional and require 
patient cooperation 





Table 2.3. Criteria for acceptable flow volume loops, from Miller et al., (2005) 
 
Within-manoeuvre criteria Between-manoeuvre criteria 
Free from artefacts: 
Cough during the first second of exhalation 
Glottis closure that influences the 
measurement 
Early termination or cut-off  
Effort that is not maximal throughout  
Leak 
Obstructed mouthpiece 
They have good starts: 
Extrapolated volume <5% of FVC or 0.15 L, 
whichever is greater 
They show satisfactory exhalation: 
Duration of 6 s or a plateau in the volume–
time curve  
The two largest values of FVC must be 
within 0.150 L of each other  
The two largest values of FEV1 must be 





Eucapnic voluntary hyperpnoea (EVH) 
As discussed in Chapter 1, eucapnic voluntary hyperpnoea (EVH) is a surrogate for exercise 
and has previously been reported to provide greater sensitivity in comparison to other  airway 
challenges in providing a diagnosis of EIB (Dickinson et al. 2006; Holzer et al., 2002). On 
this basis, EVH has been endorsed by the International Olympic Committee Medical 
Commission (IOC-MC) as the preferred bronchoprovocation challenge to diagnose EIB in 
elite athletes (Anderson et al., 2001). 
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EVH challenges were performed using the methods described by Anderson et al., (2001) 
following baseline spirometry to establish maximal lung flow volume loops. An EVH 
challenge was not performed if a participant’s baseline FEV1 was less than 70% of predicted 
normal for age, gender and height (Weiler et al., 2016). In this case they instead performed 
a reversibility challenge as described below. The target V̇E the participant was required to 
reach during the EVH challenge was 85% of their maximal voluntary ventilation (MVV). 
This was calculated by  multiplying their best baseline FEV1 by 30 (Argyros et al., 1996) to 
establish a target V̇E. Participants were seated in front of the EVH set up (figure 2.1) and 
sealed their lips around the mouth piece, they also wore a soft nose clip. Participants inspired 
a medical grade dry gas comprising 5% CO2, 21% O2 and 74% N2, <2% RH at 19°c (BOC, 
UK). The 5% CO2 is to ensure eucapnia is maintained and reduce the chances of 
experiencing adverse effects from prolonged hyperventilation such as syncope or light-
headedness. Participants were instructed to breathe ‘hard and fast’ for 6 minutes, aiming for 
the target V̇E. Encouragement was provided throughout, and participants were able to see 
the elapsed time and the total volume of expired air through the dry gas meter. V̇E was 
recorded throughout and a minimum threshold for an acceptable test was considered if the 
participant achieved at least 60% of their predicted MVV (Anderson et al., 2001). 
On completion of the EVH challenge, maximal flow volume loops were measured in 
duplicate at 3, 5, 7, 10 and 15 minutes using the methodology described above and the 
highest FEV1 at each time point recorded. The test was deemed positive if there was a fall 
in FEV1 of ≥ 10% from baseline at two consecutive time points (Hurwitz et al., 1995). At 
this point 4 ×100 µg of inhaled salbutamol was self-administered using a metered dose 
inhaler (MDI) and spacing device (van der Palen et al., 1995)  after which maximal flow 
volume loops were recorded 15 minutes post inhalation. Severity of EIB was classified as 
mild, moderate or severe dependant on the fall in FEV1 post EVH: ≥10% to <25%, ≥25% to 
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<40% and ≥40% respectively (Anderson and Kippelen, 2013). Participants were required to 
remain in the laboratory until their FEV1 had returned to within 10% of baseline.  
 
1: Medical grade dry air. 2: Gas regulator. 3: High pressure tubing. 4: Flow meter. 5: 
Reservoir. 6: Flexible 35mm tubing. 7: Mouthpiece attached to chamber with one-way valve. 
8: Dry Gas Meter 
Figure 2.1. EVH set up 
 
Exercise Challenge 
Within the experimental chapters of this thesis two exercise challenges have been utilised. 
Two slightly different methods were used as the first was designed as a one-off diagnostic 
test and the second was within a study which required an initial V̇O2peak test. The cycle 
ergometers used, and the environmental conditions of the environmental chamber also 
differed. Described below is the general methodology employed for exercise testing and the 
differing details are defined within each chapter. 
An exercise challenge would appear to be the logical choice of test to diagnose an exercise 
induced conditions, however, despite clear guidelines (Crapo et al., 2000; Weiler et al., 2016) 
there remains a lack of one definitive standardised test. We followed recommended 











medical grade dry air. A cycling challenge was decided upon due to the facilities available 
to us and the practicalities of administering the challenge. 
As described for the EVH challenge above, baseline spirometry was performed to establish 
maximal lung function. Exercise challenges were conducted in an environmental chamber 
(TIS Services, Hampshire, UK) on a cycle ergometer. Following a standardised four minute 
incremental warm up, participants were given a target power output which was then 
maintained for the final six mins of cycling at this work rate. There was no break between 
the warm up and the main challenge and the warm up was purposely short to ensure that no 
refractoriness occurred. Heart rate was recorded throughout (Polar RS400; Polar Electro Oy, 
Kempele, Finland) and V̇E was recorded for the final six mins of exercise via expired air 
passing directly through a dry gas meter using a mouth piece with a one-way valve (figure 
2.2) and participants wore a nose clip throughout to ensure oral breathing. As with the EVH 
challenge, the threshold for an acceptable test was considered if the participant achieved at 
least 60% of their MVV (Weiler et al., 2016). On completion of the exercise challenge 
participants were seated outside the chamber and maximal lung function was once again 
measured after 3, 5, 7, and 10 and 15 minutes using the methodology described above. If a 
participant demonstrated a fall in their FEV1 of ≥ 10% following the exercise challenge at 
two consecutive time points, this was deemed a positive test. At this point they self-
administered 4 ×100 µg of inhaled salbutamol using an MDI and spacing device (van der 
Palen et al., 1995)  and maximal flow volume loops were once again performed 15 minutes 
post inhalation. Participants were required to remain in the laboratory until FEV1 returned 
to within 10% of baseline. In keeping with the EVH challenge participants were not 
permitted to undergo exercise challenge testing if their baseline FEV1 was < 70% of their 




1: Environmental Chamber. 2: Mouth piece with one-way valve. 3: Flexible 35mm tubing. 
4: Dry gas meter.  
Figure 2.2. Exercise challenge set up 
 
Reversibility challenge 
Participants were unable to undergo bronchoprovocation challenges (either by EVH or 
exercise) if their baseline FEV1 was below 70% of predicted. Instead, they undertook 
reversibility challenge by self-administering 4 ×100 µg of inhaled salbutamol using a 
metered dose inhaler (MDI) and spacing device. Maximal flow volume loops were then 
performed 15 minutes post inhalation. A positive bronchodilator response was defined as a 














OBJECTIVES: To compare an exercise challenge (EX) in a controlled dry air environment 
to EVH for the diagnosis of exercise induced bronchoconstriction (EIB) in athletes. 
METHODS: Seventeen male and ten female participants (age: 36 ± 11 yrs, height: 174.3 ± 
7.8 cm, mass: 72.6 ± 11.3 kg, exercising 7.6 ± 3.0 hrs per week) were included in the final 
analysis. Seven had a history of asthma/EIB, 4 of whom were taking medication in the form 
of SABAs. Participants completed an EX on a cycle ergometer and an EVH challenge in a 
randomised order. EXs were conducted in an environmental chamber at 16.5°C and 26% 
RH. Following a 4-min warm up, participants completed 6-min of cycling at a work rate 
associated with 85% HRmax. EVH required participants to breathe a gas mixture (5% CO2, 
21% O2 and 74% N2, <2% RH) at 85% predicted MVV. Challenges were deemed positive 
if there was a fall in FEV1 of ≥ 10% from baseline. RESULTS: Six participants were positive 
to EVH (% fall in FEV1 16 ± 5%, range -11 to -25%), of these, only two had a positive 
response to EX (11 % fall in FEV1). There was a moderate correlation between the % fall in 
FEV1 post EVH and EX (rs = 0.50, p = 0.01), however agreement analysis showed no useful 
agreement between methods. The % fall in FEV1 post EVH was significantly greater than 
post EX (EVH: -7.7 ± 5.4 %, EX: - 2.0 ± 4.0 %, p < 0.01). CONCLUSION: EVH challenge 
provides greater sensitivity than a cycle exercise challenge in a cold, dry environment 
(16.5°C and 26% RH) in the diagnosis of EIB, which may be due to the lower water content 






Securing a diagnosis of exercise-induced bronchoconstriction (EIB) in athletes as discussed 
in chapter 1 remains a challenge. This is principally due to the poor relationship between the 
presence of classic airway centric respiratory symptoms (e.g. wheeze, cough, dyspnoea), and 
objective evidence of EIB (Simpson et al., 2015; Rundell et al. 2001; Turcotte et al., 2003; 
Price et al. 2016).  
As highlighted in chapter 1, EIB is highly prevalent in both elite (21 – 68% (Dickinson et 
al., 2005; Levai et al., 2016)) and recreational (13% (Molphy et al., 2014)) athletes. 
Unrecognised or inadequately treated EIB can have significant health consequences and  is 
linked to exercise related mortality (Becker et al., 2004). There is also evidence to 
demonstrate that EIB has the potential to impair exercise performance (Price et al. 2014; 
Stensrud et al., 2007; Brukner et al. 2007; Spiteri et al. 2014). For the aforementioned reasons 
it is important to secure a diagnosis of EIB through objective airway challenge testing 
(Parsons et al., 2013) to ensure optimal treatment or  differential diagnosis. 
As exercise is the provocative stimulus to induce bronchoconstriction in athletes, it would 
seem logical to implement an exercise challenge (EX) as way of diagnosis, however despite 
clear guidelines (Crapo et al., 2000; Weiler et al., 2016) there remains limitations when 
employing this methodology as the sensitivity of EX is highly dependent on control over the 
two main contributors to the airway response: the water content of inspired air (Evans et al., 
2005) and minute ventilation (V̇E) (Carlsen et al., 2000).  
Eucapnic voluntary hyperpnoea (EVH) can be used as a surrogate for exercise and has been 
shown to provide greater sensitivity in comparison to EX and direct airway challenges 
(Dickinson et al. 2006; Holzer et al., 2002). On this basis, EVH is currently endorsed by the 
International Olympic Committee Medical Commission (IOC-MC) as the optimal 
bronchoprovocation challenge to diagnose EIB in elite athletes (Anderson et al., 2001).  At 
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present a positive result, suggestive of EIB, in both EVH and EX is currently defined as a 
10% pre-to post challenge fall in FEV1 (Weiler et al., 2016). This cut-off value remains much 
debated, with a cut off of 15% for EVH being proposed by some authors (Price et al. 2016) 
and a fall of 6.5% (Helenius et al., 1998) and 7.1% (Rundell et al., 2000) suggested more 
appropriate for EX in an athletic population.  
Due to the lack of a standardised EX, athletes can currently demonstrate EVH positive, 
without knowing if exercise is likely to trigger the same degree of bronchoconstriction. With 
this in mind, the aim of the current study was to compare a standardised EX in a dry 




3.2 METHODS  
 
Study population 
Following approval from the School of Sport & Exercise Sciences Research Ethics 
Committee (Prop 29_2014_2015). Thirty-three recreationally active volunteers provided 
written informed consent to participate (appendix 3). Inclusion criteria were: male or female, 
aged 18 – 65 years, training ≥ 3 times a week, healthy or exercise induced asthmatics whose 
only medication was inhaled short-acting β2-agonist (SABA).  
 
Study design 
In a randomised order, participants were required to attend the laboratory on two separate 
occasions to complete either an EVH or EX on a cycle ergometer. Each visit was separated 
by at least 48 hrs and was completed within one week at the same time of day. All 
participants reported that they were free from illness in the two weeks prior to assessment. 
Participants were instructed to maintain their usual diet throughout the duration of the study, 
to avoid exercise and caffeine for 24 hrs and 4 hrs respectively before each visit and arrive 
at the laboratory at least 2 hrs postprandial. Participants with a prior diagnosis of asthma 
and/ or EIB were asked to refrain from taking any SABA on the day of testing. 
At their initial visit participants completed a questionnaire to determine their medical history 
and evaluate the presence of respiratory symptoms (appendix 1). Airway inflammation was 
assessed prior to both challenges by determining fraction of exhaled nitric oxide (FeNO) 
(NIOX VERO, NIOX, Aerocrine, Sweden) (Dweik et al., 2011). Resting lung function was 
assessed by maximal flow volume spirometry (Spiro-USB and MicroLab, CareFusion, 
Germany) (Miller et al. 2005). Maximal flow volume loops were then measured in duplicate 
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at 3, 5, 7, 10- and 15-mins post challenge, with the flow loop with the best FEV1 accepted at 
each time-point. A positive diagnosis for EIB was defined by a fall of 10% or more in FEV1 
at two consecutive time-points. Following a positive diagnosis of EIB, inhaled salbutamol 
(4 ×100 µg) was self-administered and maximal flow volume loops were recorded 15 mins 
post inhalation to ensure lung function returned to within 10% of baseline.  
 
Eucapnic voluntary hyperpnoea  
The EVH challenge was conducted as described in chapter 2. In brief, participants inspired 
a medical grade dry gas (5% CO2, 21% O2 and 74% N2, <2% RH) for 6 mins at a target 
ventilation rate equivalent to 85% predicted maximal voluntary ventilation (MVV) (30 
×FEV1) (Argyros et al., 1996). V̇E was recorded and a minimum threshold for an acceptable 
test was considered 60% MVV (Anderson et al., 2001). 
 
Exercise challenge test 
The EX was conducted in an environmental chamber (TIS Services, Hampshire, UK) 
(16.5°C, 25.5% RH) on a Wattbike cycle ergometer (Wattbike Ltd, Nottingham, UK). 
Further details are provided in chapter 2, however following a standardised 4 min 
incremental warm up (1 min at 40, 75, 110 and 145 Watts), participants were given a target 
power output which was a work rate associated with 85% HRmax and they went straight 
into 6 mins of cycling at this work rate. This work rate was determined using submaximal 
heart rate data from the first three stages of the warm up and the algorithm described by 
Ansley et al., (2010). Heart rate was recorded throughout (Polar RS400; Polar Electro Oy, 
Kempele, Finland) and V̇E was recorded for the final 6 mins of exercise via expired air 
passing directly through a dry gas meter using a mouth piece with a one-way valve to match 
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the method in the EVH test (Figure 3.1). Again, the threshold for an acceptable test was 
considered 60% MVV (Weiler et al., 2016). 
 





Data are presented as Mean ± SD unless otherwise stated. Results for FeNO, pre to post 
challenge spirometry, challenge and exercise data were analysed using paired t-tests, or 
Wilcoxon signed rank test where the data was not normally distributed. Correlation between 
challenges was determined by Spearman’s rank correlation and agreement by Bland Altman 
analysis (Bland and Altman, 1986). Associations between gender and challenge result were 
assessed using Chi-squared analysis. All analysis was conducted using SPSS software, V.23 




Seventeen male and ten female participants (age: 36 ± 11 yrs, height: 174.3 ± 7.8 cm, mass: 
72.6 ± 11.3 kg, exercising 7.6 ± 3.0 hrs per week), were included in the analysis (n = 1 
excluded due to inability to perform reliable spirometry and n = 5 due to not achieving an 
acceptable EX i.e. did not achieve a V̇E of ≥ 60% predicted MVV). Seven participants 
reported a history of asthma/EIB, five of these had a current diagnosis and four were 
currently taking medication for this in the form of a SABA when required. 
 
Baseline lung function 
All participants demonstrated normal spirometry at baseline with no evidence of obstruction 
(FEV1 ≥70%, FEV1/FVC ≥70% predicted). Eleven participants had an elevated FeNO 
(>25ppb) under resting conditions prior to EVH and/or EX (Nine had an elevated FeNO 
prior to both tests, one prior to EVH only and one prior to EX only). There were no 
differences in resting lung function or FeNO prior to each challenge (Table 3.1). 
 
Minute ventilation, power output and heart rate 
The percentage of predicted MVV achieved in the EVH challenge was greater than that 
achieved during EX (p = 0.03) (table 3.1), although not all participants had a greater V̇E 
during EVH than EX; 18 achieved a greater V̇E in EVH, 8 during EX and one participant 
had an equal V̇E. Power output attained during EX was lower than the target power (244.5 ± 
57.2 W compared to 288.4 ± 71.3 W, P < 0.001). All participants achieved a HR greater than 




Table 3.1. FeNO, pre to post challenge spirometry and challenge data. 
  EVH EX Sig. 
    
FeNO (ppb) 18 (29) 19 (23) 0.17 
FEV1 (L) 3.89 ± 0.61  3.88 ± 0.62 0.90 
FVC (L) 5.00 ± 0.88 4.97 ± 0.89 0.33 
PEF (L/min) 556 ± 96 557 ± 87 0.89 
FEV1/FVC (%) 78 ± 7 78 ± 7 0.34 
%MVV during challenge 83.0 ± 10.3 77.2 ± 10.7 0.03* 
Maximal % change in FEV1 post 
challenge -6.0 (6.0) -1.0 (5.0) <0.01* 
 
Data mean ± SD. * indicates a significant difference between EVH and EX. Data for FeNO 
and % fall in FEV1 post challenge were not normally distributed and therefore analysed with 
Wilcoxon Signed Rank tests and are presented as the median score (IQR).  
FeNO, fraction of exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; FVC, forced 
vital capacity; PEF, peak expiratory flow; %MVV, percent of predicted maximal voluntary 
ventilation. 
 
EVH vs. EX 
Of the 27 participants, six had a positive EVH challenge (EVH+) (16 ± 5% fall in FEV1; 
figure 3.2a), and of those, two participants were also positive to EX (EX+) (both with 11% 
fall in FEV1; figure 3.2b). There were no participants who were positive to EX but not EVH 
(figure 3.3). There was no association between gender and response to EVH (p = 0.7) or EX 
(p = 0.69). 
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There was a moderate positive correlation between the % fall in FEV1 post EVH and EX (r 
= 0.50, p = 0.01). Bland Altman analysis revealed poor agreement between methods (Figure 
3.4), with wide limits of agreement (LOAs) (+ 3.5% to - 15%). The % fall in FEV1 post EVH 
was greater than post EX (- 7.7 ± 5.4% compared to -2.0 ± 4.0% respectively; p < 0.01; table 
3.1). The sensitivity, specificity and likelihood ratios for EVH and EX to diagnose EIB are 
shown in tables 3.2a and 3.2b respectively.   
 
































Figure 3.2a. Maximal % change in forced expiratory volume in 1 s (FEV1) post eucapnic 
voluntary hyperpnoea (EVH) challenge and % of maximal voluntary ventilation (MVV) 
achieved during EVH. Dashed line indicates the threshold for a positive EVH test. 
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Figure 3.2b. Maximal % change in forced expiratory volume in 1 s (FEV1) post exercise 
challenge (EX) and % of maximal voluntary ventilation (MVV) achieved during EX. Dashed 
line indicates the threshold for a positive EX test. 
 


































Figure 3.3. Maximal % change in forced expiratory volume in 1 s (FEV1) post eucapnic 
voluntary hyperpnoea (EVH) and exercise (EX) challenges. Dashed lines represent the 
thresholds for a positive test.  
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Figure 3.4. Bland-Altman plot of difference in % change in forced expiratory volume in 1 s 
(FEV1) between eucapnic voluntary hyperpnoea (EVH) and exercise (EX) challenges. Solid 
line represents the mean difference. Dashed lines represent limits of agreement (LOAs). 
 
Table 3.2a. Sensitivity, specificity and likelihood ratios for EVH to diagnose EIB. 
  EX+ EX - 
EVH + 2 (true positive) 4 (false positive) 
EVH - 0 (false negative) 21 (true negative) 
      
  
Sensitivity = 100% Specificity = 84% 
Positive likelihood ratio = 6.25 Negative likelihood ratio = 0 
Accuracy = 85%   
 






Table 3.2b. Sensitivity, specificity and likelihood ratios for EVH to diagnose EIB. 
  EVH+ EVH - 
EX + 2 (true positive)  0 (false positive) 
EX - 4 (false negative) 21 (true negative) 
      
  
Sensitivity = 33.3% Specificity = 100% 
Positive likelihood ratio = 0  Negative likelihood ratio = 0.67 
Accuracy = 85%   
 
EVH, Eucapnic voluntary hyperpnoea; EX, Exercise challenge. 
 
Reversibility 
All EVH+ participants demonstrated a subsequent improvement in FEV1 following 
administration of bronchodilator treatment (improvement in FEV1 = 18 ± 8%, with a range 
of 8-28%). Following the EX these participants had a 22 ± 6% improvement with a range of 
17 and 26% following the administration of salbutamol. 
 
Respiratory symptoms 
A total of 19 out of 27 (70%) participants reported troublesome respiratory symptoms 
including cough, chest tightness, excessive mucus production, dyspnoea and wheeze at a 
frequency of 37, 22, 30, 19 and 26% respectively. Although respiratory symptoms were 
frequently reported, there was no relationship between the presence of symptoms and the 





Table 3.3. Association between symptoms and EVH and EX result.  
 
Reporting at least 1 symptom Reporting no symptoms Sig. 
EVH+  4 (5%) 3 (11%) 
0.34 EVH- 15 (56%) 5 (19%) 
EX+ 0 (0%) 2 (7%) 
0.42 EX- 19 (17%) 6 (22%) 
 






Our findings demonstrate that when compared with an EVH challenge, exercising on a cycle 
ergometer for 6 minutes at 85% predicted HRmax in a cold, dry environment (16.5°C and 
26% RH), resulted in fewer participants presenting with bronchial hyper-responsiveness in 
line with a diagnosis of EIB. Specifically, we found that only two of the five EVH+ 
participants were also EX+. Indeed, Dickinson et al., (2006) report that out of 14 winter 
sports athletes tested, 10 were EVH+, but only 3 were positive to a sport specific challenge 
where conditions were either 8°C and 35% RH or 1.5°C and 33% RH, and no athletes were 
positive to a lab based challenge where the conditions were 18°C and 56% RH. Similarly, 
Mannix et al., (1999) compared an on ice skating challenge to EVH in 29 ice skaters and 
found 12 were positive by EVH, 9 were positive by on-ice testing, with 5 individuals positive 
for EIB on both tests. They concluded that EVH had greater sensitivity than on-ice exercise 
for identifying EIB in competitive figure skaters. Rundell et al., (2004) screened 38 winter 
sports athletes for EIB; they identified 17 athletes by EVH and only 11 by EX. Despite our 
control of both humidity and V̇E, results of this study also suggest that EVH provides a more 
sensitive diagnosis of EIB than EX.  
We found that there was a greater fall in the % of FEV1 relative to the baseline following 
EVH than after EX. Despite standardising the humidity of the environment that the EX 
challenges were conducted in, the medical grade dry air with which EVH is conducted is 
<2% RH, which will never be possible to match during an EX, unless the dry air is inspired 
directly as carried out by some groups (Anderson et al., 2010). We were keen to avoid this 
method, opting for more realistic environment in which an athlete may train or compete, and 
the lowest humidity we could achieve at 16°C, which was 25% RH. This is a lower humidity 
than Dickinson et al., (2006) whose lab conditions were 18°C and 56% RH, and would 
therefore account for why we had a greater number of athletes positive to a lab exercise 
challenge. The % of MVV achieved during 6 minutes of EVH was significantly higher than 
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that achieved during the 6 minutes of EX. The target workload during Ex was a workload 
equating to 85% predicted HRmax; participants in this study struggled to achieve this 
workload and their achieved workload was significantly lower than this threshold. Despite 
this, average HR for the EX challenge was 89 ± 5% of predicted, and as such was above that 
of 80-90% which is recommended (Crapo et al., 2000). Due to the aforementioned 
differences in the two challenges, the greater sensitivity with EVH is most likely due to the 
lower water content of inspired air and greater V̇E.  
A ≥10% fall in FEV1 is the cut off value for a positive test recommended in the ERS (Sterk 
et al., 1993) and ATS (Crapo et al., 2000) guidelines for the diagnosis of EIB by EVH or EX 
challenges. The 10% diagnostic threshold for a positive EVH test was proposed following  
a study of army recruits with asthma (Hurwitz et al., 1995). Recent retrospective analysis of 
data from asymptomatic athletes suggested that a cut off of 15% might be a more appropriate 
threshold in this population (Price et al. 2016), particularly because poor reproducibility of 
mild EIB (a 10-15% fall in FEV1 following EVH) has been demonstrated in recreational 
athletes (Price et al., 2015). Others however, have found a good reproducibility of EVH at 
all severities in physically active participants (Williams et al., 2015) and these discrepancies 
may be due to the transient nature of EIB (Cockcroft and Davis, 2006). There have also been 
suggestions that the criteria for a positive EX should be lower than the 10% threshold 
originally suggested. A 6.5% fall in FEV1 following EX has been shown to be the threshold 
of an abnormal response in elite runners (Helenius et al., 1998), and a 7.1% fall in a 
population of winter athletes (Rundell et al., 2000). A change in criteria for a positive EX to 
two consecutive falls of ≥6.5% in FEV1 would have led to no additional participants being 
identified as EX+ in our study. If we used an amended threshold of ≥15% fall in FEV1 for a 
positive EVH challenge, 3 participants would no longer be classed as EVH+. One of these 
athletes was EX+, which highlights the increased risk of detecting false negatives with this 
threshold change. It is therefore clear that EVH is more sensitive than EX, however further 
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work is required in athletic individuals to evaluate what comprises an ‘abnormal’ response 
in this population. The transient nature of EIB means that individuals with a small (10-15%) 
fall in FEV1 following EVH in a one-off test, may be susceptible to EIB. Therefore, prior to 
considering any changes in threshold, further research is required to look at the effect of mild 
EIB on airway health and performance.  
In agreement with previous studies in athletes (Simpson et al., 2015; Rundell et al. 2001;  
Turcotte et al. 2003; Price et al. 2016), we found that there was no association between the 
presence of symptoms and evidence of EIB through either an EVH or EX challenge. This 
combined with the negative effects of EIB on athlete health (Price et al., 2013) highlights 
the importance of having a robust objective airway challenge to secure a diagnosis of EIB 
by confirming any reversible change in airway function (Parsons et al., 2013). The EVH 
challenge is often quoted as ‘gold standard’ challenge, however a recent review by Hull et 
al. (2016) challenged this assumption and concluded that ‘the wide sensitivity and specificity 
indices and poor repeatability preclude EVH being termed a ‘gold standard’ test for EIB’. 
As exercise is the provocative stimulus to induce bronchoconstriction in athletes, the true 
gold standard may be a sport and environment specific exercise challenge. However, it may 
be an athlete has to perform multiple exercise challenges on separate days before they are 
able to present with a positive challenge, due to variable factors such as environment on the 
day of test and the athlete’s ability to sustain exercise to achieve significant airway 
ventilation. Our study highlights this difficulty in establishing a standardised exercise which 
is sensitive enough and more work is needed to establish appropriate diagnostic thresholds. 
With the absence of a reliable sport specific standardise challenge, EVH remains a valuable 
indirect bronchoprovocation challenge (Hull et al., 2016). The majority of participants (78%) 
in the current study were negative to both types of challenge, meaning we had a limited 
number of comparisons for EVH+ and EX+ results. Most of our subjects who did 
demonstrate EVH+ were deemed as having a mild response (10 – 15% fall in FEV1). It 
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would be beneficial to look at the comparison of EX and EVH in participants with a current 
diagnosis of EIB to get a much wider spread of the EIB spectrum in this population. The 
environmental conditions for the EX challenge in this study were able to be standardised 
through use of an environmental chamber which means to carry out the EX described in this 
study specialised equipment is required, which involves significant costs and is not 
transportable. Moreover, achieving a suitable V̇E remains easier to standardise with EVH. 
From a practical standpoint, conducting multiple challenge tests remains far easier with 
EVH.  
 
In conclusion, the EVH challenge provides greater sensitivity than a cycle exercise challenge 
in a cold, dry environment (16.5°C and 26% RH) in the diagnosis of EIB, which may be due 
to the lower water content of inspired air and a greater V̇E. The ability of EVH to rule out 
EIB if a test is negative makes EVH a superior objective test for screening for EIB in athletes 
with a one-off test. It is not known however whether EVH is too sensitive, or whether athletes 
diagnosed with EIB through EVH screenings experience improvements in airway health and 









OBJECTIVES: To evaluate the prevalence of exercise induced bronchoconstriction (EIB) 
in elite football players and assess subsequent impact of therapy on airway health and 
exercise performance. METHODS: Ninety-seven male professional football players 
completed an airway-health assessment with a eucapnic voluntary hyperpnoea (EVH) 
challenge to diagnose EIB. Players demonstrating a positive result (EVH+) were prescribed 
inhaler therapy depending on the severity including inhaled corticosteroids and inhaled 
short-acting β2-agonists and underwent repeat assessment after 9 weeks of treatment. Eight 
players (3 EVH+, 5 EVH-) completed a V̇O2 peak test at initial and follow-up assessment. 
RESULTS: Of the 97 players, 27 (28%) demonstrated a positive EVH result. Of these, ten 
had no prior history (37%) of EIB or asthma. EVH outcome was not predictable by 
respiratory symptoms. Seven of the 27 (24%) EVH+ players attended follow-up and 
demonstrated improved post-challenge spirometry (FEV1 post-test; pre = -22.9 ± 15.4 %, 
post = -9.0 ± 1.6 %, p = 0.02). At follow-up V̇O2 peak improved by 3.4 ± 2.9 ml.kg-1.min-1 
in EVH+ players compared to 0.1 ± 2.3 ml.kg-1.min-1 in EVH- players. Magnitude of 
inference analysis indicated treatment was possibly beneficial (74%) for exercise capacity. 
CONCLUSION: Elite football players have a high EIB prevalence. Treatment with inhaler 




Eucapnic voluntary hyperpnoea (EVH) is a well standardised and widely accepted 
bronchoprovocation methodology (Hull et al., 2016) and was demonstrated in chapter 3 to 
be a highly sensitive test in the diagnosis of exercise induced bronchoconstriction (EIB). As 
discussed in chapter 3, the ability of EVH to rule out EIB in the event of a negative challenge 
makes it a suitable objective tool for screening for EIB in athletes with a one-off test. It is 
not known however if athletes diagnosed with EIB as a result of a positive EVH challenge 
will experience any health or performance benefits from treatment with standard asthma 
medication. 
In chapter 1 it was highlighted that the nature of elite-level football would suggest that 
exercise induced bronchoconstriction (EIB) may be relevant and pose a particular risk to this 
group of athletes. Specifically, elite football players regularly sustain high ventilation rates 
(Bangsbo, 1994), from a young age (Read et al., 2016), whilst often training and competing 
in an asthmogenic environment i.e. in cold air, high pollen and areas of high pollution. 
Despite this, little is currently known regarding the nature of EIB in professional football 
players.  
Previous studies suggest that football players are often misdiagnosed or incorrectly labelled 
as having EIB or asthma (Ansley et al., 2012), highlighting that respiratory symptoms are 
poorly predictive in the diagnosis of EIB and therefore limit the accuracy of a symptom 
based approach to diagnosis (Rundell et al., 2001). There have however, been no prospective 
studies evaluating the prevalence of EIB or indeed the benefits of treating EIB in this group 
of elite athletes.  
It is recognised that EIB has deleterious effects on gas exchange efficiency (Haverkamp et 
al., 2007), and therefore can impair performance. Indeed, Stensrud et al., (2007)  report 
impaired oxygen uptake (V̇O2 peak) in individuals with EIB, and an improvement in peak 
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oxygen uptake was reported in Australian Rules football players following the initiation of 
treatment for previously undetected EIB (Brukner et al., 2007b).  
Football clubs have a duty of care for their players; to protect their health whilst at the same 
time optimising their performance. There are rigorous medical guidelines in place which 
include screening players for certain medical conditions (e.g. cardiac abnormalities) (UEFA, 
2014), however clubs do not routinely assess players for EIB. Some authors have called for 
screening for EIB to be implemented (Dickinson et al., 2005; Holzer and Brukner, 2004), 
however before a screening programme can be put in place, a number of stringent criteria 
must be met, including demonstrating prevalence, ability to detect the condition of interest 
and an understanding of the impact of intervention in the population of interest (Wilson and 
Jungner, 1968; Hull et al., 2007).  
The aim of this chapter was therefore to address these deficiencies by using robust objective 
tests to provide a comprehensive assessment of the impact of EIB in professional football 
players by: (I) determining the prevalence of EIB in elite footballers; (II) assessing the 
impact of appropriate therapy on airway inflammation and EIB control and (III) 
investigating the effect of treating players with EIB on exercise performance.  
It was hypothesised that EIB would be highly prevalent and that initiation of standard asthma 
therapy would be beneficial for airway health, as assessed by physiological measures of 




Study population  
Male professional football players from the English Premier League, Championship and 
League One were invited to participate in a detailed respiratory health assessment, as a 
component of their pre-season medical examination in July 2016, prior to their preseason 
training period.  
 
Study design  
All players attended for a detailed respiratory assessment, including screening for EIB using 
an EVH challenge (part I). Subsequently, players with EIB were treated for 9 weeks, after 
which they had a follow-up respiratory assessment (part II). A subgroup of players 
completed maximal exercise testing at both baseline and follow-up (part III). All players 
were free from illness in the two weeks prior to assessment and were requested to avoid 
exercise and caffeine for at least 4 hrs before assessment. Ethical approval for the study was 
obtained from the School of Sport & Exercise Sciences Research Ethics Committee (Prop 
144-2014_2015) and participants provided written consent (appendix 4).  
 
Part I: Baseline assessment 
Players completed a detailed respiratory assessment as described in Chapter 2 and briefly 
below. They initially completed a questionnaire to determine their medical history and 
evaluate presence of respiratory symptoms (appendix 2). Players previously prescribed 
medication for asthma / EIB (n = 7) were asked to withhold treatment at the time of 




Airway inflammation was assessed by determining fraction of exhaled nitric oxide (FeNO) 
(NIOX VERO (NIOX, Aerocrine, Sweden) (Dweik et al., 2011) and lung function was 
assessed by maximal flow volume spirometry (Spiro-USB and MicroLab, CareFusion, 
Germany) (Miller et al. 2005).  
An EVH challenge was then conducted as described in chapter 2. In brief, players were 
required to inspire a medical grade air (21% O2, 5% CO2 and 74% N2 with <2% humidity) 
for 6 minutes at a target ventilation rate of 85% Maximal voluntary ventilation (MVV). 
Target MVV was calculated as 30 × FEV1 (Argyros et al., 1996) and V̇E was recorded. 
Maximal flow volume loops were measured in duplicate at 3, 5, 7, 10- and 15-minutes post 
EVH, with the flow loop with the best FEV1 accepted at each time-point. A test was 
considered positive for EIB if FEV1 fell by ≥ 10% from baseline at two consecutive time 
points. At this point 4 × 100 µg of inhaled salbutamol was administered by a metered dose 
inhaler (MDI) and maximal flow volume loops were recorded 15 minutes post inhalation.  
Severity of EIB was classified as mild, moderate or severe dependant on the fall in FEV1 
post EVH (≥10% to <25%, ≥25% to <40% and ≥40% respectively) (Anderson and Kippelen, 
2013). Players with a positive EVH challenge (EVH+) test were then prescribed medication 
by their team physician, in accordance with recommendations (Parsons et al., 2013) with a 
spacing device and inhaler technique advice (van der Palen et al., 1995) (see below). 
Treatment 
Medication was prescribed according to EIB severity; players with ‘mild EIB’ were 
prescribed a daily inhaled corticosteroid (ICS), in conjunction with an inhaled short-acting 
b2-agonist (SABA) as needed. Those with ‘moderate’ EIB were prescribed a combination 
inhaler of ICS and a long-acting b2-agonist (LABA), with a SABA as needed. Finally, 
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players with ‘Severe’ EIB were prescribed the combination inhaler with the addition of a 
daily Montelukast and a SABA as required.  
 
Part II: Follow-up assessment 
Players continued with their usual pre-season training and no change was made to training 
load. After 9 weeks, EVH+ players underwent a further respiratory assessment (as above).  
 
Part III: Performance assessment 
A subgroup of players (n = 8) completed a V̇O2 peak test on a motorised treadmill with 
simultaneous gas analysis (Oxycon Pro, Jaeger, Germany). Initial running speed was set at 
11 km.h-1 and a gradient of 1%. Speed increased 1 km.h-1 every 3 minutes until 16 km.h-1, 
at which point the gradient was increased by 1% every minute until volitional exertion. 
V̇O2 peak was determined as the single highest 30 s average in V̇O2. 
 
Statistical analysis 
Data are presented as Mean ± SD unless otherwise stated. Players were grouped according 
to the result of their EVH challenge (EVH+, EVH-). Group differences in player 
characteristics and baseline respiratory assessment data were analysed using independent t-
tests, or Mann Whitney U tests where the data was not normally distributed. Respiratory 
symptom data and association between league and EVH result were analysed by Chi-square 
analysis and Fisher’s Exact test. Differences in lung function data and EVH results pre and 
post treatment were assessed using paired t-tests and Sign Exact tests where data was not 
normally distributed and symmetrically shaped. Given the small number of subjects 
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completing performance assessment magnitude-base inference analysis was also utilised 
using the excel spreadsheet from Hopkins (2007) to assess the clinical impact of detection 
and treatment of EIB. All other analyses were conducted using SPSS software, V.23 (SPSS, 




Ninety-eight players (age: 24 ± 4 yrs, height: 183 ± 7 cm, mass: 80.3 ± 7.2 kg) completed 
the initial respiratory assessment however one player was subsequently excluded due to his 
inability to perform reliable spirometry (Table 4.1). Seventeen players reported a previous 
diagnosis of asthma and/or EIB, of whom only seven were currently prescribed medication. 
A total of 16 players reported troublesome respiratory symptoms, including cough, wheeze 
and dyspnoea at a frequency of 5%, 3% and 8% respectively. 
 
(I) Baseline Assessment 
Pulmonary function, inflammation and EIB  
Lung function was normal in all players at the baseline assessment with no evidence of 
significant airflow obstruction (FEV1>70% predicted). In 39 (40%) players the FeNO was 
raised above normal (> 25 ppb), with 19 players (20%) having a value above 50 ppb (Table 
4.1).  
A positive EVH result was found in twenty-seven (28%) players, of which the majority (n = 
21, 78%) were classified as having a mild response and fewer having a moderate (n = 4 
(15%) or severe (n = 2 (7%) response (Figure 4.1). There was no association between the 
league the footballers played in and their EVH result (p = 0.31). All EVH + players 
demonstrated a subsequent improvement in FEV1 following administration of 
bronchodilator treatment (ΔFEV1 = 20.6 ± 11.6%, with a range of 6 - 40% (p = <0.001)). 
There was a weak inverse relationship between FeNO and % fall in FEV1 post EVH (rs = -





Table 4.1. Player characteristics and baseline respiratory assessment data for the 97 players 
who performed the baseline EVH challenge. 
 
  
All player  
(n = 97) 
EVH+ 
(n = 27) 
EVH- 
(n = 70) Sig. 
Age (yrs) 24 ± 4 24 ± 4 24 ± 4 0.56 
Height (cm) 182.6 ± 6.8  183.0 ± 6.7 182.5 ± 6.9 0.77 
Weight (kg) 80.3 ± 7.2 80.7 ± 6.3 80.2 ± 7.5 0.73 
FeNO (ppb) 21 (25)    36. (63) 19 (17) <0.01* 
FEV1 (L) 4.71 ± 0.65  4.51 ± 0.55 4.78 ± 0.68 0.07 
FVC (L) 5.67 ± 0.76 5.68 ± 0.64 5.67 ± 0.81 0.95 
PEF (L/min) 630 (135) 616 (102) 635 (149) 0.29 
FEV1/FVC 83 ± 7 79 ± 8 84 ± 6 0.01* 
%MVV during EVH 77.7 ± 11.8 83.1 ± 10.9  75.5 ± 11.5  <0.01* 
% fall in FEV1 from 
EVH -8 (5.5) -13 (10.0) -6 (4.0)  <0.01* 
 
Data presented as mean ± SD. * indicates a significant difference between EVH+ and EVH-
. Data for FeNO, PEF and % fall were not normally distributed and therefore analysed with 
Mann Whitney U tests and data presented as the median score (IQR). 
EVH, eucapnic voluntary hyperpnoea; FeNO, exhaled nitric oxide; FEV1, forced expiratory 
volume in 1 s; FVC, forced vital capacity; PEF, peak expiratory flow; %MVV, percent of 







Figure 4.1. Maximum fall in forced expiratory volume in 1 s (FEV1) post eucapnic voluntary 
hyperpnoea (EVH) challenge. Dashed line indicates the cut off for a positive EVH test. 
MVV, maximal voluntary ventilation. 
 
Relationship between EVH result and prior diagnosis and symptoms  
Only ten (37%) of the EVH+ players reported a history of asthma and/or EIB and four (15%) 
of these were currently prescribed asthma medication. Although respiratory symptoms were 
frequently reported, there was no relationship between the presence of symptoms and 
likelihood of a positive EVH result (Table 4.2). Moreover, the most severe EVH result (49% 
reduction in FEV1) was observed in a player with no prior history of airways disease or 






Table 4.2. Respiratory symptoms reported by players (n = 95).  
 















+  19 (70%) 8 (30%) 1 (4%) 1 (4%) 2 (7%) 4 (15%) 1 (4%) 
EVH
- 60 (89%) 8 (11%) 4 (6%) 1 (1%) 2 (3%) 4 (6%) 2 (3%) 
Sig. 0.06 0.06 1.00 0.50 0.32 0.22 1.00 
 
NB. n = 2 did not complete questionnaires.  
EVH, Eucapnic voluntary hyperpnoea; EX, Exercise challenge. 
 
(II) Follow-up Assessment 
Following nine weeks, only eleven of the twenty-seven (41%) EVH+ players attended for 
the follow-up visit. Reasons for not attending included: club not permitting time for the 
medical team to schedule follow-up, not believing it was necessary, away for international 
competition, injured, and not wanting to repeat the EVH test. A further four players were 
excluded from follow-up analysis due to them not taking medication as prescribed. 
No difference was seen in resting FEV1 between baseline and follow-up visits (Table 4.3), 
however FeNO was lower at follow-up (p = 0.04) (Table 4.3, Figure 4.2a). There was also a 
reduction (p = 0.02) in the % fall in FEV1 following EVH and this was apparent despite 
players achieving a similar total ventilation during the challenge tests (Table 4.3, Figure 
4.2b). Moreover, all but two players had a negative EVH test at the second visit (i.e. fall in 
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FEV1 <10% post challenge). Despite these findings two of the seven (29%) players reported 
an increase in symptoms. 
 
Table 4.3. Differences before and after treatment in EVH+ players on medication (n = 7). 
 
Pre-Treatment Post-Treatment Sig. 
FeNO (ppb) 85 ± 61  28 ± 11 0.04* 
Baseline FEV1 (L) 4.41 ± 0.55 4.25 ± 0.32 0.23 
%MVV during EVH 85.3 ± 13.6 87.8 ± 13.6 0.38 
% fall in FEV1 post EVH 14 (28) 8 (9) 0.02* 
 
Data presented as mean ± SD * indicates a significant difference between pre-treatment and 
post treatment. Data for % fall was not normally distributed and therefore analysed with Sign 
Exact tests and data presented as the median score (IQR). 
EVH, eucapnic voluntary hyperpnoea; FeNO, exhaled nitric oxide; FEV1, forced expiratory 












Figure 4.2. A. Exhaled nitric oxide (FeNO) before and after 9 weeks treatment. B. 
Percentage change in forced expiratory volume in 1 s (FEV1) following eucapnic voluntary 
hyperpnoea (EVH) challenge before and after 9 weeks treatment. Grey bars indicate mean 
data. # indicates a significant change from pre-treatment (P < 0.05). 
 
(III) Performance Assessment 
All EVH+ treated players (n = 3) showed an improvement in V̇O2 peak (Pre: 50.60 ± 5.65 
to Post: 53.98 ± 2.80 ml.kg-1.min-1 (Figure 4.3), however the magnitude of this change was 
not significant (p = 0.18). Three EVH- players had a decrease in V̇O2 peak and two 
demonstrated an improvement (Pre: 53.06 ± 2.14 to Post: 53.15 ± 2.38 ml.kg-1.min-1). No 
significant difference was found in the change in V̇O2 peak between the two groups (p = 
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0.13); EVH+ players had an improvement of (3.38 ± 2.93 ml.kg-1.min-1) and EVH- players 
(0.09 ± 2.30 ml.kg-1.min-1) however, the effect of treatment on maximal exercise capacity, 
from magnitude-base inference analysis, was found to be possibly beneficial (74%). 
 
 
Figure 4.3. V̇O2 peak before and following 9 weeks of treatment. Solid lines represent 
EVH+ with medication and dashed lines represent EVH-. 




In a cohort of elite football players completing a pre-season medical screening a high 
prevalence of both respiratory symptoms and airway dysfunction was found. Indeed, by 
employing a widely accepted bronchoprovocation methodology (Weiler et al., 2016), 
namely EVH testing, it was found that approximately one third of this prospectively screened 
cohort of elite football players had evidence of EIB. Moreover, subsequent treatment with 
appropriate therapy was associated with a clear attenuation in airway dysfunction and 
improvement in markers of airway inflammation and hyper-reactivity. In addition, all treated 
players demonstrated an improvement in peak exercise capacity. 
The high prevalence of EIB in elite footballers observed in this study concurs with previous 
but smaller scale studies that have reported a prevalence of between 29% (Dickinson et al., 
2013) and 51% (Ansley et al., 2012) in this group of athletes. Dickinson et al., (2013) 
included only a small sample of one elite football team (n = 21), whilst Ansley et al., (2012) 
studied a highly selected population of football players using inhaler therapy. Thus, this is 
the first study to truly assess prevalence in a prospective ‘medical screening’ type scenario 
across several elite football teams. 
The study findings are consistent with other studies demonstrating a heightened prevalence 
of airway dysfunction in ‘running-based’ sports (Dickinson et al., 2011). They also, yet again 
highlight the poor predictive value of symptoms in the diagnosis of EIB (Rundell et al., 2001; 
Turcotte, Jean Bruno Langdeau, et al., 2003). Indeed ‘undetected’ EIB was found in 63% of 
players, and no single symptom or combination of symptoms was predictive of the presence 
of EIB. Accordingly, it is concerning that there appears to be a high proportion of 
professional footballers currently training and playing with undiagnosed and uncontrolled 
EIB. Moreover, in keeping with Ansley et al., (2012), evidence of players with a prior 
diagnosis of EIB / asthma that was incorrect and not supported by the objective test findings 
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was seen. Indeed 71% of players with a prior diagnosis and treatment plan were either over 
or under-medicated.  
It is also apparent that respiratory symptoms are not useful in predicting the airway response 
following treatment (Brannan et al., 2007). Specifically, it was found that despite a reduction 
in the FEV1 fall post EVH challenge, almost one third of players with EIB reported an 
increase in symptoms at the follow-up assessment. This is in keeping with the findings of 
Simpson et al., (2015) who reported that half of athletes assessed reported at least one 
ongoing respiratory symptom despite their fall in FEV1 post EVH being blunted by the use 
inhaled terbutaline. Indeed, in this study 28% had a higher symptom score when this fall was 
blunted. These findings act to emphasis the poor relationship between the presence of 
respiratory symptoms and airway dysfunction and highlight our current limited 
understanding of the pathophysiological mechanisms underpinning airway-centric 
symptoms in athletes (Hull et al., 2017). It also serves to promote the importance of other 
conditions, such as exercise-induced laryngeal obstruction (EILO), which may co-exist with 
EIB and cause symptoms (Nielsen et al., 2013; Hall et al. 2016).  
In the current study, objective testing was repeated nine weeks after EIB therapy was 
initiated to ensure adequate control of EIB (Weiler et al., 2016). Data from this follow-up 
assessment reveals that standard asthma therapy can improve EIB and airway inflammation. 
Although treatment was recommended for all twenty-seven EVH+ athletes, only seven took 
the medication as prescribed. This represents an attrition rate of 74%, which suggests a 
degree of resistance to football players engaging in therapy for this condition. Certainly, 
anecdotally, EIB often appears to be discounted as medically relevant by medical staff in 
football squads and viewed as of secondary importance to cardiac screening (Hull and 
Rawlins, 2016). These findings will hopefully challenge this presumption and provide the 
supporting basis to educate both players and team clinicians regarding the importance of EIB 
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in elite football players. This work acts to address some of the concerns regarding screening 
athletes for airway dysfunction (Hull et al., 2007) and certainly suggests that a focus on 
airway health is important in football players, given the work suggesting that EIB in 
endurance athletes could be considered akin to an ‘occupational lung disease’ (Price et al., 
2013). 
A key driving factor in elite sport is the impact of any intervention (e.g. screening or new 
treatment) on athlete performance and in addition to improving airway health, treating EIB 
may also be beneficial for performance. Studying performance impact at the elite level is 
clearly complex with multiple potential confounding factors and very few footballers 
completed this component of this study for the reasons aforementioned, meaning this section 
of data is difficult to interpret. Although not statistically significant, EVH+ players had mean 
increase in V̇O2 peak of 7.2%, whereas EVH- players had only a 0.2% increase over the 
same time, with the observed increases in V̇O2 peak bringing the performance of the EVH+ 
players in line with EVH- players. As previously stated, due to the small sample size, these 
results should be interpreted with caution and future research should aim to follow this up 
with an adequately powered study.  Similar findings have been reported in sports with similar 
demands. Brukner et al., (2007) found that Australian Rules football players with newly 
diagnosed EIB had a significant improvement (9%) in V̇O2 max following six weeks of 
treatment compared to players without EIB. In addition, Spiteri et al., (2014) demonstrated 
that appropriately medicating elite rugby players with previously undiagnosed EIB improved 
their performance in a rugby specific aerobic exercise challenge by 8% over the course of 
12 weeks compared to 6% EIB negative control group, however this was not a significant 
finding. The potential impact of treating EIB on performance may be due in part to 
attenuating bronchoconstriction during and following exercise which has been shown to 
result in reduced alveolar ventilation and efficiency of alveolar-to-arterial blood O2 exchange 




A key limitation of this study is that the findings represent the result of a cross-section 
assessment. Specifically, players were not studied in a prospective randomised placebo-
controlled fashion and thus our results have to be interpreted in view of their pragmatic 
limitations. Due to the elite nature of the football players involved, clubs would not allow 
medication to be withheld from those who needed it or provide a placebo medication to those 
who did not. Players are also subject to anti-doping regulations and need to know exactly 
what they are taking at all times. It is also recognised that diagnosis of EIB from a one-off 
test is not entirely robust (Price et al., 2015), however due to time restraints from the clubs 
and the large numbers of players to screen, it would not have been practical to carry out 
multiple tests. This study design also replicates how a screening programme would work in 
‘real-life’ practise and is similar to the way football players are currently screened for cardiac 
conditions.  
During the EVH test, the %MVV achieved was significantly lower among EVH- players 
than among EVH+, however both groups achieved a %MVV greater than that of 60% which 
is required for an adequate test (Anderson et al., 2001) and it is most unlikely that the mean 
difference of 8% between groups would explain the major findings of this study.   
The study was initially powered based on approximately 30% of players being found to have 
evidence of EIB. Initial power calculations showed that 15 EVH+ players were required to 
detect a 10% change in FEV1 in follow-up assessments. To accommodate for an anticipated 
high drop-out rate in this population, a higher number of players were deliberately recruited. 
However, even with a sample size of 97 players, the high drop-out rate meant that the study 
was under powered. 
As discussed above, it was difficult for us to follow-up EVH+ players and clearly it would 
have been desirable to significantly increase the number of players undergoing repeat 
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assessment, including performance assessment. It may be possible to reduce the attrition rate 
by working with sub-elite cohorts or academy players, however this limits potential 
generalisation to the elite population. Players and medical staff at clubs are under huge 
pressures from clubs and it is hard for them to allocate time for follow-up testing. At the 
follow-up assessment, it became evident that despite support from coaching and medical 
staff, many players had decided not to take the inhalers, and there was some confusion 
amongst these players regarding what they should be taking and when. Miller et al., (2005) 
highlights the importance of educating coaching staff in the management of asthma and this 
is maybe an area which needs to be addressed when establishing a screening programme. 
For a screening programme to be effective in elite level football, time needs to be invested 
in educating players about EIB and its treatment. Although there is a lack of evidence in the 
athletic population, it is clear educational interventions can have a positive effect on clinical 
patients’ asthma management (Gibson et al., 2002). It is vital therefore to have the 
cooperation of players at the start of the treatment. 
Conclusion 
In conclusion, this study revealed that approximately one third of a cohort of elite football 
players appear to have EIB when screened for respiratory dysfunction at a pre-season 
medical assessment, which in the majority of cases was not predictable by symptom-based 
assessment.  Treatment of screen-detected EIB positive players resulted in improved airway 
inflammation and reduced airway-hyper-responsiveness.  
Overall the findings of this study support the use of screening for EIB in elite athletes and 
treating with appropriate asthma inhaler therapy. What this study does not investigate is the 
long-term impact of treatment upon wellness of the athletes and if the improvement in airway 
health as shown by a reduction of airway inflammation and reduced severity of EIB 
translates into a reduction in respiratory illness.   
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Chapter 5. Evaluating and managing EIB, respiratory health and overall wellbeing in 




OBJECTIVES: To report the findings of a 3-part body of work designed to investigate 
optimal management of respiratory health in elite British swimmers. METHODS: Part 1: 14 
swimmers entering the GB funded programme (age 19 ± 1.5 yrs, training for 10.8 ± 2.5 yrs) 
gave informed consent to take part in a one-year study. Swimmers completed an online 
training and wellness diary daily for 6 months either side of a detailed respiratory assessment 
which included measurement of FeNO, EVH and PNIF. Following assessment, swimmers 
were treated for EIB where necessary, or had previous treatment adjusted where appropriate. 
Swimmers were grouped as EVH+ and compliant with the treatment intervention (INT) and 
EVH– or EVH+ not compliant with treatment (NI). Part 2: 21 elite swimmers training ≥ 25 
hrs per week in an indoor pool gave informed consent. 10 swimmers underwent monitoring 
of their respiratory health including spirometry, FeNO and PNIF before, during and 2 weeks 
following a 7-week warm weather training camp where training was undertaken in an 
outdoor pool. The remaining 11 swimmers continued training at their usual indoor pool 
throughout this period. All swimmers completed a daily online training and wellness diary 
for the 11-week period. Part 3: 15 elite swimmers underwent a systematic assessment of 
total airway health three months prior to competing at the Rio 2016 Summer Olympic 
Games. All swimmers had a prior diagnosis of EIB, confirmed by EVH and all were 
prescribed inhaler therapy and educated on inhaler technique. At the assessment spirometry, 
FeNO, inhaler flow-rate and PNIF was measured, and they underwent an assessment with a 
pulmonologist. Data was statistically analysed against their initial diagnostic assessment 
data.  RESULTS: Part 1: 75% of swimmers entering the GB funded swim programme 
demonstrated evidence of asthma/ EIB. No differences were found between the INT and NI 
groups in the 6 months post respiratory assessment for the % of days the swimmers carried 
out modified training due to illness (p = 0.17), the % of days that swimmers reported 
symptoms of respiratory illness, or for scores for energy (p = 1.00) and sleep quality (p = 
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1.00). Part 2: No differences were found between pre, during or post the period of outdoor 
pool training in FEV1 (p = 0.41), FeNO (p = 0.12) or PNIF (p = 0.67). Data from the training 
and wellness diaries showed no significant interaction for the % time swimmers carried out 
modified training due to illness (p = 0.45). Stress levels of the swimmers attending training 
camp group were found to be significantly higher than the swimmers remaining at home (p 
< 0.01). Part 3: FeNO was significantly reduced compared to their initial screening visit (p 
= 0.01). All swimmers were found to have at least one co-existing condition in addition to 
EIB. All swimmers demonstrated sub-optimal inhaler technique. Despite being prescribed 
treatment for EIB, three swimmers had on-going airflow obstruction with bronchodilator 
reversibility of FEV1 by 12.9 ± 7.7 % above baseline. CONCLUSION: It appears that on an 
individual level, respiratory health in elite swimmers can be optimised through a systematic 
assessment of airway health and modification of training environment. Larger, well 
controlled studies are still required in this area and should investigate the impact of this 





Results in chapter 4 demonstrated support for screening for exercise induced 
bronchoconstriction (EIB) and subsequent treatment with appropriate standard asthma 
medication. It was shown that over a relatively short time period (9 weeks), in athletes with 
screen detected EIB, treatment led to a decrease in airway inflammation and EIB severity. It 
is not known however if prolonged treatment to control EIB will have an effect on an 
athlete’s overall health and wellbeing.  
A sport in which a high prevalence of EIB and other respiratory disorders has been 
demonstrated amongst its elite athletes is swimming. As discussed in chapter 1, there is a 
substantial body of evidence demonstrating a high incidence of asthma, EIB, rhinitis and 
allergic disease in elite swimmers compared to the general population and other elite athletes 
(Helenius and Haahtela, 2000; Levai et al., 2016; Bougault et al., 2010; Valerie Bougault et 
al., 2009). This high prevalence is thought to arise due to the combined effects of the high 
ventilatory requirement of swimming and the noxious environment of the chlorinated indoor 
pools in which swimmers train and compete (Bougault et al. 2009). There is a paucity of 
studies looking at the management of these conditions in swimmers and none investigating 
the impact of a screening programme on health and wellbeing of swimmers or strategies to 
reduce the risk of exacerbations to optimally manage EIB. 
A study by Levai et al., (2016) reported that 67% of elite British swimmers demonstrated 
objective evidence of EIB when screened using eucapnic voluntary hyperpnoea (EVH). 
Many competitive swimmers report symptoms arising from the upper airway tract. Indeed 
nasal obstruction, rhinorrhoea, sneezing, congestion and itching are reported by 74% of 
competitive elite swimmers (Bougault et al., 2010). The ‘united airways disease’ theory 
(Rimmer and Ruhno, 2006; Daabis, 2016) suggests that a single inflammatory process within 
the respiratory tract leads to manifestations in both the upper and lower airways and in the 
general population  it is recognised that chronic rhinitis is a contributing factor to the 
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development of asthma and may affect its control (Pedersen and Weeke, 1983). A study of 
young competitive swimmers with rhinitis (Gelardi et al., 2012) found that in swimmers with 
non-allergic rhinitis, 63% had a predominant nasal neutrophilic inflammation. The 
mechanisms are still unclear, but it is thought that epithelial damage may occur as in lower 
airways (Bernard et al., 2003). As in the case of EIB, swimmer’s rhinitic symptoms have 
been reported to attenuate and even disappear following a 2-week rest period (Bougault et 
al., 2010). Nasal obstruction can lead to sleep disturbance and fatigue, which has the 
potential for deleterious effect on swimming performance and athletes often report that 
exercise-induced rhinitis alters their ability to train and compete to their full potential 
(Silvers and Poole, 2006).  
As well as affecting an athlete’s quality of life, nasal obstruction and EIB may also contribute 
to an increased rate of upper respiratory tract infection (URTI). Nasal obstruction can lead 
to an increased reliance on mouth breathing, particularly during sleep and as such, swimmers 
can have an increased inhalation of dry, unfiltered air (Hellard et al., 2015). Helenius and 
Haahtela (2000) concluded that increased bronchial responsiveness and airway 
inflammation may predispose athletes to URTIs and in the general population asthma is 
associated with an increased incidence of pneumococcal disease and pneumonia, with a 
decreased risk when asthma is well controlled (O’Byrne et al., 2013). 
The work of Levai et al., (2016) highlighted the potential for improvement in the 
management of respiratory health. A unique opportunity to work with British Swimming 
arose, to optimise respiratory health in swimmers with the long-term aim being to improve 
overall management of EIB to enhance health and thereby reduce the amount of training 
athletes miss, and consequently promoting optimal performance. This resulted in a three-
part body of work: 
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Part One: The effect of screening and initiating treatment for EIB on health and 
wellbeing in elite swimmers. 
Aim: To investigate the effect of screening and appropriate treatment for EIB on health and 
wellbeing in elite swimmers entering the British Swimming funded programme. 
 
Part Two: Monitoring respiratory health with a change in training environment. 
Aim: To assess the impact of a 7-week training camp in an outdoor pool on lung function, 
airway inflammation and respiratory symptoms in swimmers usually training indoors during 
the build-up to the Rio 2016 Olympic Games. 
 
Part Three: A systematic approach to optimise total airway health prior to the 2016 
Olympic games. 
Aim: To report the findings of a systematic approach to evaluating  the airway health of elite 




Ethical approval for this series of studies was obtained from the School of Sport & Exercise 
Sciences Research Ethics Committee (Prop 007_2015_2016 and Prop 120_2015_2016) and 
all swimmers provided written consent prior to testing (appendix 5). 
 
Part One: The effect of screening and initiating treatment for EIB on health and 
wellbeing in elite swimmers. 
 
Study overview 
Elite swimmers entering the GB Swimming funded programme were invited to participate 
in the study. None of the swimmers had previously participated in respiratory screening. The 
total study duration was one year, and the swimmers continued with their usual training and 
competition schedule throughout. On the 25th November 2015, swimmers entered the GB 
funded swim programme and began completing an online training and wellness diary on a 
daily basis. After 6-months on the programme they completed a detailed respiratory 
assessment. Following the assessment, swimmers were treated for EIB where necessary and 
previous medications were adjusted where appropriate. All swimmers continued completing 









Prior to assessment swimmers who were already prescribed medication for asthma / EIB (n 
= 2) were asked to withhold treatment at the time of assessment in accordance with guideline 
recommendations (Crapo et al., 2000). All swimmers reported that they were free from 
illness in the two weeks prior to assessment. They were requested to avoid exercise and 
caffeine for 4 hrs before each visit and arrived for testing at least 2 hrs postprandial. 
Swimmers initially completed a health questionnaire to determine their medical history and 
evaluate the presence of respiratory symptoms (appendix 1). Peak nasal inspiratory flow 
(PNIF) was measured as an index of nasal obstruction (Ottaviano and Fokkens, 2016), with 
a peak flow meter (In check, Clement-Clarke International Ltd, Harlow, Essex, UK). Airway 
inflammation was assessed by determining fraction of exhaled nitric oxide (FeNO) (NIOX 
VERO (NIOX, Aerocrine, Sweden) (Dweik et al., 2011) and lung function was assessed by 
maximal flow volume spirometry (Spiro-USB and MicroLab, CareFusion, Germany) (M. R. 
Miller et al., 2005).  
An EVH challenge was then conducted, as described in chapter 2. A test was considered 
positive for EIB if FEV1 fell by ≥ 10% from baseline at two consecutive time points. At this 
point 4 × 100 µg of inhaled salbutamol was administered, and maximal flow volume loops 
were recorded 15 minutes post inhalation. Severity of EIB was classified as mild, moderate 
or severe dependant on the fall in FEV1 post EVH (≥10% to <25%, ≥25% to <40% and 
≥40% respectively) (Anderson and Kippelen, 2013). Swimmers with a positive EVH 
challenge were then prescribed medication by their physician in accordance with 
international guideline recommendations (Parsons et al., 2013). They were also given a 
pocket spacing chamber through which to take their inhaler and education regarding optimal 
inhaler technique (van der Palen et al., 1995). 
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Swimmers who failed to demonstrate normal baseline lung function (FEV1 < 80% predicted) 
carried out a reversibility challenge instead of an EVH challenge. These swimmers self-
administered 4 × 100 µg of inhaled salbutamol and maximal flow volume loops were once 
again recorded 15 minutes post inhalation. A positive reversibility challenge was defined as 
an increase in FEV1 of ≥ 12% (Fitch et al., 2008). 
Online training and wellness diary 
Swimmers completed an online daily wellness questionnaire (Apollo Wellbeing Score) 
(appendix 7). First, they recorded their training status as either ‘full training’, ‘modified 
training due to illness’, ‘modified due to injury’, ‘off training due to injury’, ‘off training 
due to illness’, ‘travelling’ or ‘day off resting’. Then they scored the following items on a 
scale of 1-7: ‘Energy’, ‘Sleep’, ‘Stress’, ‘Do you feel ill?’. If the item ‘Do you feel ill?’ was 
scored as 3 or below, additional symptom options then became available to rate: ‘runny 
nose’, ‘blocked nose’, ‘sneezing’, ‘sore throat’, ‘cough’, ‘head congestion’, ‘chest 
congestion’, ‘fever and muscle ache’. Scoring was on a scale of 1 to 7 for all items (1 = low 
energy, very poor sleep, extremely stressed, severely ill, severe symptom through to 7 = high 




Part Two: Monitoring respiratory health with a change in training environment 
 
Study Overview 
Twenty-one elite internationally competitive swimmers, 10 males and 11 females training ≥ 
25 hours per week in an indoor pool gave informed consent for their data to be used as part 
of a research study. Respiratory health was monitored in ten swimmers prior to, during and 
following a 7-week warm weather training camp, where all training took place in an outdoor 
pool (figure 5.1). Swimmers continued with their usual training and competition schedule 
throughout. Once prior to departure, once midway through the training camp and once two 
weeks after they returned home, swimmers completed a respiratory assessment.  This 
comprised: measurement of fraction of exhaled nitric oxide (FeNO), Peak Nasal Inspiratory 
Flow (PNIF) and maximal lung function measured by spirometry and completion of the Mini 
Asthma Quality of Life Questionnaire (MiniAQLQ) (Juniper et al., 1999) (appendix 8) and 
the Mini Rhinoconjuntivitis Quality of Life Questionnaire (MiniRQLQ) (Juniper et al., 
2000) (appendix 9). Data from an online wellness diary which the swimmers complete daily 
as part of them being on the funded programme was collected for 2 weeks prior to the 
training camp, throughout the training camp and for an additional 2 weeks on their return 
home. Wellness diary data was also collected from the 11 swimmers who did not attend the 
warm weather training camp and continued training at home in the indoor pool. These 
swimmers were used as a control group, however did not complete the respiratory 
assessments. 
All respiratory assessments were completed ≥ 4 hours after the swimmers completed a 
training session and taken any short acting β2-agonists (SABA). Swimmers also abstained 








Maximal resting lung function was assessed by spirometry and performed in accordance 
with the ATS/ERS recommendations (M. R. Miller et al., 2005) using digital spirometers 
(Spiro-USB and Microlab, Carefusion, Germany). Measurement was repeated until three 
acceptable attempts had been obtained. Forced expiratory volume in one second (FEV1), 
peak expiratory flow (PEF), forced vital capacity (FVC) and FEV1: FVC ratio (FEV1/FVC) 
were recorded for each effort and the highest values used for analysis. Measurement of FeNO 
was performed in accordance with ATS/ERS recommendations (Dweik et al., 2011) using a 
NIOX analyser (NIOX VERO, (NIOX, Aerocrine, Sweden). Measurement was done in 
duplicate and the mean value used. Peak Nasal Inspiratory Flow (PNIF) was measured as an 
index of nasal obstruction (Ottaviano and Fokkens, 2016), with a peak flow meter (In check, 
2 Weeks Baseline Training  
(Home, indoors) 
7 Weeks Training 
(Warm weather, outdoors) 
2 Weeks Post Training  
(Home, indoors) 
Daily (14 days) 
Wellness Diary 
Once (week 2) 
FeNO, Nasal Peak 
Flow, Spirometry, 
Questionnaires 
Daily (49 days) 
Wellness Diary 
Daily (14 days) 
Wellness Diary 
Once (week 5) 
FeNO, Nasal Peak 
Flow, Spirometry, 
Questionnaires 
Once (week 9) 





Clement-Clarke International Ltd, Harlow, Essex, UK). Three satisfactory maximal 
inspirations were obtained, and the highest value was used for analysis. 
Wellness Diary  
 









Fifteen elite level swimmers (9 males, 6 females, age 22.2 ± 2.9 yrs) selected to compete at 
the 2016 Olympics provided written consent for their data to be used for research purposes. 
All swimmers had a prior diagnosis of EIB confirmed by EVH screening (Levai et al., 2016) 
and had previously been prescribed appropriate inhaler therapy and received education 
regarding inhaler technique.  
Three months prior to the Olympic Games the swimmers underwent a systematic assessment 
of total airway health. At the assessment, maximal lung function, fraction of exhaled nitric 
oxide (FeNO) and peak nasal inspiratory flow (PNIF) were assessed. The swimmers also 
underwent an evaluation of total airway health, including co-morbidities with a respiratory 
consultant and an assessment of inhaler technique. Where appropriate, following the 
assessment the swimmer’s treatment was changed to optimise their respiratory health.  
 
Respiratory assessment 
All respiratory assessments were completed ≥ 4 hours after the swimmers completed a 
training session. They were instructed to refrain from taking SABAs or consuming caffeine 
within this time. Nitrate supplementation was recorded and FeNO results of those swimmers 




Maximal lung function  
Maximal lung function was assessed by spirometry and was performed in accordance with 
the ATS/ERS recommendations (M. R. Miller et al., 2005) using digital spirometers (Spiro-
USB and Microlab, Carefusion, Germany). Measurement was repeated until three acceptable 
attempts had been obtained. FEV1, PEF, FVC and FEV1: FVC ratio were recorded for each 
effort and the highest values used for analysis. 
Fraction of Exhaled Nitric Oxide (FeNO) 
Measurement of FeNO was performed in accordance with ATS/ERS recommendations 
(Dweik et al., 2011) using a NIOX analyser (NIOX VERO, (NIOX, Aerocrine, Sweden). 
Measurements were carried out in duplicate and the mean value taken.  
Peak Nasal Inspiratory Flow (PNIF) 
PNIF was measured as an index of nasal obstruction (Ottaviano and Fokkens, 2016), with a 
peak flow meter (In check, Clement-Clarke International Ltd, Harlow, Essex, UK). Three 
satisfactory maximal inspirations were obtained, and the highest value was used for analysis. 
Consultation 
During the consultation with the respiratory consultant a systematic review of all symptoms 
was carried out along with a discussion of current medication and co morbidities.  
Inhaler Technique 
Inhaler technique was assessed first by asking swimmers to replicate the rate at which they 
inhaled through a flow meter to assess the inspiratory flow rate they typically generated. 
Then they were asked to take their inhaler as they would usually and were scored on the nine 
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items in Table 5.1 using ‘completed’ or ‘not completed’. Swimmers were given immediate 
feedback and had further instruction and practice where necessary. 
 
Table 5.1. Items for inhaler check score. 
Remove cap 
Shake inhaler  
Hold the inhaler upright 
Exhale to residual volume 
 Keep head upright 
Put mouthpiece in mouth 
Inhale slowly and deeply (at less than 30L/min) 
Actuate after starting to inhale 




Data are presented as Mean ± SD unless otherwise stated. Associations between gender and 
EVH result were assessed by Chi-square square analysis. In part 1 for the wellness 
questionnaire data swimmers were grouped according to whether there was an intervention 
in their treatment (INT) or not (NI). Data from the four weeks immediately after the 
respiratory screening were removed to account for treatment changes within this period. Data 
from ‘pre’ and ‘post’ respiratory screening were analysed as % of days to account for the 
difference in number of days in the Pre and Post time periods and were examined using 2-
way mixed model ANOVA with repeated measures, or the non-parametric equivalent 
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Wilcoxon sign rank tests and Sign rank tests were used where appropriate. Symptom data 
was examined by Fisher’s Exact test. In part 2 differences in data before, during and after 
the training camp were assessed using one-way repeated measures ANOVA. Where the 
assumptions of ANOVA were violated, Friedman tests were employed. Data from the 
wellness diaries were analysed using two-way mixed ANOVAs. In part 3 results were 
analysed using paired t-tests. All analyses throughout were conducted using SPSS software, 






Part One: The effect of screening and initiating treatment for EIB on reports of health 
and wellbeing in elite swimmers. 
 
Subject characteristics 
Fourteen swimmers completed the initial respiratory assessment; 7 males, 7 females, age 19 
± 1.5 yrs, height 177.2 ± 10.1cm, weight 68.9 ± 8.8kg. Swimmers had been training for 10.8 
± 2.5 years and were currently training 23.5 ± 2.6 hrs per week. Two swimmers had a history 
of asthma and both were currently taking preventative medication. One of these swimmers 
completed the respiratory screening having come off their medication as advised, the other 




Three swimmers did not complete the respiratory questionnaire. Six of the remaining 11 
swimmers reported troublesome respiratory symptoms including cough, chest tightness, 
wheeze and dyspnoea at a frequency of 45, 36, 36 and 18% respectively.  
 
Baseline spirometry & FeNO 
All but one swimmer had normal resting lung function (FEV1 > 80% predicted). This 
swimmer completed a reversibility challenge and demonstrated significant reversibility (an 
increase in FEV1 of 19%). All remaining swimmers (n = 13) had resting lung function > 
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100% predicted (FEV1: 119 ± 15%, FVC: 128 ± 15%). Five swimmers demonstrated an 
elevated FeNO (> 25 ppb). Only one swimmer demonstrated a high FeNO (>50 ppb) and 
this was the swimmer who demonstrated airway obstruction at rest.  
 
Table 5.2. Respiratory assessment data. 
   % Predicted 
FeNO (ppb) 24 ± 13 - 
PNIF (L/s) 183 ± 67 - 
FEV1 (L) 4.68 ± 0.83  115.5 ± 18.6 
FVC (L) 6.00 ± 1.15 126.0 ± 16.7 
PEF (L/min) 524 ± 112 98.9 ± 17.0 
FEV1/FVC (%) 78.1 ± 8.5 78.1 ± 8.5 
%MVV during challenge 63.1 ± 13.8 - 
Maximal % fall in FEV1 from EVH -14.6 ± 7.8 - 
 
FeNO, fraction of exhaled nitric oxide; PNIF, peak nasal expiratory flow; FEV1, forced 
expiratory volume in 1 s; FVC, forced vital capacity; PEF, peak expiratory flow; %MVV, 
percent of predicted maximal voluntary ventilation; EVH, eucapnic voluntary hyperpnoea. 
 
EVH challenge 
In addition to the swimmer who did not complete the EVH test due to resting FEV1 being < 
80% predicted, two additional swimmers were excluded from the EVH analysis due to not 
achieving an acceptable test, resulting in a borderline result (i.e. failed to achieve a V̇E of ≥ 
60% predicted MVV), this included the swimmer already on medication. A further two 
swimmers did not achieve a V̇E of ≥ 60%, however they still demonstrated a positive test. 
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Eight out of the eleven swimmers (75%), demonstrated EVH positive (EVH+). The majority 
(n = 7) were classified as demonstrating mild EIB and one swimmer with moderate EIB, 
who was the swimmer with a previous history of asthma. There was no association between 
gender and EVH result (p = 0.31). All EVH+ swimmers demonstrated a subsequent 
improvement in FEV1 following administration of 400 µg of inhaled salbutamol (FEV1 = 19 
± 4%), with a range of 14-25%. Despite resting lung function being greater than predicted, 
3 swimmers had reversibility to above baseline by 3 to 7%. 
 

































Figure 5.2. Percentage fall in FEV1 after EVH (n = 11). 
Vertical dashed line represents the threshold for mild EIB (>10 <25%) and moderate EIB 
(>25 <40%).  
FEV1, forced expiratory volume in 1 s; %MVV, percent of predicted maximal voluntary 






There was a significant association between the presence of symptoms and likelihood of a 
positive EVH result as assessed by Fishers exact test in those who completed both the health 
questionnaire and EVH test (n = 10, p = 0.05).  
 
PNIF 
Two swimmers did not complete this part of the assessment (n = 12). Eleven swimmers 
demonstrated no evidence of nasal obstruction (PNIF > 120 L/min), one swimmer 
demonstrated moderate nasal obstruction (PNIF 50-80 L/min). 
 
Wellness questionnaire data 
Analysis for this section was carried out on n = 10, due to the remaining swimmers not 
completing the diary adequately. The total number of days included in the analysis were 183 
days Pre-assessment (November to May) and 156 days post assessment (June – November). 
Prior to the respiratory screening 96% of wellness data was captured and following the 
respiratory screening 71% was captured. The majority of swimmers had a one-month break 
at some point during August or September during which the majority failed to enter data. 
Six swimmers formed the INT group; these were 5 newly diagnosed EVH+ and 1 previously 
diagnosed EVH+ whose medication had been increased. Four swimmers formed the NI 
group; these were 1 EVH-, 1 previously diagnosed asthmatic with no change in medication 
and 2 newly diagnosed EVH+ swimmers who didn’t take any of the prescribed medication. 
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There was no difference in groups between the % of days for which they completed the 
online diary Pre (INT: 94.3 ± 5.3%, NI: 97.5 ± 1.7, p = 0.29). There was a difference post 
with the INT group completing fewer days than the NI group (INT: 68.2 ± 5.6, NI 78.0 ± 
7.9%, p = 0.05).  
There was no main effect (p = 0.94), group (p = 0.66), or interaction (p = 0.17) for time the 
percentage of time swimmers spent carrying out modified training. 
 
Table 5.3. % of days in which training was either modified or lost due to illness. 
    INT NI Sig. 
% Days completed diary 
Pre 94.3 ± 5.3 97.5 ± 1.7  0.29 
Post 68.2 ± 5.6 78.0 ± 7.9   
% Days modified training 
Pre 1.8 ± 1.0 1.5 ± 1.3  0.17 
Post 1.0 ± 1.1 2.3 ± 3.3   
% Days lost to illness 
Pre 0 ± 0 0 ± 0   
Post 0.1 ± 0.3 0 ± 0   
 
INT, Intervention group; NI, No intervention group. 
 
There was an increase in the % days rated as 6 or 7 over time (90.5 ± 6.9% to 93.7 ± 6.6%, 
p = 0.01) for all swimmers combined, but there was no difference between group (p = 0.78) 
or an interaction (p = 0.55). There were no differences in the median scores for energy (p = 
1.00, p = 1.00), sleep (p = 1.00, p = 1.00) or stress (p = 0.50, p = 1.0) for over time for either 
the INT or NI group respectively. There were no significant main effects for time, group or 
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interactions for the % of days that the swimmers reported symptoms for (runny nose, blocked 




Part Two: Monitoring respiratory health with a change in training environment  
 
Subject Characteristics 
Ten swimmers attended the warm weather outdoor training camp. One swimmer was 
excluded from the data analysis as they were not available for the final respiratory 
assessment due to media commitments. The characteristics of the remaining swimmers (n = 
9) comprised 5 females, 4 males, age 22.7 ± 2.9 years, height 178.9 ± 6.4 cm, weight 71.4 ± 
9.0 kg. Six of the swimmers had a previous diagnosis of EIB confirmed by EVH, five of 
whom were taking preventative medication in form of ICS, one of whom was not taking any 
treatment. Two of the swimmers had demonstrated a negative result to EVH and one had not 
been previously screened by EVH but had no previous history, reported no symptoms or 
demonstrated any evidence of asthma in baseline spirometry. 
The control group for the wellness data comprised 11 swimmers (6 females, 5 males, age 
22.2 ± 4.5 years, height 179.0 ± 4.5 cm, weight 73.0 ± 11.8 kg). Eight of these swimmers 
had a diagnosis of EIB by EVH, 6 of whom were taking preventative medication. Two 











Table 5.4. Results from the respiratory assessments prior to, during and following the 
training camp. 
 
Pre  During Post Sig. 
FEV1 (L) 4.54 ± 0.58  4.55 ± 0.66 4.49 ± 0.63 0.41 
FeNO (ppb) 21 (14) 15 (12) 14 (10) 0.12 
PNIF (L/min) 170 (80) 180 (73) 180 (73) 0.67 
MiniRQLQ score 2.2 (2.4) 1.0 (1.6) 1.4 (1.6) 0.28 
MiniAQLQ score 6.5 (0.6) 6.5 (1.4) 6.3 (1.0) 0.50 
 
Data mean ± SD. Data for FeNO, PNIF, RQLQ and AQLQ were not normally distributed 
and therefore analysed with Friedman tests and are presented as the median score (IQR).  
FEV1, forced expiratory volume in 1 s; FeNO, exhaled nitric oxide; PNIF, peak nasal 
inspiratory flow; MiniRQLQ, Mini rhinoconjuntivitis quality of life questionnaire; 
MiniAQLQ, mini asthma quality of life questionnaire. 
No changes were seen in FEV1 throughout the monitoring period (p = 0.41). Across the 
monitoring period, FeNO changed from  Pre = 21.00 ppb, to during = 15.0 ppb, to Post = 
13.5 ppb), however these differences were not statistically significant (p = 0.12). Nasal Peak 
Flow increased from Pre to During and stayed the same Post (170, 180 and 180 L/min 
respectively). These differences were not statistically significant (p = 0.67).  
Over the monitoring period MiniRQLQ score decreased from Pre (2.20) to during the camp 
(1.00) and then increased again post camp (1.40). These differences were not significant (p 
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= 0.28). There was no difference (p = 0.50) in MiniAQLQ score across the monitoring period 
(Pre = 6.5, During = 6.5 and Post = 6.3).  
 
Wellness Data 
In the warm weather training camp group 11 days were spent performing ‘modified training 
due to illness (2 during the camp and 4 on their return home) and 2 days were lost to illness 
(on the return home). In the control group, a total of seven days were spent performing 
‘modified training’ (3 days during the camp and 4 when the other athletes returned) and three 
days training were lost due to illness (all whilst the other athletes were away). There was no 
significant interaction for the percentage of time spent by swimmers doing modified training 
(p = 0.45). There was also no significant main effect for group (p = 0.41). There was a main 
effect for time (p = 0.01) showing that the % of days spent doing modified training was 4% 
higher post training camp than pre-training camp. For the percentage of training days lost to 
illness there was no significant interaction (p = 0.45). There was also no significant main 
effect for group (p = 0.41). There was a main effect for time (p = 0.01), showing that the % 
of training days lost to illness was 4% higher post training camp than pre-training camp. 
There was no significant interaction of time or group for stress scores (p = 0.07). There was 
also no main effect for time (p = 0.60). There was however a main effect for group (p < 0.01) 
with the stress level of the training camp group 16% higher than the control group, showing 
the training camp group reported being more stressed than those who stayed at home. There 
was no significant interaction in energy scores (p = 0.45). There was also no main effect for 








Fifteen elite level swimmers (9 males, 6 females, age 22.2 ± 2.9 yrs) selected to compete at 
the 2016 Olympics. All apart from one swimmer were regularly taking preventative 
medication for their asthma/ EIB; six in the form of an inhaled corticosteroid inhaler (ICS) 
and eight in the form of a combination inhaler (ICS with long acting β2-agonist (LABA). 
 
Maximal lung function 
All swimmers demonstrated ‘normal’ spirometry (> 80% predicted, FEV1/FVC >70%) 
(Table 5.5). FEV1 at rest remained unchanged from their initial assessment (Pre: 4.79 ± 1.13, 
Post: 4.78 ± 1.10 (p = 0.78). Despite being prescribed treatment for EIB, three swimmers 
had an on-going airflow obstruction, recognised by a concave flow loop and bronchodilator 
reversibility of FEV1 by 12.9 ± 7.7% above baseline (figure 5.3). 
Table 5.5. Resting lung function 
  Measured % Predicted 
FEV1 (L) 4.78 ± 1.10 111.1 ± 16.6    
FVC (L) 6.05 ± 1.33  121.4 ± 14.3 
FEV1 / FVC (%) 77.7 ± 6.2 93.47 ± 7.92 
PEF L/min 498.07 ± 228.08 101.40 ± 12.54 
 





Figure 5.3. Example of flow volume loop of swimmer with airflow obstruction and 
subsequent reversibility with salbutamol.  
 
FeNO 
FeNO (n = 14 as one swimmer was removed due to nitrate supplementation) was 
significantly reduced compared to their initial screening visit (Pre: 28 ± 15 ppb, Post: 16 ± 
7 ppb (p = 0.01) (Figure 5.4). Only two of the remaining 14 swimmers had an elevated FeNO 
(>25ppb) at the post measurement, however they both still showed improvement from their 
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Figure 5.4. FeNO at Pre and Post. Dashed line indicates normal FeNO < 25 ppb and high 
FeNO > 50ppb. 
FeNO, exhaled nitric oxide; Pre, initial EVH screening; Post, Pre-Olympic assessment. 
 
PNIF 
Three swimmers were found to have mild nasal obstruction (80 - 120L/min) and one had 
moderate obstruction (50-80L.min). There was no previous data for comparison. 
 
Coexisting Conditions 
All but one swimmer had at least one co-existing condition in addition to EIB including nasal 
disease, reflux, sensations of laryngeal closure, recurrent respiratory tract infection and 
abnormal breathing sensations (Figure 5.5). The highest of these comorbidities was nasal 
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disease (68%). 37% of the swimmers reported side effects from inhaler use (e.g. throat 
discomfort or voice disturbance). 
 
 
Figure 5.5. Coexisting conditions alongside EIB 
 
Inhaler technique 
All swimmers demonstrated an inhaler technique which was sub-optimal based on the rate 
of inhalation; flow rate = 348 ± 49 L.min-1 (recommended 30 L/min for a standard metered 
dose inhaler (MDI)). Mean score for technique was 8 ± 1, out of 9 (Table 5.6), with the main 






















Table 5.6. Inhaler technique results 
 
Inhaler Technique % of swimmers demonstrating technique 
correctly 
Remove Cap 100 
Shake Inhaler 89 
Hold Inhaler Upright 100 
Exhale to Residual Volume 89 
Keep Head Up 96 
Mouth Piece in Mouth 96 
Inhale Slowly 4 
Actuate after inhale 92 








Prevalence of EIB 
In part one of this study, it was found that 75% of a cohort of elite swimmers entering the 
GB funded swim programme demonstrated evidence of airway hyper-responsiveness. 
Although it is widely acknowledged that there is a high prevalence of EIB amongst elite 
swimmers, this level is above what has previously been reported. Most recently Levai et al., 
(2016) found that upon screening 44 members of the GB swimming squad, 67% 
demonstrated objective evidence of EIB, however current results are in a small sample 
number (n = 14) and were not intended to assess the prevalence of EIB in swimming.   
It is thought that swimmers are at particular risk of developing EIB due to their unique 
training environment. They are exposed to by-products of chlorine disinfection, in particular 
trichloramines which due to the nature of the sport they will inhale via oral breathing in high 
concentrations.  Bougault and Boulet, (Bougault and Boulet, 2013) suggested that the by-
products of chlorine which swimmers are inhaling have the potential to interact with airway 
epithelium resulting in oxidative stress and airway inflammation. Evidence of this 
inflammatory and remodelling processes have been observed in the bronchial mucosa of 
competitive swimmers (Bougault et al., 2012).  
 
Respiratory symptoms 
In contrast to the previous studies in this thesis and also in the literature, in the swimmers 
entering the GB programme, there was an association between respiratory symptoms and the 
incidence of EIB. Clearie et al., (2010) found that less than half of the elite swimmers they 
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assessed presenting with EIB reported symptoms that were suggestive of EIB. Similarly, 
none of the swimmers in the current study had reported them to the doctor previously and so 
it is likely that the athletes did not recognise them as troublesome. This is not unusual; it has 
been suggested that most competitive swimmers do not report their respiratory symptoms to 
a physician and in particular younger swimmers may consider nociceptive respiratory 
symptoms to be a ‘normal phenomenon’.  
 
Baseline lung function 
Similar to prior reports in the literature (Rundell et al., 2001) the swimmers who presented 
EVH+ all had greater than predicted lung function at rest (FEV1: 119 ± 15%, FVC: 128 ± 
15%). Despite this, following administration of Salbutamol following EVH, FEV1 still 
reversed to above baseline. As has been shown consistently, screening this group of elite 
athletes identified the presence of EIB in athletes with no previous history, in this study 67% 
of the swimmers who tested EVH+ had no history of asthma or EIB. Dickson et al., (2011) 
screened 228 elite athletes using EVH and of those who presented as EVH+ 73% had no 
previous history. They also (Dickinson et al., 2013) found that 66% of football players 
demonstrating EVH+ had no prior history and 67% of swimmers with objective evidence of 
EIB had no previous history (Levai et al., 2016). 
 
Impact of treatment 
What hasn’t yet been determined in the literature is what effect treating EIB with standard 
asthma medications has upon athlete health. In chapter 4 we showed that treating EIB in 
footballers had a positive impact upon airway health and reduced the severity of EIB when 
assessed by response to an EVH challenge. In part one, one step further was attempted; to 
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investigate the impact this treatment had upon overall health and wellbeing and in doing so 
was the first study to attempt this. Unfortunately, due to time constraints of training and 
competition, permission was not given to carry out a follow up visit on the swimmers in part 
one to determine the effect of the treatment intervention on airway health and EIB severity. 
Looking at the health and wellbeing data collected from the daily online questionnaire, no 
significant differences were seen between the intervention and no intervention groups in the 
percentage of days lost to illness or, to the percentage of days spent carrying out modified 
training due to illness.  
Whether or not uncontrolled EIB in athletes leads to an increased risk of illness and the 
potential mechanism behind this is still unknown. In the general population uncontrolled 
asthma appears to be linked to an increased risk of pneumococcal disease and pneumonia 
(O’Byrne et al., 2013), Helenius and Haahtela, (Helenius and Haahtela, 2000) have 
suggested that increased airway inflammation may predispose athletes to upper respiratory 
symptoms and it has been hypothesised that it may be a transient loss of control of this local 
inflammation which may account for some upper respiratory illness often seen in athletes 
(Bermon, 2007).  
To collect data regarding the swimmers’ wellness, the British Swimming online diary was 
used because swimmers were already required to complete this daily as part of being on the 
funded programme. Unfortunately, there were several limitations inherent to this approach. 
Firstly, swimmers complete this questionnaire first thing in the morning and as such we do 
not know if this accurately reflects what training was carried out that day. Also, the 
questionnaire was not designed for assessing control of respiratory symptoms and as such 
questions were not specific to this. No differences were found in the illness symptoms data, 
however, this may have been different if a questionnaire was completed after training which 
asked more specifically about symptoms of coughing, wheezing, dyspnoea etc. The 
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drawback with all these questionnaires is that it has been shown that athletes are often not 
able to perceive respiratory symptoms due to altered lung function (Simpson et al., 2015). 
Also, statistically this data is difficult to assess due to very small group sizes and small 
proportions of days reported as ‘off training due to illness’ or ‘modified due to illness’. There 
was a higher proportion of days rated 6 or 7 in answer to ‘Do you feel ill?’ in the time period 
following the screening, however there was no difference between the two groups. This is 
most likely down to the timing of the screening which split the two periods of time as 
November to May and May to November. It is well known that illness risk is higher in winter 
than in summer and this has been confirmed by studies in athletes (He et al., 2013). The first 
time period in this study captured the entirety of the UK winter (November to March) where 
there is a surge of viral outbreaks. It would therefore have been beneficial for the monitoring 
period to continue until the following May so that two 6-month periods at the same time of 
year could be observed.  
In part three, the significant reduction in FeNO demonstrates that the long-term treatment of 
EIB in swimmers, leads to an improvement in airway health. A greater reduction in FeNO 
was seen in those swimmers who had an elevated FeNO initially, with FeNO that was already 
low remaining unchanged. This confirms that inhaled corticosteroids (ICS) are beneficial in 
the treatment of EIB (Weiler et al., 2016).  
 
Impact of training environment 
The high prevalence of EIB in UK swimmers, even compared to other endurance athletes is 
thought to be due to the indoor pool environment in which chlorine is used as a disinfectant, 
often with inadequate control or ventilation. Indeed, one study showed a significant 
reduction in airway hyperresponsiveness in swimmers after an annual swimming pool clean 
(Simon-Rigaud et al., 1997). 
144 
 
The results from part two of this work showed no significant differences in respiratory health 
measured by resting FEV1, FeNO, PNIF, MiniAQLQ and MiniRQLQ in a group of 
swimmers changing to training in an outdoor pool from their usual indoor pool environment. 
It is to be expected that no differences were seen in resting lung function measured by FEV1. 
There was a trend however for FeNO, PNIF and MiniRQLQ score to improve whilst on 
training camp and training in an outdoor pool. It was hypothesised that removing the athletes 
from the indoor environment to train in an outdoor pool may remove the effect that 
chloramines may have on the airway; in an outdoor environment, there are no issues 
regarding poor ventilation and so there is no layer of chloramine on top of the pool where 
the swimmers breathe (Drobnic et al., 1996). Although the swimmers were taken out of the 
chlorine environment however, due to being in Australia and it was summer season rather 
than the UK, there were several anecdotal reports of swimmers reported suffering from hay 
fever symptoms.  
Despite not being able to answer the initial question, monitoring spirometry, FeNO and 
NPIF; quick and easy measures of airway health whilst on training camp proved useful when 
used on an individual basis and treatment for allied conditions such as hay fever optimised 
as a result.  
The wellness data in part two also showed no significant differences between the swimmers 
who were away on training camp and those training at home. There was however a 
significantly higher percentage of days spent completing modified training and of lost 
training due to illness on the return home from the training camp, compared to when the 
swimmers were away. There was also a significantly higher score for overall stress in the 
swimmers away on camp, than in the group who stayed at home. It is difficult to identify 
why these results were observed, however it highlights that although there may be some 
benefit of altering the swimmers training environment by travelling overseas to train 
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outdoors, there are many other factors to take into consideration to find an optimal balance 
of risk factors for overall health and wellbeing. The training camp environment increases the 
threat to an athlete’s immunity in several ways; through the risk of long haul air travel 
(Schwellnus et al., 2012), an increase in training load, and an increase in other stressors such 
as decreased sleep, psychological stress, heat and potential changes in diet (Walsh, 2018). 
There are several other ways in which the training environment can be improved for 
swimmers by reducing levels of trichloramines. Alternative methods for pool disinfection 
could be considered such as ozone, ultra violet and copper or silver (World Health 
Organisation, 2006). The chlorine concentration should be carefully monitored and adequate 
ventilation ensured (Bougault and Boulet, 2013). Other simpler measures can be taken by 
the swimmers themselves; it is the interaction between chlorine and nitrogen containing 
matter such as sweat and urine which results in the release of trichloramines and nitrogen 
chloride. By showering before swimming, using swimming costumes only for swimming 
and not urinating in the pool these interactions will lessen (Bougault and Boulet, 2012). 
There were several limitations in the way part two was conducted, which made it difficult to 
establish if changing a swimmer’s training environment leads to a change in airway health. 
It would have been ideal to conduct EVH tests on the swimmers at each of the measurement 
point to establish EIB control, however this was not possible due to the constraints of 
specialist equipment and trained staff to carry out these tests in Australia. It was also thought 
by the British Swimming medical staff that the swimmers would refuse repeat EVH testing 
due to the discomfort of the test.  
In part two the respiratory assessment was conducted three weeks into the training camp. 
The original intention was that two assessments would be performed during the camp, 
however for logistical reasons this did not happen. Three weeks may have been too short a 
time for any significant changes in airway health to occur because of a change in 
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environment. There is evidence however that a period of as little as 15 days of light or no 
training normalises the response to EVH and methacholine in swimmers with previous 
evidence of EIB (Bougault et al., 2011).  
 
The importance of follow up assessment 
Despite being part of a screening programme and being prescribed treatment, in part three it 
was seen that in a final respiratory health check prior to the Olympics, some swimmers were 
still not taking their medication as prescribed and three swimmers demonstrated evidence of 
airway obstruction at rest. This was despite their lung function appearing ‘normal’ based on 
predicted values. It is common for athletes to demonstrate normal lung function at rest 
despite disease being present (Bonini et al., 2007) and so it would be beneficial for 
practitioners working with elite athletes to know what is optimal for individual athletes and 
to ensure the flow loops and reversibility are considered in any review of respiratory health. 
Over half of the cohort of swimmers assessed in part three also reported troublesome 
respiratory and allied symptoms including laryngeal dysfunction, reflux and nasal disease. 
This highlights the importance of including an in depth consultation as part of a screening 
programme as it is common for elite swimmers to suffer from these often coexisting 
conditions ( Hull et al., 2017) and as discussed previously many swimmers do not recognise 
symptoms as abnormal and as such they go un reported. Nasal disease, in particular chronic 
rhinitis has been shown to be a contributing factor to the development of asthma and may 
also affect its control (Pedersen and Weeke, 1983). Nasal symptoms have also been shown 
to impair swimmer’s quality of life and have the potential to worsen their performance 
(Bougault et al., 2010), however simple interventions such as swimmers using a nose clip 
during training may be beneficial in alleviating these symptoms (Gelardi et al., 2012). In 
addition to rhinitis, some swimmers in the current study demonstrated nasal obstruction. 
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Long term nasal obstruction has the ability to impair swimmers quality of life due to 
decreased sleep quality leading to chronic tiredness (Alaranta et al., 2005). There is also an 
increased risk of URTIs (Hellard et al., 2015) and as such its detection is important.  
 
Inhaler technique 
Inhaler technique amongst the swimmers was found to be sub-optimal and there were 
frequent reports of inhaler side-effects such as voice disturbance and sore throat. All 
swimmers had previous education in inhaler technique, so this emphasises the importance 
of reviewing athletes with a diagnosis of EIB regularly. Inhaler technique is particularly 
important in minimising laryngeal symptoms; when the inhalation rate is too high, the larynx 
will close, meaning the inhaler is deposited on the larynx increasing symptoms.  
 
Summary and future directions 
There were many limitations to this body of work, which have been discussed above. 
Unfortunately, usual scientific vigour could not be applied throughout due to working within 
the restrictions of elite sport. Nonetheless despite the lack of significant results this body of 
work serves as a useful pilot study and some important findings were made which will enable 
improved care of respiratory health within British swimming. These studies once again 
highlight the high prevalence of EIB and other allied respiratory conditions within elite sport, 
the majority of which were previously undiagnosed. This was the first study to attempt to 
look at the impact of a screening programme for EIB on athlete health. It would seem logical 
that the introduction of a screening programme has the potential to improve athlete wellness 
and to reduce the days spent carrying out modified training, however more robust ways to 
measure athlete wellness and training are required. Respiratory questionnaires, NPIF and 
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FeNO appear to be useful tools in monitoring respiratory health in athletes and future work 
should investigate their sensitivity. Alterations in training environment have the potential to 
improve swimmer’s respiratory health, however these changes need to be managed carefully 
considering other aero allergens, travel and life stressors and as such improving indoor home 
training environment could produce a better benefit. It has also been shown that to ensure 
respiratory screening programmes are successful, regular in depth follow up and education 
must be included. 
 
In conclusion it appears that respiratory health in elite swimmers can be optimised through 
systematic assessment of airway health and modification of training environment. Larger, 
well controlled studies are still required in this area and should investigate the impact of this 










OBJECTIVES: To determine if a heat and moisture exchanger (HME) face mask can be 
effective in protecting against acute bronchoconstriction and post exercise cough in response 
to a cycle challenge in a cold, dry environment in asthmatic individuals. METHODS: 
Twenty-six participants with a clinician diagnosis of asthma (20 males, 6 females, age:  27.6 
± 9.2 yrs, height: 172.7 ± 7.3 cm, mass: 71.2 ± 12.8 kg, V̇O2peak: 42.75 ± 8.17 ml.kg.min-
1) gave informed consent and completed three standardised exercise challenges (EX) on a 
cycle ergometer in a randomised order. During EX participants wore either an HME mask 
(MASK), a sham mask (SHAM) with no HME, or no mask (CON). EXs were conducted at 
8 o C and 24% RH. Following a 3-min set warm up participants completed 6-min cycling at 
80% peak power output. Before and after each EX, maximal flow volume loops were 
recorded. Immediately post EX participants were fitted with a Leicester Cough Monitor 
(LCM) which they wore for 24-hours.  Results were analysed using repeated measures 
ANOVA and Friedman’s tests and data presented as the mean ± SD or median score. 
RESULTS: Eleven participants were removed from the analysis as they failed to 
demonstrate evidence of EIB. There were no differences in temperature (p = 0.81), humidity 
(p = 0.25), mean power (p = 0.98) or baseline FEV1 (p = 0.76) between EX conditions. There 
was a difference in the % fall in FEV1 following EX (MASK: -6.0, SHAM: -11.0, CON: -
13.0%, p <0.01), with the % fall following CON greater than that of MASK (p < 0.01). No 
differences were found between EX in cough count per hour over the 24-hour monitoring 
period or the number of coughs in the first hour post EX. CONCLUSION: HME masks can 






In chapter 4 of this thesis a high prevalence of EIB was found amongst footballers. In this 
cohort it was also observed that a high proportion of athletes were reluctant to take traditional 
standard asthma inhalers to control their EIB, particularly when the condition was mild. It is 
well known that environmental conditions play a large role in the development and 
exacerbation of EIB and in chapter 5 an attempt was made to investigate the impact that 
improving a training environment could have on respiratory health and EIB severity in 
athletes. Unfortunately, however there were many variables in the method in which this was 
carried out that were not able to be controlled. Another asthmogenic environment in which 
many athletes train in the UK is a cold, dry environment. It is not currently known however 
if reducing exposure to this environment during training and competition could lessen EIB 
severity providing an alternative non-pharmacological method of protecting athletes from 
EIB. 
Inspiring relatively dry and cold air during moderate and vigorous physical activity is a 
significant trigger for bronchoconstriction. Bronchoconstriction following exercise is 
thought to be caused by dehydration of the airway surface liquid (ASL) which causes cell 
shrinkage and release of inflammatory mediators precipitating airway smooth muscle 
constriction (Anderson and Kippelen, 2005). This respiratory water loss and resultant airway 
surface mucosal drying may also lead to both physical and chemical activation of cough 
receptors (Banner et al., 1984). At rest, inspired air is warmed and humidified through heat 
exchange in the nasal cavity, however this mechanism is compromised during exercise, 
because when V̇E exceeds approximately 35 L/min there is a switch from a nasal to oral 
predominant breathing pattern (Niinimaa et al., 1980). This alteration has a particular impact 
in cold weather, as the air temperature travelling through the trachea and bronchi has been 
shown to be as low as 20°C (McFadden et al., 1985). Repeated exercise in the cold is thought 
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to result in a continuous cycle of injury and repair, leading to chronically inflamed airways 
with the potential for cellular airway changes (Karjalainen et al., 2000). These modifications 
to airway structure and function may play a key role in the increased prevalence of EIB and 
cough observed in athletes who train and compete in cold and dry environments (Turmel, et 
al., 2011). 
An increase in temperature and water content of inspired air has long been shown to prevent 
EIB in asthmatic subjects (Chen et al., 1979). More recently, Bolger et al., (2011) 
demonstrated that EIB in athletes was completely prevented by increasing the temperature 
and water content of an inspirate from 4°C, 37% RH to 25°C, 94% RH and that this warm, 
moist air also limited the disruption of the airway epithelium. Post exercise cough is also 
more likely in environmental conditions which promote airway heat and water loss from the 
airways (Banner et al., 1984).  
One method of increasing the temperature of inspired air thereby potentially diminishing 
airway dehydration is to use a face mask which incorporates a heat and moisture exchanger 
(HME).  The limited number of studies that have investigated the use of HME masks and 
have demonstrated a promising protective effect against EIB as measured by an attenuation 
in the fall in forced expiratory volume in one second (FEV1), following exercise (Beuther 
and Martin, 2006; Brenner et al., 1980; Millqvist et al., 2000; Nisar et al., 1992). However, 
Parsons et al., (2013) suggest recommendations to use HME masks are weak based on the 
current availability of low-quality evidence. As well as having the ability to protect against 
EIB, HME masks may also have the potential to decrease the incidence of cough amongst 
athletes engaging in sports in cold dry environments through the warming and humidifying 
of inspirate.  
In chapters 4 and 5 observations were made of athletes who were reluctant to take or did not 
take their prescribed medication, preferring to minimise pharmacological approaches to 
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treatment. It has also been shown that HME face masks may have an additive effect in 
controlling EIB in conjunction with prophylactic β2-agonist (Millqvist et al., 2000). 
Additionally,  despite EIB being attenuated by the administration of inhaled β2-agonists, 
cough can remain a prominent symptom (Banner and Green, 1984). Therefore, the aim of 
this study was to determine if an HME face mask can be effective in protecting against acute 
bronchoconstriction and post exercise cough in response to a cycling exercise challenge in a 






Following approval from the Faculty of Sciences Research Ethics Advisory Group for 
Human Participants, University of Kent (0881516) thirty recreationally active participants 
exercising at least twice per week provided written informed consent to participate (appendix 
6). All participants had a clinician-based diagnosis of asthma with experience of worsening 
symptoms consistent with EIB when exercising in cold dry environments. Exclusion criteria 
included daily use of oral corticosteroids, hospitalisation due to asthma in the six months 
prior to study commencement and resting FEV1 <80% of predicted value. Furthermore, if 
participants didn’t have a fall in FEV1 of ≥10% at two consecutive time points following at 
least one of the exercise challenges (see below) they were not included in the analysis. All 
participants were free from illness in the two weeks prior to assessment. Participants were 
instructed to maintain their usual diet for the duration of the study, to avoid exercise and 
caffeine for 24 hrs and 4 hrs respectively before each visit and arrive at the laboratory at 
least 2 hrs postprandial.  
 
Study design  
All participants expressing an interest in taking part in the study initially completed a health 
questionnaire (appendix 1) and provided contact details for their general practitioner (GP), 
along with their consent for their GP to be notified that they intended to take part in the study 
(appendix 10). All GPs were notified by letter (appendix 11) and 14 days was allowed for 
any response to be received prior to the participant’s first visit to the laboratory.  
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Once it was confirmed a participant met the inclusion criteria, they attended the laboratory 
on five occasions (figure 6.1). During visit one participants completed a V̇O2 peak test on a 
cycle ergometer, visit two was a familiarisation visit, and during visits three to five, 
participants completed a standardised cycle exercise challenge (EX) in a cold, dry 
environment. During these EXs, participants wore either an HME mask (MASK), a sham 
mask (SHAM) or no mask (CONT). 
 
 
Figure 6.1. Flow chart of study design. 
 
The HME MASK (ColdAvenger balaclava, USA) creates a micro-climate in front of the 
nose and mouth.  A portion of each exhaled breath is retained in the ventilator cup and 
passively humidifies the next inhaled breath.  The ventilator also manages extra moisture 
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away from the skin. The SHAM was the same HME mask with holes cut across the entire 





Figure 6.2. A: Participant wearing the SHAM during an EX; B: MASK. C: SHAM. 
 
The EXs were completed in a randomised order at the same time of day. The time between 
each visit was dependant on which medication a participant was currently taking. 
Participants previously prescribed inhaler medication for asthma / EIB ceased medication 
prior to each assessment (inhaled corticosteroids (ICS): 72 hours before; inhaled long-acting 
β2-agonists (LABA): 48 hrs before; inhaled short-acting β2-agonists (SABA): the day of the 
test) (Dickinson et al., 2011). Following each trial, participants had the same amount of time 
on their medication prior to once again stopping treatment before their next exercise 









Participants initially completed the Leicester cough questionnaire (LCQ) (Birring et al., 
2003) (appendix 12).  Anthropometric measures were taken, and they then performed a 
standardised incremental ramp test to volitional exhaustion to establish Peak Power on a 
cycle ergometer (Lode; Corival, Groningen, Netherlands) with simultaneous gas analysis 
(Cortex Metalyser 3b, CORTEX Biophysik GmbH, Germany). Initial power output was set 
at 50 Watts for 3 mins and thereafter the work rate increased by 20 Watts every 60 seconds. 
Participants were instructed to maintain their chosen cadence (between 70 & 100 rpm) for 
the duration of the test. The test was terminated upon volitional exhaustion or when the 
participant was no longer able to maintain their chosen cadence (i.e. a drop of >10 rpm) and 
V̇O2 peak was determined as the single highest 30 s average in V̇O2. Heart rate was recorded 
throughout (Polar RS400; Polar Electro Oy, Kempele, Finland) and Peak Power Output 
(PPO) was recorded. 
 
Visit Two 
Participants completed the EX challenge protocol as detailed below. Participants remained 
on prescribed asthma therapy for this visit as its purpose was familiarisation to the protocol 
and the EX was completed in a normal lab environment, without a mask. V̇E was recorded 
for the final 6 mins of exercise via expired air passing directly through a dry gas meter using 
a mouth piece with a one-way valve. Spirometry was completed prior to and at 3, 5, 7, 10 
and 15 mins after the challenge. Following the challenge, participants were given a cough 
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monitor which they were instructed to wear for the following 24-hour period (detailed 
below).  
 
Visits Three to Five 
Initially participants completed a cough 0-100mm visual analogue scale (VAS) (Spinou and 
Birring, 2014) (appendix 13). Airway inflammation was then assessed prior to each 
challenge by fraction of exhaled nitric oxide (FeNO) (NIOX VERO, NIOX, Aerocrine, 
Sweden) (Dweik et al., 2011). Resting lung function was measured by maximal flow volume 
spirometry (Spiro-USB and MicroLab, CareFusion, Germany) in accordance with 
international standards ( Miller et al., 2005). Maximal flow-volume loops were subsequently 
measured in duplicate at 3, 5, 7, 10- and 15-mins post challenge, with the highest value at 
each time point used for analysis. If there was a >10% fall in FEV1, 400 µg inhaled 
salbutamol was self-administered by the participant and maximal flow loops were repeated 
15 minutes post administration to ensure FEV1 had returned to within 10% of baseline. The 
EXs were conducted in an environmental chamber (TIS Services, Hampshire, UK) (8.6 ± 
0.9 °C, 24.2 ± 4.2% RH) on a cycle ergometer (Lode; Corival, Groningen, Netherlands). A 
target power was set at 80% of peak power.  
Details of the EX are described fully in chapter 2. In brief, participants first completed a 3-
minute incremental warm up, cycling at work rate of 60, 75 and 90% of their target power 
for one minute at each stage. Participants then went straight into the EX cycling at their 
target power for 6 minutes. Heart rate was recorded throughout by a heart rate monitor (Polar 
RS400; Polar Electro Oy, Kempele, Finland). 
Immediately after EX, participants were fitted with a Leicester Cough Monitor (LCM) 
(figure 6.3) (Matos et al., 2007) which they wore for a 24-hr period (see below for details). 
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Participants were asked to complete a paper diary in this period to detail sleep and wake time 
and any time in which they removed the monitor (appendix 14). They were also given an 
additional VAS to fill out on completion of the 24-hr period. 
 
Leicester Cough Monitor 
The LCM consists of an MP3 recording device and a lapel microphone (Sony, PX333). The 
monitor was fitted to the participants in a small unobtrusive running waist belt, with the 
microphone clipped to the participants clothing as close to the larynx as possible. Recording 
was initiated immediately on completion of each EX and the device was locked to ensure 
the participant could not stop the recording (see appendix 15 for full details). Participants 
were advised that the recording on the LCM would not be listened to at any point and were 
instructed to:  
- Always wear the recorder and microphone unless having a shower or going to bed 
- To keep microphone exposed and attached to a similar position on their clothing. 
- To remove the recorder on going to bed and place it on a bedside table nearby. 
- To remove the microphone and monitor if taking a bath or a shower, leaving it outside 
of the bathroom, re-attaching both when finished. 
On completion of the 24 hr recording period participants were instructed to return the 
monitor as soon as possible. Data collected by the LCM was analysed by cough detection 
software based on the Hidden Markov model as described by Birring et al., (2008). This is 
a method used in speech recognition and automatically detects cough events whether 
occurring in isolation or in a bout. The LCM is a validated methodology (Birring et al., 2006, 
2008) and has been used previously in patients with acute cough, chronic cough, and COPD 




Figure 6.3. Leicester Cough Monitor (LCM)  
 
Statistical analysis 
Data are presented as mean ± SD unless otherwise stated. Differences between the three EX 
conditions were examined using repeated measures ANOVA. Where data was not normally 
distributed, Friedman’s test was used with post hoc pairwise comparisons where appropriate. 
All analysis was conducted using SPSS software, V.23 (SPSS, IBM, Armonk, NY, USA) 






Thirty-four recreationally active participants initially enrolled in the study. Two dropped out 
following the V̇O2 peak trial, three following the familiarisation and two following the initial 
exercise trial. One subject was excluded due to poor resting lung function (FEV1 <70% at 
baseline). Twenty-six participants (20 males, 6 females, age:  27.6 ± 9.2 yrs, height: 172.7 ± 
7.3 cm, mass: 71.2 ± 12.8 kg, exercising: 5.8 ± 2.2 hours per week, V̇O2peak: 42.75 ± 8.17 
ml.kg.min-1) completed all exercise trials. All had a history of asthma/ EIB, 17 were 
currently using inhaled therapy for their asthma/ EIB; seven were using ICS, four a combined 
ICS and LABA and eight of whom were only using a SABA as needed.  
Prior to analysis, flow volume loops from the exercise tests were inspected and those who 
failed to demonstrate a fall of FEV1 of ≥10% from baseline measures following any of EX 
challenges were removed from subsequent analysis. These participants (n = 11) 
demonstrated either no fall, a very small <10% fall, or an increase in FEV1 post exercise 
(range = +4 to -9% change in FEV1 post EX), usually with a concomitant fall in FVC. Three 
of these participants had a history of EIB only, three were currently taking preventative ICS 
for their asthma, two a combination inhaler. Two were using SABA only and four were using 
no therapy.  
 
Participant characteristics and baseline lung function 
Characteristics of the fifteen remaining participants (12 males, 3 females) are shown in table 
6.1. Lung function was normal in all participants at the familiarisation visit with no evidence 
of significant airflow obstruction (FEV1 > 80% predicted). Three were currently not using 
any therapy, four were taking preventative ICS, two a combination inhaler and six were 
using inhaled SABA as required. 
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Table 6.1. Participant characteristics, V̇O2peak and baseline respiratory assessment data 
(Whilst using current medication) (n = 15).  
 
  Measured % of predicted 
Age (years) 29.3 ± 9.2  - 
Height (cm) 172.2 ± 8.1  - 
Weight (kg)  73.4 ± 14.0   - 
V̇O2peak 43.26 ± 8.11 - 
Peak Power Output (W) 246.3 ± 42.7   - 
FEV1 (L) 3.57 ± 0.64  93.7 ± 9.0 
FVC (L) 4.67 ± 0.87  103.7 ± 11.1 
PEF (L/min) 536 ± 93 99.3 ± 11.0 
FEV1/FVC 76.7 ± 8.8   93.9 ± 10.2 
 
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; PEF, peak expiratory 
flow. 
 
During the familiarisation exercise trial, V̇E was 68.50 ± 11.66 L.min-1, which was 56.8 ± 
9.1% of their maximum observed in the V̇O2 peak test, Mean HR was 165.2 ± 16.57 bpm, 







During the three exercise trials (MASK, SHAM, CONT), there were no differences in 
conditions in the environmental chamber (Table 6.2). There were also no differences in 
exercise intensity (Mean Power and Mean HR; Table 6.2). 
Table 6.2. Chamber conditions and exercise performance between acute MASK, SHAM and 
CONT trials (n = 15). 
  MASK  SHAM CONT Sig. 
Temperature (°C) 8.4 (1.0) 8.3 (0.5) 8.6 (1.1) 0.81 
Humidity (%) 24.8 ± 4.2  22.9 ± 3.8 24.3 ± 3.9 0.25 
Mean Power (W) 172.3 ± 47.5  172.2 ± 46.5   172.3 ± 47.5 0.98 
Mean HR (bpm) 165 ± 16  163 ± 14 165 ± 17 0.16 
 
Data for temperature was not normally distributed and therefore analysed with Friedman’s 
test and presented as the median score (IQR).  
 
Exercise Trials 
Results of spirometry and assessment of FeNO conducted prior to each exercise challenge 
showed no differences in resting lung function between trials (FeNO, FEV1, FVC, PEF, 
FEV1/FVC) (Table 6.3).  
There was a significant difference (p <0.01) in the maximal % change in FEV1 following the 
exercise challenges, with the % fall following the CONT exercise trial being significantly 
greater than that of the fall following the MASK trial (p <0.01), with all but one participant 
having a greater fall in FEV1 following CONT than MASK (figure 6.4). Ten out of 15 
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participants also had a greater drop in SHAM than MASK (figure 6.4), however this was to 
a lesser extent and SHAM was not different to either the MASK (p = 0.17) or CONT (p = 
0.51) trial. 
 
Number needed to treat (NNT) analysis showed that in the MASK group, participants were 
33% likely to have a ≥10% fall in FEV1 post EX and in the CONT 87%. The absolute risk 
reduction of wearing an HME mask was therefore 0.54, meaning that the number of people 
who would need to wear an HME mask to avoid one participant having a ≥10% fall in FEV1 
post EX would be two people.  
 
Table 6.3. Lung function pre and post challenge, n = 15. 
 
  MASK SHAM CONT Sig. 
FeNO (ppb) 39 (33) 42 (33) 38 (51) 0.88 
FEV1 (L) 3.52 ± 0.58  3.51 ± 0.58 3.53 ± 0.61 0.76 
FVC (L) 4.68 ± 0.81  4.65 ± 0.83 4.64 ± 0.80 0.62 
PEF (L/min) 536 ± 81  531 ± 80  533 ± 89 0.57 
FEV1/FVC 75.60 ± 9.26 75.67 ± 8.82 76.33 ± 9.77 0.59 
Maximal % change in FEV1 
post challenge 
-6.0 (7.0) #  -11.0 (11.0) -13.0 (9.0) <0.01* 
 
Data for maximal % change in FEV1 and FeNO was not normally distributed and therefore 
analysed with Friedman’s tests and presented as the median score (IQR). * indicates a 
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significant difference between exercise condition. # indicates significant difference to 
CONT. 
 
FeNO, exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital 
capacity; PEF, peak expiratory flow. 
 








































Figure 6.4. Maximum % fall from baseline in FEV1 post exercise challenge. * indicates 
significant difference to CONT. 








One participant could not participate in the cough monitoring due to their occupation. Four 
of the remaining 14 participants reported cough as a symptom they experienced following 
exercise. 
Results from the LCQ showed all but one participant scored either a 6 = hardly any of the 
time or 7 = none of the time in all domains (physical, psychological and social) for the impact 
cough has upon the different aspects of their lives. The remaining participant scored 5 for all 
domains (a little of the time). At baseline (pre-familiarisation exercise trial) VAS score was 
9 ± 7 mm out of 100 mm, with a range of 1 to 19 mm.  
Four participants demonstrated a higher number of coughs per hour than considered normal 
in a 24-hour period (Normal = <5 females, <2 males) following all Ex trials. One of these 
participants demonstrated cough counts indicative of chronic cough > 20 coughs per hour. 
There were also 5 additional participants who demonstrated greater cough count per hour 
than normal following one or more EX trial (figure 6.5).  
 

























No differences were seen between EX trials in cough count per hour over the 24-hours, 
number of coughs recorded in the first hour following Ex or participants self-report of cough 
24-hours post EX trial using VAS (table 6.4).  
 
Table 6.4. Cough Results n = 13 
 
  MASK SHAM CONT Sig. 
Number of coughs per hour 3 (3) 2 (3) 3 (3) 0.06 
Number of coughs in first hour post EX 17 (17) 15 (17) 8 (24) 0.92 
VAS 24-hour post EX (mm) (n = 15) 7 (24) 14 (27) 10 (24) 0.52 
 
Data was not normally distributed and therefore analysed with Friedman’s test and presented 
as the median score (IQR).  
 
The data was also analysed separating those who reported cough as a troublesome symptom 
(Yes Cough) and those who did not (No Cough), no difference was seen in LCQ total sore 
between the two groups (n = 15, Yes cough: 20 ± 1, No cough: 19 ± 2, p = 0.14). There was 
also no difference between these groups in the number of coughs in the first hour (n = 14, 
Yes cough: 18 ± 14, No cough: 13 ± 13, p = 0.56) or cough per hour in the 24-hour monitoring 
period (n = 14, Yes cough: 2 ± 2, No cough: 3 ± 2, p = 0.88), in the familiarisation visit or 




No linear relationships were found between VAS score and cough per hour, % fall in FEV1 
and coughs per hour, % fall in FEV1 and number of coughs in the hour after EX or LCQ 





This study demonstrates that wearing an HME mask during a cycle exercise challenge (6 
mins and 80% Peak power output) in a cold, dry (8.6 ± 0.9 o C and 24.2 ± 4.2% RH) 
environment results in an attenuation in % fall in FEV1 post exercise, compared to not 
wearing a mask. Furthermore, we found that only 33% of participants with a clinician’s 
diagnosis of asthma/ EIB demonstrated evidence of EIB (≥10% fall in FEV1 post exercise) 
whilst wearing a mask, compared to 87% of participants who did so after EX with no mask, 
making the number needed to treat (NNT) two participants. 
Results from our study are in agreement with earlier studies: Stewart et al.,  (1992) exercised 
asthma patients on either a cycle ergometer or a treadmill to 80% predicted HRmax wearing 
a mask in one trial and no mask in another. The author concluded that the mask which 
retained heat and moisture, effectively controlled EIB in most patients. They also noted that 
even whilst wearing the mask FEV1 post exercise decreased by 9%, however this was similar 
to that produced by sodium cromoglycate which had been used for more than 20 years in 
treating EIB. The mask in our study was more effective in controlling EIB, however without 
the mask their patients exhibited a larger drop in FEV1 of 18 to 52%. Similarly, in a study 
by Nisar et al., (1992) participants cycled for 6 mins whilst inhaling air from a cold air supply 
(-13°C). Participants completed both a mask and a control mask trial and results showed that 
with the control mask there was a 22% fall in FEV1 post exercise, and this was reduced to -
10% in the mask trial. This group also monitored temperature inside the two masks and 
discovered some warming of the air in the control mask to 10°C, whereas the active mask 
warmed the air to 19°C. In the present study our intention was to monitor both temperature 
and humidity inside the two mask trials, however in pilot testing we found that the 
commercially available probes were too large and therefore were highly affected by each 
expiration leaving us unable to achieve a reliable reading. Although we were not able to 
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measure temperature and humidity inside the used masks our results seem to indicate that 
some degree of warming and humidification of the inspired air took place. This was also in 
accordance with anecdotal reports of the subjective feedback of our participants. Two 
previous studies have also compared HME masks to pre-treatment with a bronchodilator and 
found that they were equally effective in attenuating a drop in lung function (Beuther and 
Martin, 2006; Millqvist et al., 2000). In Beuther and Martin’s (2006) study, participants 
completed  treadmill exercise tests, running for 10 min at 85% HR max, breathing medical 
grade air (-15 to -25°C). They found that FEV1 fell 28% with a placebo mask, 6% with an 
active mask, and 11% with pre-treatment with albuterol. The authors concluded that the 
HME mask prevents the cold exercise induced decline in lung function at least as effectively 
as pre-treatment with albuterol. This study also showed that those with a <10% fall in FEV1 
also benefitted from wearing the active mask, which is what we found in the current study. 
Millqvist et al., (2000) showed that combining pre-treatment with β2-agonists with a HME 
mask completely preserved lung function. Using an 18-minute exercise protocol of 
increasing load in an environment of around -10°C participants completed a no therapy trial, 
a β2-agonist trial and a combined face mask and β2-agonist trial and demonstrated mean falls 
of -27, -12 and -7% respectively. The authors noted that their results show that there may be 
various mechanisms underlying EIB; the combination of oedema and bronchoconstriction 
causing a fall in FEV1. Whereas β2-agonists cannot prevent possible oedema, a face mask 
probably can, on the other hand, results showed that the mask alone was not enough to 
prevent EIB entirely, so it seems likely that the exercise itself induces a certain amount of 
bronchoconstriction, probably via mediators. This may also be why we saw that those with 
a fall in FEV1 of 25-40% was not completely effective. 
In contrast to our study, these previous studies used asthmatic subjects who demonstrated 
larger drops in FEV1 and utilised subfreezing conditions but did not control for humidity. 
We decided not to use such cold conditions, but looked at cold, dry conditions which athletes 
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training outdoors in the UK are more likely to encounter. We aimed to recruit participants 
with more severe asthma, however despite all participants having a physician’s diagnosis of 
asthma, and the majority taking prescribed medication, 9 out of 27 (33%) demonstrated no 
evidence of EIB. This is an important issue by itself and is in support of the study in which 
Aaron et al., (2017) who found that in 33.1% of  adults with physician-diagnosed asthma, 
evidence of asthma could not be established. This highlights that objective testing should be 
utilised more frequently in the diagnosis and follow up of asthma patients. 
Athletes, particularly winter sport athletes are at increased risk of developing EIB and this 
could possibly be due to inspiring large amounts of cold and dry air during training and 
competition, leading to drying of and injury to the mucosa, ultimately inducing EIB 
(Anderson and Kippelen, 2008). It has been suggested that the use of β2-agonists may make 
it possible for more cold, dry air to reach the lower airways and although reduce 
bronchoconstriction, may in the end cause more injury to the mucosa (Millqvist et al., 2000). 
This combined with the effectiveness of the HME mask suggests that there may be value in 
encouraging all athletes exercising in cold, dry environments who are susceptible to EIB, to 
wear an HME mask where practical, whether they are using medication or not. Another 
potential benefit of using an HME for the prevention of EIB is that it has the potential to 
reduce the amount of β2-agonists that athletes use prophylactically, which would be 
beneficial as there is the potential for the development of tachyphylaxis and a potential 
desensitisation of repeat dosing (Anderson et al., 2006). 
Many of the earlier studies only include the use of either a sham or a no mask trial, it was 
felt important to include of both trials. We found that although not significant, there was an 
attenuation of the fall in FEV1 in the SHAM condition, this is in support of the AsthmaUK 
‘scarfie’ campaign and suggests that it may be beneficial for athletes who may not want to 
wear an actual mask to cover their nose and mouth with a scarf. Previous support of this idea 
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was shown in an earlier study where portable surgeons paper masks produced a slight 
attenuation of EIB (Brenner et al., 1980). 
None of the aforementioned studies looked at symptoms related to EIB and whether these 
could also be attenuated by wearing an HME. Recently, the Leicester Cough monitor has 
proven useful in objectively assessing cough in asthma management (Fukuhara et al., 2016) 
and an alternative automated device has also been found capable of increasing patient 
awareness of the patterns of cough for early detection of worsening asthma (Rhee et al., 
2015). These studies show that cough monitoring has great potential for assessing the 
response to asthma therapy. This was the first study to attempt to measure objective and 
subjective measures of cough following exercise in participants with EIB. Banner et al., 
(1984) showed that cough was most likely following hyperpnoea in environments which 
promoted respiratory water loss, as the resultant airway surface mucosal drying can lead to 
both physical and chemical activation of the cough receptors. Results from the present study 
however showed no differences in cough frequency following exercise between the MASK, 
SHAM or CONT trials for either cough per hour over the 24-hour monitoring period, or 
more acutely in the hour post EX. In addition, no differences were seen in the participant’s 
perception of cough as indicated by VAS. This however is unsurprising because the 
relationship between objective cough frequency and subjective measures of cough such as 
VAS has been shown to be mild to moderate (Birring et al., 2006). Only six participants in 
the present study reported cough as a troublesome symptom following exercise and although 
11 participants demonstrated a level of cough which would be considered higher than normal 
(≥5 females, ≥2 males) in one or more trial, only two demonstrated levels usually observed 
by patients with chronic cough. It may be that cough frequency in the current cohort was too 
small to observe any change. Low levels of cough were unexpected given that cough is the 
most commonly reported respiratory symptom by athletes ( Hull et al., 2017) and in previous 
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chapters this was a commonly reported symptom. Participants in this study were recreational 
athletes rather than elite so this may go some way to explain this observation.  
A limitation of this study as previously mentioned, is compared to earlier studies, 
participants in this study group in the main demonstrated mild EIB. It would be beneficial 
to see if the HME mask could attenuate the fall in FEV1 in participants with more severe 
EIB. As seen in figure 6.2 to wear the mask we used it needs to be attached to a balaclava. 
Participants reported that they became very hot even in a short exercise bout, which would 
potentially be a barrier to athletes wearing the mask during training. Future investigations 
may look to develop a heat and moisture mask that is more practical to wear in UK weather. 
Additional areas for future study may be looking at the efficacy of an HME mask compared 
to an everyday scarf which athletes may be more likely to utilise. Also, looking at the effects 
of wearing an HME long term during training to see if protecting the airway from injury 
reduces severity of EIB would be beneficial as this could be an alternative form of treatment. 
In conclusion, HME masks can attenuate bronchoconstriction in individuals with asthma/ 
EIB when exercising in cold, dry environments. HME Masks may be helpful in the 



























7.0 Key Research Study Findings 
• Chapter three demonstrated that a standardised exercise challenge (EX) in a dry (26% 
RH) environment was found less provocative than eucapnic voluntary hyperpnoea 
(EVH) and a positive EVH challenge was found not predictive of a positive response to 
EX.  
• Chapter four revealed that 29% of a cohort of elite football players demonstrated 
evidence of exercise induced bronchoconstriction (EIB) when screened using EVH. 
Treatment of these EVH positive (EVH+) players with standard asthma therapy resulted 
in improved airway inflammation and reduced airway-hyper-responsiveness, and this 
was associated with a potential beneficial impact on performance. 
• Chapter five highlighted that 75% of elite swimmers entering the GB funded programme 
appear to have EIB when screened for respiratory dysfunction. No significant differences 
between the health and wellbeing of swimmers who received a treatment intervention 
following a screening for EIB compared to those who didn’t were found. There were 
also no significant differences in respiratory health or general health and wellbeing in 
swimmers training outdoors at a warm weather training camp compared to those 
remaining at home training indoors. The findings of a systematic approach to evaluating 
total airway health in elite swimmers with EIB prior to the 2016 Olympics was also 
reported, concluding that respiratory health in elite swimmers can be optimised through 
a systematic assessment of airway health. 
• Chapter six showed that a heat and moisture exchange (HME) face mask can be effective 
in protecting against acute EIB. This however was not found to have an impact on the 
incidence of cough.  
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7.1 High prevalence of EIB in athletes 
Data from this thesis adds to the already well-established body of evidence that there is a 
high prevalence of EIB amongst elite athletes both in the UK and worldwide. Previously 
prevalence has been reported to vary between 20 and 68%  in British summer Olympic sports 
(Dickinson et al., 2005; Levai et al., 2016), and similar levels have been reported by 
numerous  authors across the world in athletes competing in both summer and winter sports 
(Bougault et al. 2009; Helenius et al. 1998; Larsson et al. 1993; Mannix et al. 1996; Mannix 
et al., 1999; Wilber et al. 2000). The two sports which were investigated in this thesis, 
namely football and swimming are two of the most popular participation sports in the UK 
(Jones et al., 2011) and in the case of football, the world (Kunz, 2007). In chapter 4 the 
largest ever cohort of elite footballers to date were screened for EIB using EVH and 29% of  
players across the three top divisions in England were found to have objective evidence of 
EIB, which concurs with previous small scale studies of footballers in the UK (Dickinson et 
al., 2013).  A recent study has since found a prevalence of only 7% in football players living 
in a humid tropical region (Mousinho Gomes et al., 2018). It is difficult to discern whether 
this is the true prevalence of players in these areas due to the differing environments in which 
they train and play, or due to the difference in methods of diagnosis. Mousinho and 
colleagues’ chosen bronchoprovocation method was a field running test in environmental 
conditions of 30°C and 82% RH, whereas recommended guidelines when using an exercise 
test are to do so in ambient conditions of 20-25°C and RH of ≤ 50%. There is the potential 
for EIB prevalence in footballers to vary around the world due to the differing environments 
in which they play, however certainly results for this thesis could be applied to other 
countries in Europe, whose football players train outside all year round and are exposed to 
cold climates, dry air and high pollen levels. As such, it is thought that this condition would 
be of interest to football governing bodies such as UEFA, who as part of their core mission 
aim to protect the health of their athletes. 
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It is well documented that swimmers have a high prevalence of EIB (Helenius et al. 1998; 
Pedersen et al. 2008; Bougault et al. 2009; Stadelmann et al., 2011; Levai et al. 2016), 
perhaps the highest of any sport and data collected as part of chapter 5 concurred with these 
previous findings showing that 75% of swimmers entering the GB funded programme 
demonstrated evidence of EIB when objectively assessed using EVH. 
There is limited literature regarding gender differences in prevalence of EIB. Although not 
a primary objective of this thesis, it was found that across all studies which determined 
prevalence recruiting both genders, there was a 35 and 22 % prevalence of EIB in females 
and males respectively when assessed by EVH and exercise challenges. This is in support of 
Norqvist et al., (2015) who demonstrated female athletes have a higher prevalence of EIB 
than their male counterparts. No associations were found however between gender and result 
of either EVH or Exercise challenges in any of the studies in this thesis.  
 
7.2 Diagnosis of EIB 
There is still some debate amongst the literature regarding the optimal bronchoprovocation 
challenge to identify EIB in athletes. The favoured bronchoprovocation challenge of the 
IOC-MC is EVH (Anderson et al., 2001) and as such EVH is often referred to as the ‘gold 
standard’ test. Recently however this has been challenged (Hull et al., 2016) and it would 
seem logical to use exercise as the provocative stimulus to detect an exercise induced 
condition. Results of chapter 3 showed that EVH demonstrated greater sensitivity than a 
standardised exercise challenge in the diagnosis of EIB. These results were in agreement 
with previous studies comparing both lab and field exercise challenges to EVH (Dickinson 
et al. 2006; Rundell et al. 2004; Mannix et al., 1999). The reduced sensitivity of exercise 
compared to EVH is thought to be due to the differences in the two main contributors to the 
airway response; inspired air water content (Evans et al., 2005) and V̇E (Carlsen et al., 2000). 
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Despite attempting to standardise these using an environmental chamber with additional 
dehumidifiers to reach a relative humidity of 26% and an algorithm using individual heart 
rate response to guide exercise intensity, it remained impossible to match the low humidity 
of the medical grade air of EVH and the high ventilation which can be achieved by 
hyperventilation. Inclusion of an additional visit to the laboratory for a V̇O2max test prior to 
the exercise challenge did not lead to a higher V̇E during the exercise challenge. Using the 
heart rate based algorithm (Ansley et al., 2010), a mean V̇E of 77 ± 11% of predicted MVV 
was achieved. However, by using 80% of peak power, V̇E was lower (57 ± 9% MVV) 
meaning that in chapter 3 only four participants out of 31 did not achieve the 60% MVV 
required for an acceptable test, whereas 10 out of 14 did not meet the 60% threshold in 
chapter 6. In both of these chapters the recommended HR target of 80-90% of predicted 
maximal heart rate (Bonini and Palange, 2015) was met 89 ± 4.8% (chapter 3) 87.70 ±6.4% 
(chapter 6). 
During chapter three, it was found that although it would seem logical to use exercise in the 
diagnosis of an exercise induced condition, there are still many limitations to using an 
exercise challenge, many of which would be particularly restrictive when attempting to carry 
out a squad screening. Firstly, as discussed above, it was difficult to ensure an adequate V̇E. 
Also, a specialist environmental chamber is required, which needs several hours to achieve 
the desired environment, can only be used by one athlete at a time to ensure control over the 
environmental conditions and needs time between each participant for environmental 
conditions to return to the correct level. The equipment for EVH testing on the other hand 
can be portable, numerous athletes can be tested back to back, there is no variation in 
environmental conditions and the test does not interfere with an athlete’s training in the same 
way as a six minute near maximal exercise test might. In addition, V̇E is easy to standardise 
ensuring athletes to achieve ≥ 60% MVV; in chapter three, all twenty-seven participants 
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achieved this level, chapter 4 only four out of ninety-five football players didn’t reach the 
target and in chapter 5 only four out of thirteen swimmers did not.  
There is some debate in the literature regarding the appropriate threshold for a positive EVH 
test indicative of EIB. The widely accepted 10% fall in FEV1 post EVH was recently 
challenged by Price et al., (2017) who suggested that a more appropriate threshold in an 
athletic population may be 15%. This was based upon analysis of 224 healthy asymptomatic 
athletes, taking an abnormal response as a mean +2 SD fall from baseline. By using only 
asymptomatic athletes in this analysis however there is a bias to the data. The authors suggest 
that using the 10% threshold, 20% of these athletes would provide a positive test and 
evidence for EIB. This level of prevalence would however be expected in an athletic 
population (Dickinson et al., 2005). The authors suggest that based on their previous work 
there is poor reproducibility of EVH suggestive of mild EIB (Price et al., 2015). Williams et 
al., (2015) however showed good reproducibility at all severities both long and short term. 
During chapter 4, the two players who performed a repeat EVH challenge despite not taking 
their recommended medication demonstrated almost identical falls in FEV1 at a level 
indicative of mild EIB (-14% to -14% and -10% to -11%). Chapter 3 provided no evidence 
to support a change in criteria to a 15% fall in EVH; in this chapter it was seen that applying 
the 15% threshold resulted in 5 participants no longer being identified as EVH+ one of whom 
demonstrated EX+, highlighting that a change in the criteria may increase the risk of 
producing false negatives.  
A change in the criteria for a positive exercise challenge to a fall in FEV1 of ≥ 6% has also 
been suggested by some authors (Helenius et al., 1998; Rundell et al. 2000). This lower 
threshold to exercise would appear logical given ‘normal’ response to exercise is mild 
bronchodilation (Todaro, 1996), whereas EVH is more provocative and a ‘normal’ response 
to EVH in non-asthmatic subjects has been found to be around 4% (Hurwitz et al., 1995). In 
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chapter 3 if the criteria had been changed to a fall in FEV1 of ≥ 6%, this would have led to 
one further participant being identified as having evidence of EIB through the exercise 
challenge. This participant however was not EVH positive and show this change in criteria 
may lead to false positive diagnoses.  
Although many authors have established that EVH is more sensitive than exercise challenges 
(Dickinson et al. 2006; Rundell et al. 2004; Rundell et al. 2000; Mannix et al., 1999) as 
Anderson and Kippelen (Anderson and Kippelen, 2013) suggest, ultimately the appropriate 
cut off will be determined by the investigators need to either be more sensitive or more 
specific. For the purposes of this thesis, where EVH was predominantly used in a screening 
scenario of elite athletes, it was decided that using the criteria of two consecutive falls in 
FEV1 of 10% was most appropriate. In these circumstances, sports only have a short time 
frame to assess large numbers of athletes and therefore athletes are only able to perform a 
one-off test. Although EVH has been cited as potentially being overly sensitive (Price et al. 
2016), if negative, then EIB is able to be ruled out. If a mild positive test is found i.e. a fall 
in FEV1 of 10-15% caution can be applied by ensuring that there is no concomitant fall in 
FVC and the flow loops demonstrate a concaving shape. Also, by using other evidence from 
the respiratory assessment such as FeNO, nasal peak flow and atopy status the physician is 
can initiate a trial of treatment. The criteria for two consecutive falls in FEV1 also protects 
against results being influence by fatigue or poor technique. In chapter 4 all four players 
with very mild EIB (falls in FEV1 post EVH of 10-14%) showed a reduction of EIB severity 
following a nine-week trial of standard asthma inhaler therapy. In addition, two of these 
players had a high FeNO (>50ppb) at baseline which was subsequently within normal limits 
at follow up. Two of these players were also included in the analysis of performance results 




7.3 Respiratory symptoms and EIB  
Literature has consistently shown a poor correlation between respiratory symptoms during 
and after exercise and objective evidence of airway narrowing (Rundell et al., 2001; 
Dickinson et al., 2005), with some athletes reporting symptoms despite airway obstruction 
being blunted by medication (Simpson et al., 2015) whereas only a minority of asthmatic 
athletes reporting any respiratory symptoms (Turcotte et al. 2003). This thesis supports this 
previous research and provides further evidence to support that objective testing is essential 
to establish a diagnosis of asthma and EIB (Parsons et al., 2013). Chapters 3 and 4 show that 
respiratory symptoms were not predictive of a positive EVH or exercise challenge. Also, 
although not reported in chapter 6, when all participants were included, respiratory 
symptoms were not predictive of a positive exercise challenge (p = 0.93). Result from 
chapter 5 do not support this finding as respiratory symptoms in this group of swimmers 
were predictive of EVH test result. Despite this however, these swimmers had not reported 
them previously as troublesome to the team physician.  
Previous studies have found that cough is the most commonly reported respiratory symptom 
in elite athletes (Dickinson et al., 2005, 2006; Rundell et al., 2001).  A high prevalence of 
cough was seen in all studies in this thesis; it was the most frequently reported symptom in 
chapters 3 and 5 and the second most reported symptom by footballers in chapter 4. The 
exception to this is that it was the third most commonly reported symptom in chapter 6 
behind chest tightness and wheezing. This could potentially be due to the different 
population used in this study; rather than elite athletes, this group were exercising asthmatics. 
As athletes do not often recognise respiratory symptoms, it would be beneficial to have a 
tool which could objectively measure symptoms such as cough in this population. Chapter 
6 showed that the Leicester cough monitor (LCM) was an easy to use tool in a recreationally 
active group. In line with research suggesting that athletes do not recognise respiratory 
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symptoms, there was no relationship between the objective measure of cough and self-report 
of cough using a VAS. The different exercise conditions (HME mask, sham and no mask 
condition) had no effect on the level of cough in this study, however cough frequency was 
low and only a few participants reported cough as a troublesome symptom. The device 
however was simple to use and unobtrusive and has the potential to be used as a monitoring 
tool for objective monitoring of cough and interventions in this population. This would likely 
be beneficial in groups such as cold weather athletes (Turcotte, J B Langdeau, et al., 2003) 
who report that coughing becomes more prominent and problematic over the course of their 
competitive season (Turmel et al., 2012). 
 
7.4 Misdiagnosis of EIB 
Throughout this thesis, by using EVH and exercise challenges as objective assessment 
methods for EIB, a high level of both under and over diagnosis of EIB and asthma has been 
found. In chapter 3, 7% of participants were found to have no objective evidence of EIB 
despite a prior diagnosis and taking medication for this condition, whereas 11% of 
participants demonstrated evidence with no prior diagnosis. Ten percent of footballers 
demonstrated a fall in FEV1 in keeping with a diagnosis of EIB despite no previous history 
and 3% of players were on medication for asthma/ EIB including daily ICS despite providing 
no objective evidence for this condition when assessed. In the population of swimmers 
screened for EIB on entry to the GB funded programme, 50% were found to have previously 
undiagnosed EIB. Furthermore, in chapter 6, 44% of a population of recreational active 
individuals with a diagnosis of asthma or EIB showed no evidence of either condition when 
objective testing in the form of spirometry and exercise challenge testing in a cold, dry 
environment was performed. Four of these individuals were not taking any medication for 
their diagnosis of asthma/ EIB, however the remaining participants were regularly using 
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inhaled therapies including, SABA, ICS and even combination ICS and LABA inhaler 
therapy. Combining the data from this thesis showed that in total, 8% of individuals may be 
taking medication unnecessarily and even more have a current diagnosis for a condition 
which they most likely do not have.  
This alarming result it not exclusive to an athletic population; Aaron et al., (2017) found no 
evidence of asthma could be found in 33% adults with physician-diagnosed asthma, 
highlighting that objective testing should be utilised more frequently in the diagnosis and 
follow up of asthma patients as well as in athletes. Worryingly when questioned, quarter of 
family practitioners said that they would initiate treatment on clinical information alone 
when presented with adults with exercise-related respiratory symptoms (Hull et al., 2009). 
There are health risks associated with unnecessary asthma medication; the long term use of 
SABAs has been associated with degenerative changes in lung function (Bonini et al., 2013) 
and improper use of ICS has been seen to lead to adrenal failure and growth suppression in 
children and mucosal immuno- suppression and an increased risk of respiratory infections 
in adults (Sabroe et al., 2013). The cost of inappropriate treatment for asthma and EIB is also 
likely not trivial. Mukherjee et al., (2016) reported that the costs to the NHS associated with 
asthma are estimated to be at least £1.1 billion, with 74% of these costs for provision of 
primary care services (60% prescribing, 14% consultations). With improved initial 
diagnostics, the initial cost of objective tests could be offset with reductions in unnecessary 
prescriptions and follow up appointments.  
Given the high prevalence of EIB in athletes, detection and appropriate treatment of EIB is 
essential. The high number of athletes demonstrating objective evidence of EIB despite not 
having a history of asthma/ EIB or reporting symptoms highlights the potential need for 
screening in this population. Failure to implement appropriate treatment presents a potential 
for deterioration and exacerbation of EIB. Undetected and uncontrolled EIB can lead to fatal 
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consequences (Becker et al., 2004) and when left untreated EIB severity may increase due 
to airway injury (Anderson and Kippelen, 2008). Untreated, EIB also has the potential to 
have deleterious effects of performance (Stensrud et al., 2007). The long-term effects of 
leaving EIB untreated in susceptible athletes is unknown however and is an important area 
for future study.  
 
 
7.5 Treating EIB in athletes 
Current guidelines for treatment of EIB in athletes is chiefly based upon guidelines for 
standard asthma care and expert opinion due to the lack of research in athletes. Chapter 4 
looked to start to fill this void and the impact of standard asthma therapy on EIB control in 
elite footballers was investigated. This study found that nine-weeks of appropriate inhaler 
therapy based on EIB severity successfully provided adequate control of EIB and a reduction 
of airway inflammation. Unfortunately, although treatment was recommended for all 
twenty-seven EVH+ footballers, only seven took the medication as prescribed, resulting in 
a large limitation of the study. This study also attempted to go one step further and be the 
first to investigate the effect of treating EIB on performance in this elite population. Once 
again, the high attrition rate meant that a small sample size was left for the final analysis, so 
the results had to be interpreted with caution. Despite not being statistically significant, 
results were however promising; EVH+ players demonstrated a larger mean increase in V̇O2 
peak higher than that of the EVH- players, bringing the mean V̇O2 peak of the two groups 
in line with each other. Further work with an adequately powered study is required to follow 
this up.  Similar findings have also been reported in sports with similar demands; Brukner et 
al., (2007) found that Australian Rules football players with newly diagnosed EIB had a 
significant improvement in V̇O2 max following six weeks of treatment compared to controls 
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and although again not statistically significant Spiteri et al., (2014) demonstrated that 
appropriately medicating elite rugby players with previously undiagnosed EIB improved 
their performance in a rugby specific aerobic exercise. It has been hypothesised that this 
impact on performance may be due in part to the attenuation of bronchoconstriction during 
and following exercise which results in reduced alveolar ventilation and efficiency of 
alveolar-to-arterial blood O2 exchange (Haverkamp et al., 2007). It may also simply be due 
to the athletes being able to complete higher quality training sessions whilst on treatment as 
their recovery between sets is not compromised due to airway narrowing. It was hoped that 
further evidence of the effects of appropriately treating screen detected EIB in athletes would 
be obtained in chapter 5 where the impacted of screening in swimmers was investigated. 
Unfortunately, due to time constraints in the swimmer’s programme, a follow up assessment 
was not able to be made. In chapter 5 however, the impact of screening and appropriately 
treating EIB on general health and wellbeing was investigated. No significant differences 
were seen in in the number of days lost to illness or spent carrying out modified training 
between the group who were given an intervention (either an initiation of treatment or a 
change in their previous medication) and the group who did not receive an intervention 
(EVH- swimmers and those swimmers who although EVH+ did not take their treatment. 
There were many limitations to results in chapter 5 as discussed within that chapter and 
future studies could investigate this area by using a larger group of athletes with EIB 
initiating treatment, looking at the impact treatment has over a certain time frame by using 
a more specific wellness monitoring tool. This is an important area of investigation as 
association between uncontrolled asthma/ EIB has been suggested to predispose athletes to 
upper respiratory tract infections (URTIs) (Helenius and Haahtela, 2000) and in the general 
population an increased risk of pneumococcal disease and pneumonia (O’Byrne et al., 2013). 
With the leading cause of time lost to training in elite sport being due to respiratory illness, 
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by treating known underlying illness may reduce an athlete’s risk of respiratory illness and 
therefore lead to less time of training lost and therefore improved performance. 
Chapter 6 demonstrated that as well as pharmacological treatment of EIB, alternative 
methods of reducing EIB may be available to athletes as an HME mask was found successful 
in attenuating the fall in FEV1 after an exercise challenge in recreationally active asthmatics. 
This result was in keeping with previous research (Stewart et al., 1992; Nisar et al., 1992; 
Beuther and Martin, 2006) and could be a useful strategy in the treatment of in mild cases 
of EIB because as highlighted in chapters 4 and 5, there are a number of athletes who 
although demonstrate EVH+ were particularly reluctant to take any standard asthma 
medication. Clearly a mask would not be feasible to wear in a sport such as swimming, 
however during training for outdoor sports particularly during the winter months a mask 
could worn by athletes which can acutely control EIB exacerbations. There is also the 
potential that if worn regularly, these masks may also have the potential to limit the 
development of EIB in cold weather athletes by interrupting the continuous cycle of injury 
and repair, which ultimately leads to chronically inflamed airways with the potential for 
cellular airway changes (Karjalainen et al., 2000). This is yet to be studied. 
 
7.6 Translation into practice 
As already discussed, there is a high prevalence of EIB which can lead to suboptimal health 
and performance in athletes. Appropriate strategies need to be put in place in elite sport to 
optimise management of EIB in athletes. There is some debate as to whether screening for 
EIB should be carried out in athletic populations; some authors have called for screening for 
EIB to be implemented (Dickinson et al., 2005; Holzer and Brukner, 2004; Vakali et al., 
2017), however others want to ensure that before widespread screening is implemented the 
prevalence, the ability to detect the condition of interest and an understanding of the impact 
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in the population of interest is demonstrated (Wilson and Jungner 1968; Ansley et al., 2013; 
Hull et al., 2007; Hull and Rawlins 2016). Results of this thesis add to the growing body of 
evidence which shows a high prevalence in an athletic population. It shows that EIB can be 
successfully detected by EVH testing and it begins to highlight the positive impact that 
treating screen detected athletes with EIB can have. Gerald et al., (2007) suggested that 
despite a lack of evidence for the adoption of screening programmes, limited case detection 
programmes could be appropriate where there is a high prevalence of undiagnosed asthma 
and where newly identified patients have access to quality care. This would certainly apply 
to an athletic population and data from this thesis would support the implementation of case 
detection programmes in elite sport. If sports are to adopt this practice however it is vital 
that programmes are structured to include monitoring and education of athletes 
demonstrating evidence of EIB. The work involving the elite footballers highlighted that 
despite support from staff, many players did not to take the inhalers, and were confused 
about what they should be taking and when. This showed that for a screening programme to 
be effective in elite sport, time needs to be invested in educating players about EIB and its 
treatment and it is vital to have the cooperation of the athletes from the start. Miller et al.  
(2005) supports this by highlighting the importance of educating coaching staff in the 
management of asthma. Whilst working with the elite swimmers, although only anecdotal 
evidence, swimmers attending the pre-Olympic assessment were attending for their third or 
fourth respiratory assessment and despite having received education at each visit, they were 
only just beginning to realise the importance of taking their preventative treatment regularly. 
Chapter 5 also demonstrated the importance of follow up testing and monitoring of athletes 
once on treatment for EIB as despite apparently taking regular preventative treatment some 
swimmers still demonstrated obstruction at rest, highlighting that either their compliance or 
inhaler technique needed improving or their medication needed to be stepped up.  
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It is recommended that repeat testing of athletes is carried out at intervals during an athletes 
career in those initially demonstrating EVH- because EIB has been shown to develop over 
the course on an athletic career (Knöpfli et al., 2007). The frequency at which repeat testing 
should be carried out has not yet been investigated. 
A key factor in the development of EIB in athletes is the interaction between the ventilatory 
demand of their sport and the environment in which it is performed, leading one group to 
consider whether in fact airway dysfunction in athletes should be considered an occupational 
lung disease (Price et al., 2013). In chapter 5, no difference was seen in airway inflammation, 
wellbeing or nasal peak flow after changing the indoor environment in which the swimmers 
usually train to the outdoor environment in Australia. One reason for this might have been 
that although the swimmers were no longer being exposed to the noxious trichloramines, 
many were instead suffering from hay fever through exposure to airborne allergens.  
Sports have a duty of care to their athletes and as such, in sports in which there is a high 
prevalence of EIB, everything possible should be done to minimise the detrimental effects. 
As well as appropriate screening and monitoring of respiratory health, in swimming for 
example as discussed in chapter 5, measures can be taken such as using alternative methods 
of pool disinfectant, ensuring adequate ventilation and establishing pool hygiene regulations. 
In outdoor sports as previously discussed an HME mask could be a viable method of 
removing some of the environmental impact. Additionally measures such as trying to ensure 
training is not scheduled outside in low humidity or during times of high pollen or pollution 
and avoiding carrying out sessions close to major roads or during rush hour would also be 
advisable where possible (Dickinson et al., 2018). 
It is not only the elite population to which the results of this thesis are relevant. A high level 
of misdiagnosis of asthma and EIB were uncovered in participants of all levels of athletic 
ability. This can be translated into general practice to add to the growing body of literature 
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which recommends objective testing for the diagnosis of asthma and EIB (Aaron et al., 
2017). This may save valuable NHS resources on unnecessary prescriptions and protect 
patients from needless medications and enable them to obtain differential diagnoses for their 
symptoms. The importance of education would also be equally, if not more important in this 
group who do not have staff on hand to remind them to take medication. 
 
7.7 Overall Limitations 
The limitations of this thesis have been discussed in the current chapter and as part of the 
individual studies. The main limitations of this thesis have largely been due to its applied 
nature. Research within elite sport is notoriously difficult to control due to the high-pressure, 
fast-moving nature, limited access to the athletes and many demands on their time. Very few 
studies have been carried out in elite athletes, particularly regarding the impact of treatment 
on EIB, wellbeing and performance and as such despite several limitations this thesis adds 
value to a scarce body of literature. The other big limitation was, ironically despite such a 
high prevalence at the very elite level, the difficulty of recruiting participants with EIB for 
the laboratory-based studies. This in itself was an interesting finding however, uncovering 
the high level of misdiagnosis amongst recreationally active individuals. 
 
7.8 Areas for future study 
A key area which requires investigation is the effect that treating screen detected EIB athletes 
has on their performance. This was attempted during chapter 4 but due to large numbers of 
dropout was not adequately powered. Similarly, the long-term impact of EIB on athlete 
health and wellbeing requires further investigation, reporting on the impact of treatment in 
optimising performance and investigating the link between asthma/ EIB and frequency of 
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respiratory tract infection. The effect of improvements in training environments, making 
them less noxious environments should also be investigated and may be an important area 
in athlete welfare and the long-term effects of wearing an HME mask during training upon 
EIB control and development could be a way of investigating this.  
 
7.9 Conclusions 
Data from this thesis demonstrates a high prevalence of EIB in elite athletes, specifically 
football players and swimmers. It was found that respiratory symptoms are not predictive of 
EIB and objective assessment is required. EVH was found to be the most sensitive diagnostic 
method for EIB in an applied sporting environment and the original 10% threshold for a cut 
off for fall in FEV1 post EVH seems appropriate in these circumstances. Standard asthma 
treatment appears to be successful in the elite athletic population in improving airway health 
and reducing EIB severity. Furthermore, it may have the potential to improve athletic 
performance in these athletes, enabling them to compete on a level playing field with their 
non-EIB counterparts. Further investigation is required to determine if screening and treating 
athletes for EIB where appropriate may also improve overall health and wellbeing. HME 
masks could be a viable alternative method of treatment for EIB. No impact on changing the 
training environment in swimmers from an indoor to an outdoor pool was found and as such 
the impact of improving training environment requires further investigation.  
Overall using evidence from this thesis, it would be recommended that case detection 
programmes are established for athletes in sports which put them at a greater risk of 
developing EIB. As part of this appropriate follow up, monitoring and education is required, 
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Permission to contact your GP 
 
Before you are able to take part in this study, we must write to your GP to let them know of 
your intention to participate and give them 14 days to respond. If we do not hear back from 
them, we will assume that there is no problem with you taking part. On the next page there 
is a copy of the letter we will send them. 
 
Please complete the form below to provide us with your GPs contact details. 
 
Your name:         I 
D.O.B:         
 
GP Name:         
Practice Name:        
Address:        I 
Postcode:        
Telephone:       I 
Email:         
 































































Subject ID:     Date:    Trial:   
    
 
 
Please put a cross on the line to indicate where on the scale your cough has been 













































Cough Monitoring Instructions 
 
Cough Monitor Initial Setup 
 
Menu options are set as follows:  
 
• Add/overwrite OFF  
• VOR OFF  
• DPC (speed con) OFF  
• Easy search OFF  
• Alarm OFF  
• AVLS OFF  
• Protect OFF  
• Divide Leave blank as it is, move on to next option.  
• Move and copy Leave blank as it is, move on to next option.  
• Delete Leave blank as it is, move on to next option.  
• Select memory Built in memory  
 
Detail memory This option contains submenus that need to be checked. Press Enter TO 
CHECK HIDDEN SUBMENU.  
 
• REC Mode appears: Press Enter to enter.  
• Find 48kbps with forward. Press Enter to select 48kbps.  
• Press forward to show next menu options, see below.  
• REC Mode 48kbps  
• Mic Sensitivity LOW  
• LCF (Low Cut) ON  
• Select Input MIC IN  
• Continuous Play OFF  
• Noise Cut Level Maximum  
• LED OFF  
• Language English  
• Date &Time (See date and time section)  
• Time display 24-Hour  
• Beep OFF  
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• Auto Power OFF 5min  
• Format Leave blank  
• [Back] Leave blank  
• Press stop button to return to main display.  
 
Preparing the Cough Monitor for a Participant 
Insert fresh new 2x AAA battery.  
 
 
Turn ON the monitor by sliding and holding the “HOLD・POWER ON/OFF” switch in 




Check Time and Date (should already be set). Note date and time will be lost 1 minute 
after removal of batteries if they are not replaced.  
  
• Press and hold the DISP/MENU button for 1 second to display menu options.  
• Press button to go to Detail menu.  
• Press Enter button  
• Use forward button to move to Date & Time.  
• Press Enter button to choose manual.  
• Press Enter button to show date and time.  
 
If date/time is incorrect, reset using following instructions:  
 
• Press and hold the DISP/MENU button for 1 second to display menu options.  
• Press button to go to Detail menu.  
• Press Enter button  
• Use forward button to move to Date & Time.  
• Press Enter button to choose manual.  
• Press Enter button and year that is set will be highlighted.  
• To change year press or button until correct year is displayed.  
• Press Enter button to confirm and to move on to the next parameter.  
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• Repeat process using or to change date/time and the Enter button to confirm until 
date and time set correctly.  
• 24H should be selected  
• When you set the minute by pressing Enter button, ensure “executing” message 
appears to confirm Date & Time are set.  
• Press stop button to return to main display.  
 
Check microphone wire is plugged into the microphone port (NOT Headphone socket).  
 
 
Check screen display shows the following: 
 
• Display should show Folder01 - - h- - m - -s at the top of screen. 
• Display should show 00/00 in centre of screen.  
• Record speed should be SP.  
• “LCF” displayed bottom left of screen.  
• The battery is full.  
 
If these settings are incorrect, ensure all old recordings have been uploaded and deleted 




Starting a recording 
When you need to start a 24-hour recording 
  
• Press record button firmly.  
• Check screen display shows REC; the recording clock is counting upwards and 
folder 01/01 is displayed.  
• Slide the hold button on the side of the monitor upwards to LOCK the controls. 
Sliding into HOLD function is critical, otherwise the recorder may accidentally 
switch off and lose data. 
• Test HOLD function by pressing DISP button. HOLD message should appear, then 
move on to next step. If HOLD is not set, keep pressing DISP button to return to 
counting timer clock display, then slide HOLD button on the side upwards and 
repeat HOLD test again.  
• Immediately, the Investigator should talk into the microphone (at a distance 30 cm) 
and say the following clearly and reasonably loudly:  
“Asthma UK Subject number…Date… Start time… Trial…”  
• Write in subject number into accompanying paperwork (participant instructions/ 
diary and VAS). 
• Give the participant the following instructions: 
o Always wear the recorder and microphone unless having a shower or going 
to bed.  




o When you go to bed, you must remove the microphone and place it on a 
bedside table close to you so that the microphone wire is not in danger of 
getting tangled around you. Place the recorder also on the bedside table.  
o If you are going to have shower/bath, then remove the microphone and 
monitor and leave it outside of the bathroom. Re-attach them both once you 
have finished showering.  
o Do not remove the recorder from bag.  
o Avoid putting pressure on the bag that may press buttons on the recorder 
and accidentally terminate recording.  
o Do not pull microphone wire as it may become disconnected from recorder 
inside bag. If microphone wire becomes disconnected, reconnect, record 
time and duration disconnected in the sleep diary and inform us.  
o Fill in the diary to record sleep and awake time and any comments. 
Returned this with the cough monitor.  
o Ensure the VAS form is completed at the end of the 24-hour period. 
• Record the cough monitor number along with participant ID and date.  
 
Attach the cough monitor to subject  
 
• Attach the microphone clip to the patients clothing so that the microphone is as 
close to the larynx as possible.  
• Position the bag/holder over the subject’s waist and place the monitor inside the 
bag so that it is protected.  
• Use cable tie to secure the two zips on the bag (if available) to prevent subjects 
from opening the bag.  
 
 
Return of the monitor from the participant 
 
• Participants should remove the monitor after 24 hours, without stopping the 
recording. 
• They should be instructed to return the monitor as soon after the 24 hours as they 
can, or on their next visit along the VAS and the diary. 
• When the monitor is returned. Stop the recording. DO NOT PLAY BACK OR 
LISTEN. 
• Upload the files via USB to be sent for analysis ASAP. 
 
 
 
